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SYNOPSIS 
In Africa, the importance of medicinal plants in folklore medicine and their contribution to 
primary healthcare is well recognized. Across the continent, local herbal mixtures still provide 
the only therapeutic option for about 80% of the population. The vast floral diversity and the 
intrinsic ethnobotanical knowledge has been the backbone of localized traditional herbal 
medical practices. In Africa, an estimated 5400 of the 60000 described plant taxa possess over 
16300 therapeutic uses. Similarly, with a therapeutic flora comprising of approximately 650 
species, herbal medical practitioners in South Africa, make use of a plethora of plants to treat 
different human diseases and infections. Over the years, studies have identified numerous plant 
species with potential against chronic metabolic diseases including type 2 diabetes mellitus 
(T2DM).  
Globally, the incidence and prevalence of T2DM have reached epidemic proportions affecting 
people of all ages, nationalities and ethnicity. Considered the fourth leading cause of deaths by 
disease, T2DM is a global health crisis with an estimated diagnosis and mortality frequency of 
1 every 5 seconds and 1 every 7 seconds respectively. Though the exact pathophysiology of 
T2DM is not entirely understood, initial peripheral insulin resistance in adipose tissue, liver, 
and skeletal muscle with subsequent pancreatic β-cell dysfunction resulting from an attempt to 
compensate for insulin resistance is a common feature of the disease. The current approach to 
treating T2DM is the use of oral antidiabetic agents (OAAs), insulin, and incretin-based drugs 
in an attempt to achieve glycaemic control and maintain glucose homeostasis. However, 
conventional anti-T2DM drugs have been shown to have limited efficacies and serious adverse 
effects. Hence, the need for newer, more efficacious and safer anti-T2DM agents. 
Sutherlandia frutescens subsp. microphylla is a flowering shrub of the pea family 
(Fabaceae/Leguminaceae) found mainly in the Western Cape and Karoo regions of Southern 
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Africa. Concoctions of various parts of the plant are used in the management of different 
ailments including T2DM. However, despite extensive biological and pharmacological studies, 
few analyses exist of the chemical constituents of S. frutescens and no Triple Time of Flight 
Liquid Chromatography with Mass Spectrometry (Triple TOF LC/MS/MS) analysis has been 
performed.   
The initial aim of this study was to investigate the phytochemical profile of hot aqueous, cold 
aqueous, 80% ethanolic, 100% ethanolic, 80% methanolic and 100% methanolic extracts of a 
single source S. frutescens plant material using colorimetric and spectrophotometric analysis. 
The hot aqueous extractant was found to be the best extractant for S. frutescens, yielding 1.99 
g of crude extract from 16 g fresh powdered plant material. This data suggests that application 
of heat and water as the extractant (hot aqueous) could play a vital role in extraction of bioactive 
compounds from S. frutescens and also justifies the traditional use of a tea infusion of S. 
frutescens. Colorimetric analysis revealed the presence of flavonoids, flavonols, tannins, and 
phenols in all extracts with varying intensity. The organic extracts 100% methanol, 80% and 
100% ethanol exhibited high color intensity (+++) for flavonoids and flavonols respectively, 
while all the extracts exhibited a moderate color intensity (++) for tannins and phenols. 
Spectrophotometric analysis of S. frutescens extracts revealed that all the organic extracts 
contained a significantly higher concentration (in mg/g of extract) of flavonols and tannins 
when compared to the aqueous extracts. All extracts contained approximately equal levels of 
phenols. These data confirm the presence of all four groups of bioactive phytocompounds in 
the S. frutescens extracts used in this study, and also confirm that different solvent extractants 
possess the capability to differentially extract specific groups of phytocompounds. 
Analysis of the ion chromatogram generated from crude and solid phase extraction (SPE) 
fractions of S. frutescens extract, using the untargeted Triple TOF LC-MS/MS separation 
technique in positive and negative ionic mode, revealed the presence of multiple compounds 
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in individual extracts. Further comparison of these compounds with online databases of anti-
diabetic phytocompounds led to the preliminary identification of 10 possible anti-diabetic 
compounds; α-Pinene, Limonene, Sabinene, Carvone, Myricetin, Rutin, Stigmasterol, Emodin, 
Sarpagine and Hypoglycin B in crude and solid phase extraction (SPE) fractions of S. 
frutesecens. 
Furthermore, using two hepatic cell lines (Chang and HepG2) as an in-vtro model system, the 
anti-T2DM properties of crude aqueous and organic extracts of S. frutescents was investigated 
and compared. Both aqueous and organic extracts of S. frutescens were found to decrease 
gluconeogenesis, increase glucose uptake and decrease lipid accumulation (Triacylglycerol, 
Diacylglycerol, and Monoacylglycerol) in Chang and HepG2 hepatic cell cultures made insulin 
resistant (IR) following exposure to high concentration of insulin and fructose. 
Using real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), the 
aqueous and organic extracts of S. frutescens were confirmed to regulate the expression of 
Vesicle-associated membrane protein 3 (VAMP3), Mitogen-activated protein kinase 8 
(MAPK8), and Insulin receptor substrate 1 (IRS1) in insulin resistant hepatic cells. IR-
mediated downregulation of VAMP3, MAPK8, and IRS1 mRNA in IR HepG2 hepatic cell 
cultures was reversed in the presence of aqueous and organic extracts of S. frutescens. The hot 
aqueous extract displayed the highest activity in all the assays, while all the organic extracts 
displayed similar potency. 
In conclusion, this study reports that aqueous and organic extracts of S. frutescens possess 
numerous anti-diabetic compounds that can be further investigated for the development of new, 
more efficacious and less toxic anti-diabetic agents. The presence of multiple compounds in a 
single extract does suggest a synergistic or combinatorial therapeutic effect. These findings 
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support the burgeoning body of in-vivo and in-vitro literature evidence on the anti-diabetic 
properties of S. frutescens and its use in folklore medicine 
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CHAPTER ONE 
GENERAL INTRODUCTION 
1.1 Introduction 
 Medicinal plants represent the oldest source of pharmacotherapy used by mankind [1]. 
According to the World Health Organization (WHO), about 80% of the world's population now 
depend on traditional medicine for their primary healthcare needs [2] due to poverty and lack 
of access to modern medicine [3] (Figure 1.1) (Table 1). Hence, over the past decade the World 
Health Organization has undertaken various strategies to further identify and strategize on the 
future of traditional medicines (TM) around the world [4]. 
 
 
Figure 1.1: Global distribution of utilization of traditional medicine [5] 
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Table 1.1: Estimated global use of traditional medicine by patients and practitioners [6, 7] 
Region or country Extent of Use 
 
Africa 
 
 Used by 80% of the population for primary health care. 
 
China 
 
 Accounts for 30% - 50% of total health care. 
 Fully integrated into the health system, 95% of Chinese hospitals 
have TM units. 
 
India 
 
 Widely used, about 2,860 hospitals provide TM. 
 
Indonesia 
 
 Used by 40% of the entire population. 
 Used by 70% of the rural population. 
 
Japan 
 
 72% of physicians practice TM. 
 
Thailand 
 
 TM integrated into 1,120 health centers. 
 
Vietnam 
 
 
Western countries 
 
 Fully integrated into the health care system.  
 30% of the population is treated with TM. 
 
 TM not strongly integrated into the health care system.  
 
 
In October, 2013, the World Health Organization launched the WHO Traditional Medicine 
Strategy 2014-2023 [8] with the view of developing TM based research innovation in line with 
the “Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property” 
adopted at the 61st World Health Assembly in 2008. It is now widely accepted that the 
traditional medical knowledge of medicinal plants and their use by indigenous cultures is not 
only useful for conservation of cultural traditions and biodiversity, but also for community 
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healthcare and drug development in the present and future [2]. Consistent with this, emerging 
evidence from pharmaceutical companies shows that natural products (including medicinal 
plants) represent a valuable source for the production of new chemical entities for the treatment 
of complex diseases [9, 10]. Based on recent technological advances in science, the options to 
produce high quality herbal medicinal products have been largely improved and the acceptance 
of phytotherapy is considered as an alternative or adjunct to conventional therapy synthetic 
drugs is presently on the rise within the general public [1]. However, in spite of this, the use of 
medicinal plants for disease management has been heavily criticized by physicians and their 
respective societies, owing to limited research and clinical trials that clearly demonstrate their 
efficacy and safety.  
 
1.2 Phytotherapy in sub-Saharan Africa 
In Africa, the importance of medicinal plants in folklore medicine and their contribution to 
primary healthcare across the continent is well recognized [11]. Across the continent, the use 
of medicinal plants has successfully complemented the orthodox medical system in the fight 
against various diseases and infections [12]. Local herbal mixtures still provide the only 
therapeutic option for about 80% of the population [13], a situation compounded by a 
persistently low medical doctor-to-patient ratio (1:40,0000) [14] and long hospital waiting 
hours (6-12 hours) in some places [15]. Furthermore, a favorable ratio of one traditional 
medicine practitioner per 500 patients [16] has made traditional medicine the most accessible 
health care system for a large number of African populations resident in the rural and semi 
urban areas [17]. The therapeutic viewpoint of the use of medicinal plants is primarily based 
on their role in the prevention and promotion of good health, hence concoctions of plant 
extracts are regularly consumed as rejuvenators, tonics and/or nutritional supplements across 
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the continent [18]. This has led to a significant amount of biomedical and pharmacological 
research being done to validate the use of plant extracts as medicinal remedies in Africa [12].   
 
1.2.1 Botanical diversity: backbone of traditional medical practices in Africa  
The vast floral diversity in different parts of the African continent and the intrinsic 
ethnobotanical knowledge has been the backbone of localized traditional herbal medical 
practices for several years [19]. Most medicinal plants still remain locally derived, but are 
utilized worldwide for disease management. In Africa, an estimated 9% (5400) of the 60000 
described plant taxa possess over 16300 therapeutic uses [20]. Over the years, scientists have 
identified numerous plant species with potential against common ailments including malaria 
[21], HIV/AIDS [22], Tuberculosis [23], microbial infection [24, 25], cancer [26], pain and 
inflammation [27], helminthiasis [28] and diabetes mellitus [29] (Table 2). Today, plants 
emanating from Africa constitute approximately 8% of the 1100 medicinal plants 
commercialized globally [30], for example, Niprisan®, is a phytomedicine used in Nigeria for 
the management of sickle cell disorder [31]. 
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Table 1.2:  Selected African plants of therapeutic importance [19, 30] 
Family Species Common names Biological activity 
 
Aizoaceae 
 
Sceletium tortuosum 
 
Sceletium herb, 
Kanna, Channa, 
Kougoe 
 
Sedative  
Anti-depressant 
Annonaceae Xylopia aethiopica  African grains of 
Selim, Ethiopian 
pepper, Senegal 
pepper 
Anti-microbial 
Bronchitis 
Female infertility 
Anti-diuretic 
Apocynaceae Cryptolepis 
sanguinolenta  
Ghanaian quinine, 
Yellow- dye root 
 
Anti-cancer 
Anti-microbial 
Anti-malaria 
Anti-inflammatory 
Anti- 
hyperglycaemic 
Burseraceae Boswellia sacra Flueck. Frankincense, 
olibanum-tree 
 
Anti-microbial 
Anti-inflammatory 
Cytotoxic 
Rheumatoid 
arthritis 
Canellaceae 
  
Warburgia salutaris  Muranga, Pepper 
Bark Tree 
Anti-microbial  
Molluscicidal  
Anti-diuretic  
Cytotoxic 
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Family Species Common names Biological activity 
 
Combretaceae 
 
Terminalia sericea  
 
Silver cluster- 
leaf, Silver 
terminalia 
 
 
Anti-oxidant  
Anti-microbial  
Anti-inflammatory  
Anti-carcinogenic  
Anti-diabetic  
Adaptogen (stress 
and anxiety) 
Convolvulaceae 
 
 
 
Ipomoea pes-caprae 
subsp. brasiliensis  
Beach morning 
glory, Goat's 
foot 
 
Anti-microbial  
Anti-histaminic  
Anti-inflammatory  
Anti-spasmodic 
Euphorbiaceae Euphorbia hirta  Asthma plant, 
Red euphorbia 
 
Anti-microbial  
Anti-spasmodic  
Anti-protozoal  
Anti-inflammatory 
Geraniaceae Pelargonium sidoides Umckaloabo, 
South African 
Geranium 
Acute bronchitis 
Anti-microbial 
 Anti-virus 
Leguminosae Sutherlandia 
frutescens  
 
Cancer bush, 
Balloon pea, 
Sutherlandia 
 
Anti-oxidant  
Anti-inflammatory  
Anti-diabetic  
Anti-HIV 
Anxiety 
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Malvaceae Trichilia emetica 
Vahl 
Natal mahogany Anti-microbial   
Anti-inflammatory  
Anti-trypanosomal  
Anti-plasmodial  
Anthelmintic  
Hepatoprotective  
Pedaliaceae Harpagophytum 
procumbens 
Devil's claw Anti-inflammatory 
Analgesic 
Antioxidant  
Anti-malaria 
Rosaceae Prunus africana 
(Hook.f.) Kalkman 
Red Stinkwood Anti-microbial 
 Anti-malaria 
Anti-inflammatory 
Kidney disease 
Strelitziaceae Ravenala 
madagascariensis 
Sonn 
Traveller's tree, 
Traveller's palm 
Anti-microbial  
Anti-septic 
Xanthorrhoeaceae Aloe ferox Mill. Cape aloe Laxative 
Skin diseases 
Zygophyllaceae  Balanites aegyptiaca 
(L.) Delil 
Soapberry tree Anti-microbial 
Anti-oxidant  
Anti-malaria 
Anti-diabetic 
Anthelmintic 
Molluscicidal 
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1.3 Medicinal plants and traditional medical practices in South Africa 
Stretching between latitude 22°S to 35°S and longitude 17°E to 33°E, South Africa’s surface 
area covers 1, 219 602 km2 [32] inhabited by diverse ethnic groups/tribes including the Nguni’s 
(Zulu, Xhosa, Ndebele and Swazi people); Tsonga and Venda; Sotho-Tswana; Afrikaners; 
colored (a group which include the descendants of unions between indigenous and European 
people and a Muslim minority known as the “Cape Malays”); English; Indians; and the Khoi 
and the San tribe [33], who depend on several species of medicinal plants for the treatment of 
diverse human ailments [34]. With a therapeutic flora comprising of approximately 650 species 
[35] of which 148 are identified as the most widely used [36, 37],  herbal medical practitioners 
make use of a plethora of plants to treat different human diseases and infections.  
In the Zululand, medicinal plants are used for the therapeutic management of neurological 
disorders (convulsion, epilepsy, Alzheimer’s disease and Parkinson) [38], cutaneous bacterial 
infections (carbuncles) [39], gynaecological disorders, contraceptive and as an abortifacient 
[40]. Similarly, in the Limpopo Province, herbal concoctions are used for the management of 
gastrointestinal (GIT) disorders such as diarrhea [41], while in the Eastern and Western Cape 
Provinces herbal mixtures are used for the management of metabolic disorders such as diabetes 
mellitus [42] and cardiovascular conditions (hypertension) [43]. In addition, a number of these 
plants are also used as traditional veterinary medicine to treat common livestock diseases [44]. 
The dependence of a vast majority of the populace on medicinal plants as an alternative health 
care has prompted significant research investment in medicinal plants in the country, which 
can be regarded as the epicenter of innovation in African ethnopharmacology [12]. 
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1.4 Bioactive phytocompounds: potent therapeutic principle in medicinal plants 
The isolation of a pure pharmacological active compound “morphine” from seed pods of the 
poppy plant, Papaver somniferum by Friedrich Sertürner [45] initiated an era wherein 
phytochemicals from plants could be purified into drugs, to be studied and administered [46]. 
It is now widely accepted that the effectiveness of medicinal plants and their 
pharmacotherapeutic action is due to their complex diversity of chemical compounds [47]. 
Different plants may possess a wide spectrum of effects due to the presence of various groups 
of chemical compounds and various microelements [48]. Preparations obtained from a single 
plant can simultaneously be analgesic, sedative, cardiotonic, anti-inflammatory, and 
expectorant [48].  
 
1.5 Classification of bioactive phytocompounds 
Phytocompounds are classified by their biogenetic origin. Based on their biosynthetic 
pathways, bioactive phytochemicals can be classified into the following groups: alkaloids, 
glycosides (saponins, phenols, cyanogenic glycoside and cardiac glycosides), lactones, and 
others (e.g. pigments and ecdysones) [48, 49].  
 
1.5.1 Alkaloids  
Alkaloids are large groups of naturally occurring nitrogen-containing organic bases found in 
plants and certain animal species [50, 51]. According to the dictionary of Natural Products 
more than 27,000 naturally occurring alkaloids have already been identified [52]. A single plant 
species usually contains few kinds of alkaloids, but certain plant families such as 
 
 
10 
 
Ranunculaceae (buttercups), Solanaceae (nightshades), Amaryllidaceae (amaryllis), and 
Papaveraceae (poppies family) are particularly rich in alkaloids [53]. Similarly, certain 
alkaloids such as latrunculin A and batrachotoxin can be found naturally occurring in animal 
species, such as Negombata magnifica (Red Sea sponge) and Phyllobates spp. (poison dart 
frogs) respectively [53].  
For over 300 years, alkaloid-containing extracts have been used as therapeutics [53]. Toxic 
alkaloids (from plant extracts) such as curare, aconitine, and tubocurarine are used to poison 
arrows in hunting, or as weapons of warfare [54]. Morphine became the first alkaloid to be 
isolated by modern chemistry in the 19th century [55], since then several other alkaloids such 
as caffeine, coniine, and nicotine have been discovered [53]. Because of their potent biological 
effects, alkaloids and their derivatives have an array of pharmacological applications in 
contemporary medicine. These include anti-hypertensive (e.g. reserpine), anti-pyretics (e.g. 
quinine), antibacterial (e.g. ciprofloxacin), anti-hyperglycemic (e.g. piperine) analgesic (e.g. 
morphine), anti-asthmatic (e.g. ephedrine), anti-arrhythmic (e.g. quinidine), and anti-cancer 
(e.g. eberberine) effects [53].  
In contrast to other classes of natural compounds, alkaloids have practically unlimited 
structural frame works and contain an N atom in their molecules. For this reason, alkaloids are 
highly variable [56]. In plants, alkaloids are found mainly in leaves, seeds, or roots as salts of 
various organic and mineral acids. Their content varies widely depending on the species and 
its origin, the vegetation period of the plant, and the environmental conditions such as climate, 
soil, and humidity [56]. According to the distribution of their principal structure i.e. the 
principal C-N skeleton [56], alkaloids are classified into the following large groups: 
pyrrolidine, pyridine, quinoline, isoquinoline, indole, quinazoline, steroidal, diterpenoid, and 
other alkaloids, with each group subdivided into several subgroups depending on the structural 
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features of its representatives [57, 58]. 
 
 1.5.1.1 Pyrrolidine, Pyridine, and Piperidine alkaloids  
Pyrrolidine, pyridine and piperidine alkaloids are widely distributed in nature and have been 
found in about 27 plant species. These compounds are subdivided into simple derivatives of 
pyridine (3-methoxypyridine) and piperidine (coniine), and bi- and tricyclic uncondensed 
derivatives of pyridine (anabasine) and piperidine (lobeline). Codonopsine represent a new 
type of pyrrolidine base [56] (Figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Chemical structure of Pyridine (Anabasine), Piperidine (lobeline and piperidine), 
and Pyrrolidine (Condonopsine) alkaloids [56]. 
 
 
Taxonomy: Physicochemical and Pharmacological
Properties of Alkaloids – Pyridine, Piperidine, and
Pyrrolidine Alkaloids
Biological sources: Pedicularis olgae, Verbascum
nobile
C10H13NO: 163.0997
Mp: 133–134 C (Me2CO), 161 C (picrate) [1]
[a]D 0 (EtOH) [1]
UV: 262, 269(3.33, 3.23) [1]
IR: 3400-3200, 1595 [1]
MSm/z: 163(M+), 161, 146, 145, 131, 130, 119, 118,
117, 91, 77 [1]
1H NMR: 1.57, 1.98(each 2H, t, 2H-6, 2H-8),
2.40–3.05(4H, m, 2H-5, 2H-9), 4.01(2H, m, H-7,
OH), 6.93(1H, d, J ¼ 5, H-4), 8.19(2H, m, H-1,
H-3) [1]
References
1. A. Abdusamatov, S.Yu. Yunusov, Chem. Nat. Comp. 7, 294
(1971)
Piperidine
CASRegistry Number: 110-89-4
a
b
g
Taxonomy: Physicochemical and Pharmacological
Properties of Alkaloids – Pyridine, Piperidine, and
Pyrrolidine Alkaloids
Biological sources: Petrosimonia monandra
C5H11N: 85.0892
Bp: 106.5 C [1]
Mp: 246 C (hydrochloride), 152 C (picrate), 201 C
(chloroplatinate) [1]
[a]D 0 [1]
IR: 3270, 3080, 2930, 2845, 2800, 2730, 2670, 2625,
1468, 1442, 1385, 1365, 1345, 1330, 1319, 1286,
1259, 1191, 1168, 1148, 1118, 1051, 1037, 1009,
965, 940, 860, 825, 745 [2]
13C NMR: [3]
Table 1
C-a 47.3 C-b 27.2 C-g 25.4
References
1. N.K. Yurashevskii, S.I. Stepanov, Zh. Obshch. Khim. 9,
1687 (1939)
2. J. Holubek, O. Strouf, Spectral Data and Physical Constants
of Alkaloids (PraguePublishing House, Czechoslovak Acad-
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3. M. Shamma, D.M. Hindenlang, Carbon-13 NMR Shift
Assignments of Amines and Alkaloids (Plenum Press, New
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(+)-Plantagonine
Taxonomy: Physicochemical and Pharmacological
Properties of Alkaloids – Pyridine, Piperidine, and
Pyrrolidine Alkaloids
Biological sources: Catalpa speciosa, Pedicularis
dolichorhiza, P. ludwigii, P. macrochi lla, P. olgae,
P. rhinanthoides, P. violascens, Plantago indica,
Verbascum songoricum
C10H11NO2: 177.0790
Mp: 218–220 C (dec., Me2CO), 169 C (dec., nitrate)
[1]
[a]D +40 (MeOH) [1]
UV: 270(3.12) [2]
IR: 1715, 1595 [2]
MSm/z: 177(M+), 162, 133, 118, 91, 77 [2]
1H NMR: 1.15(3H, d, CH3) [2]
1H NMR (O-Meester): 1.26(3H, d, J¼ 7, CH3), 1.57,
2.29(each 1H, m, CH2), 3.12(3H, m, CH, CH2),
3.84(3H, s, OCH3), 8.44, 8.88(each 1H, s, 2
H-Ar) [3]
(+)-Plantagonine 523
(+)-Anabasine [C10H14N2] (±)-Lobeline [C22H27NO2] 
Piperidine [C5H11N] Codonopsine [C14H21NO4] 
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1.5.1.2 Quinoline alkloids 
Quinoline alkaloids are found in about 13 plant families. However, most quinoline alkaloids 
have been isolated from plants of the genus Haplophyllum from the Central Asian region. 4-
hydroxyquinolin-2-one is an example of a quinolone alkaloid [59] (Figure 1.3). 
 
 
 
 
 
 
Figure 1.3: Chemical structure of quinoline (quinoline and 4-hydroxyquinolin-2-one) 
alkaloids [56] 
 
 
1.5.1.3 Isoquinoline alkaloids (Aporphine alkaloids) 
Isoquinoline alkaloids represent a large family (more than 700 compounds) [56, 60] of 
medicinal alkaloids found abundantly in plant families including Berberidaceae, Fumariaceae, 
Magnoliaceae, Papaveraceae, and Ranunculaceae [61].  Largely represented by aporphine 
alkaloids, isoquinoline alkaloids have a biphenyl system, which can be substituted (di-, tri-, 
tetra-, penta-, and hexa) with a hydroxyl, methoxyl, and methylenedioxy derivatives on all four 
rings [56]. Morphine and Berberine are examples of isoquinoline alkaloids (Figure 1.4) 
 
Quinoline [C9H7N] 4-hydroxyquinolin-2-one [C9H7NO2] 
 
 
13 
 
 
 
 
 
 
 
    Figure 
1.4:Chemical structure of isoquinoline (Berberine and Morphine) alkaloids [60, 61] 
 
1.5.1.4 Indole alkaloids 
Indole alkaloids consist of a large family of compounds (about 4100) [62]  that contain an 
indole moiety (an aromatic heterocyclic organic compound) included in their structure [63]. In 
addition, many indole alkaloids also include isoprene groups and are thus called terpene indole 
alkaloids [64]. These complex organic compounds possess significant biological activities and 
some of them are used in medicine [64]. Examples are ajmalicine from Catharanthus roseus 
and yohimbine from Rauwolfia serpentine which are used as an anti-hypertensive and an 
adrenergic receptor blocker, respectively [64-66] (Figure 1.5). 
 
 
 
 
 
 
 
Figure 1.5: Chemical structure of indole (Ajmalicine and yohimbine) alkaloids [56] 
Berberine [C20H18N+O4] Morphine [C17H19NO3] 
Ajmalicine [C12H24N2O3] Yohimbine [C21H26N2O3] 
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1.5.1.5 Quinazoline alkaloids  
Quinazoline alkaloids form a small group of secondary natural occurring heterocyclic 
compounds [67]. Pharmacological studies of the properties of quinazoline alkaloids and their 
synthetic analogs revealed their anti-inflammatory [68], anti-HIV [69] and bacterial [70] 
properties. An example of quinazoline alkaloids is vasicinone, an anti-cancer compound 
obtained from methanolic extracts of Peganum harmala seed [71] (Figure 1.6).  
 
 
 
 
 
Figure 1.6: Chemical structure of quinazoline  (Vasicinone) alkaloid [56] 
 
1.5.1.6 Steroidal alkaloids 
Steroidal alkaloids are an important class of alkaloids and secondary metabolites isolated from 
about 30 species of plant genera including Veratrum, Petilium, Korolkowia, Rhinopetalum, 
Fritillaria, Zygadenus (Liliaceae), Solanum (Solanaceae), and Buxus (Buxaseae) [72]. Similar 
to other alkaloids, steroidal alkaloids and their glycosides have been reported to have arrays of 
bioactivities, including anti-microbial [73], anti-inflammation [74]  and anti-nociceptive [75] 
actions. An example of steroidal alkaloid is α-chaconine (Figure 1.7), which has been shown 
to exhibit anti-cancer activity in-vitro [76, 77].  
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Figure 1.7: Chemical structure of steroidal (α-
chaconine) alkaloid [56, 77] 
 
1.5.1.7 Diterpenoid alkaloids 
Diterpenoid alkaloids were first isolated from roots of the plant genera Aconitum and 
Delphinium [78]. Based on extensive spectroscopic analyses diterpenoid alkaloids, have been 
structurally classified into three categories as C18-, C19-, and C20- [79]. Diterpenoid alkaloids 
have been shown to exhibit anti-inflammatory (Lappaconitine) in vitro [80] (Figure 1.8), anti-
cancer [81, 82] and anti-viral [79] activities.  
 
 
 
 
 
 
 
 
 
α-Chaconine [C45H73NO14] 
Lappaconitine [C32H44N2O8] 
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Figure 1.8: Chemical structure of diterpenoid (Lappaconitine) alkaloid [56, 80] 
1.5.1.8 General physical and chemical properties of alkaloids 
Alkaloids can exist in solid state (atropine) or liquid state. The solutions of alkaloids are known 
to be intensely bitter [83].  Alkaloids are basic in nature and the degree of basicity varies 
considerably, depending on the structure of the molecule and the presence and location of 
functional groups [84]. Alkaloids react with acids to form crystalline salts without the 
production of water [85]. Although alkaloids are sparingly soluble in water, most alkaloids and 
their salts are readily soluble in alcohol [86].  
 
1.5.2 Glycosides 
Plant glycosides are organic compounds composed of a sugar (glycoside, glycone) and a non-
sugar (aglycone, genin) moiety [48, 85], with the aglycone forming the main physiologically 
active part [48]. The glycone (sugar moiety) can be attached to the aglycone in several ways. 
The most common bridging atom is oxygen (O-glycoside), however, it can also be sulphur (S-
glycoside), nitrogen (N-glycoside) or carbon (C-glycoside). Based on the chemical nature of 
the aglycone, type of sugar constituent or pharmacological action, glycosides are categorized 
into saponins (the aglycones are triterpene and steroid compounds), phenolics (the aglycones 
are coumarins, flavonoids and others), cyanogenic glycosides (the aglycones contain prussic 
acid), cardiac glycosides (the aglycones are cardinolides and bufadienolides), anthraglycosides 
(the aglycones are derivatives of anthracene), and glycoalkaloids (the aglycones are nitrogen-
containing steroid compounds) [48, 86]. Furthermore, based on the configuration of the 
hemiactal hydroxyl group, glycosides can be classified as α-glycosides or β-glycosides.  The 
majority of the naturally occurring glycosides are β-glycosides [87].  
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1.5.2.1 Saponins 
Saponins are naturally occurring high molecular weight glycosides originally isolated from the 
root of Saponaria vaccaria (soapwort plant) [88, 89]. Saponins are natural surfactants and 
detergents, giving stable foams in water [90]. The non-sugar (aglycone) portion of saponin is 
called sapogenin (genin) [90]. Depending on the type of genin present, saponin can be 
classified into three major classes: steroidal alkaloid saponin, steroidal saponin and 
triterpenoidal saponin [86, 90] (Figure 1.9). Furthermore, based on the numbers of sugars 
chains attached to the aglycone, saponins can be grouped into monodesmosidic (one sugar 
chain), bidesmosidic (two sugar chain) or tridesmosidic saponin (three sugar chain) (rarely 
found) [90] (Figure 1.10). Saponins are soluble in water and alcohol, but insoluble in non-polar 
organic solvents. Saponins are constituents of many plant drugs used in folk medicine. In 
contemporary medicine, the therapeutic uses of saponins include: expectorants, diuretics, 
hypocholesterolemics, and hypotensives [48]. However, in spite of their therapeutic usage, 
saponins are extremely toxic, causing irritation to the mucous membranes and hemolysis of the 
red blood cells when introduced intravenously [48, 91]. 
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Figure 1.9: Chemical structure of Triterpenoidal saponin, Steroidal saponin and Steroidal 
alkaloid saponin [90] 
 
1.5.2.2 Phenolics (phenols) 
Phenolics are compounds that possess one or more aromatic ring with one or more hydroxyl 
groups [92]. Phenols are broadly distributed in plants, where they function in defense, as well 
as contributing to plants’ colors [92]. More than 8,000 phenolic structures are currently known 
[92]. Phenols have the most diverse pharmacological activity. Amongst them are compounds 
with anti-hypoxic, anti-oxidant, choleretic, cardio-, angio-, and hepato- protecting and 
hemostatic actions [48]. Plant phenolics are classified into phenolic acids, flavonoids, tannins 
and the less common stilbenes and lignans [91, 92].  
Triterpenoidal saponin 
Steroidal saponin Steroidal alkaloid saponin 
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1.5.2.3 Phenolic acid  
Phenolic acids can be divided into two groups: derivatives of benzoic acid (gallic acid) (Figure 
1.11) and derivatives of cinnamic acid (coumaric, caffeic and ferulic acid). Caffeic acid is 
regarded as the most abundant phenolic acid, distributed in many fruits and vegetables [92]. 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Chemical structures of phenolic (gallic, ferulic and caffeic) acids [92]  
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1.5.2.4 Flavonoids 
Flavonoids are a group of heterocyclic polyphenolic compounds widely distributed in plant 
flora [83] . The basic flavonoid structure is the flavan core, containing 15 carbon atoms 
arranged in three rings (C6-C3-C6), labeled A, B and C. Based on the oxidation state of the 
central C ring, flavonoids are divided into six subgroups namely: flavones, flavonols, flavanols, 
flavanones, isoflavones, and anthocyanins [86, 92] (Figure 1.12). Within each subgroup, 
structural variation is partly dependent on the degree and pattern of hydroxylation, 
methoxylation, prenylation, or glycosylation.  
 
 
 
 
Figure 1.12: Chemical structures of flavonoids (flavanone, flavanol, flavone, flavonol) [92]. 
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1.5.2.5 Tannins 
Tannins are subdivided into two major groups: hydrolysable tannins and condensed tannins 
[83]. Hydrolysable tannins are compounds containing a central core of glucose or another 
polyol esterified with gallic acid, called gallotannins, or with hexahydroxydiphenic acid, called 
ellagitannins [93]. Common examples of hydrolysable tannins include theaflavins (from tea), 
daidezein, genistein and glycitein [93] (Figure 13). Condensed tannins also called 
proanthocyanidins are oligomers or polymers of flavan-3-ol linked through an interflavan 
carbon bond (Figure 1.13). Tannins possess a wide variety of structures due to the many 
possibilities in forming oxidative linkage [93]. Tannin-rich medicinal plants are used as healing 
agents in a number of diseases including: diarrhea, leucorrhoea, and rhinorrhea [83]. 
 
 
 
 
 
 
 
Figure 1.13: Chemical structure of Tannin (theaflavin and proanthocyanidin) [92] 
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1.5.2.6 Cyanogenic glycosides 
Cyanogenic glycosides (CGs) are bioactive secondary metabolites of plants derived from 
amino acids with oximes and cyanohydrins (α-hydroxynitriles) as key intermediates [94]. The 
distribution of cyanogenic glycosides in the plant kingdom is relatively wide. About 2500 plant 
species belonging to families Fabaceae, Rosaceae, Linaceae, and Compositae are rich in CGs 
[95]. CGs are stable compounds, but when the β-glycosidic linkage is hydrolysed through the 
action of a β-glycosidase, the unstable cyanohydrin that is formed dissociates to release 
hydrogen cyanide in a process known as cyanogenesis [96]. Acute or chronic exposure to 
hydrogen cyanide can lead to severe morbidity or mortality in humans [94], and animals [97] 
due to its role in inhibiting the activity of cytochrome c oxidase, the final enzyme in the 
respiratory electron transport chain [98]. Prunasin and linamarin are examples of cyanogenic 
glycosides (Figure 1.14). 
 
 
 
 
 
 
Figure 1.14: Chemical structures of prunasin and linamarin (cyanogenic glycosides) [94]. 
 
1.5.2.7 Cardiac glycosides 
Cardiac glycosides are secondary metabolites found in diverse groups of plants including 
Prunasin Linamarin 
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Digitalis purpurea and Digitalis lanata (foxgloves), Nerium oleander (common oleander), 
Thevetia peruviana (yellow oleander), Convallaria majalis (lily of the valley), Urginea 
maritima and Urginea indica (squill) [99]. In clinical practice, cardiac glycosides are used in 
the treatment of congestive heart failure and cardiac arrhythmia (Digoxin; derived from 
Digitalis purpurea) [100] (Figure 1.15). 
 
 
 
 
 
 
Figure 1.15: Chemical structure of cardiac glycoside (Digoxin) [100] 
 
1.5.2.8 Anthraglycosides 
Compounds belonging to the anthraglycosides are reddish in color. Plant extracts containing 
anthraglycosides exhibit purgative and choleretic actions [48].  
 
1.5.2.9 Glycoalkaloids 
Glycoalkaloids are secondary plant metabolites found in the family Solanaceae that include 
species such as Solanum tuberosum (potato) and Solanum lycopersicum (tomato). They may 
be toxic to bacteria, fungi, viruses, insects, animals and humans at differing concentrations 
[101]. In plants, glycoalkaloids (e.g. solamargine) have been shown to exhibit phytoparasitic 
Digoxin [C41H64O14] 
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nematocidal activity against root-node nematodes [102]. In humans, glycoalkaloids (solanine) 
(Figure 1.16) have been shown to exhibit anti-allergic properties in patients suffering from 
allergy to nightshade and cereals [101]. Similarly, in normal and adrenalectomized rats, 
intraperitoneal injection of solanine has been shown to induce a reversible decrease in blood 
sugar [101]. Furthermore, several in-vitro cell lines and animal studies have demonstrated the 
anti-pyretic, anti-inflammatory and anti-cancer properties of plant glycoalkaloids [101, 103, 
104]. 
 
 
 
 
 
 
 
 
 
Figure 1.16: Chemical structure of solanine (glycoalkaloid) [101] 
 
1.5.2.10 General physical and chemical properties of glycosides  
Glycosides are colorless, crystalline carbon, hydrogen and oxygen-, nitogen-, or sulfur-
containing water-soluble phytocompounds found in the cell sap. Glycosides are neutral in 
reaction and can be readily hydrolysed into their components with ferments or mineral acids 
[83].  
Solanine [C45H73 NO15] 
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1.6 Factors influencing levels of bioactive phytocompounds in medicinal plants 
Variations in the level and type of phytochemicals found in plants largely depend on the active 
biosynthetic pathways during plant growth and development. Within the plant, biosynthetic 
pathways can be regulated by both intrinsic factors (genetic or species variation) and extrinsic 
factors (environmental conditions) [105].  
 
1.6.1 Species variation 
Over the years, several studies have shown that the phytochemical content found in plants 
exhibits high levels of interspecies and intraspecies variations [105]. However, while species 
variation invariably influences phytochemical content, interaction with environmental 
conditions can also influence the level of phytochemicals found in the same plant species.  
 
1.6.2 Environmental conditions  
Environmental factors such as soil composition, ultraviolet radiation, temperature variation and 
climatic conditions (rainfall and humidity) within a geographical location can affect the 
concentration of phytochemicals present in plants [105]. Wang et al. (2001) established a 
relationship between the level of phenolic acid, flavonols and anthocyanin content of plants 
with varying day/night temperature. In this study, a decrease in the level of phenolic acid was 
associated with day/night temperature of 18/22 °C, whereas an increase was observed with 
temperatures between 25/30 °C during the growing season [106]. In a similar study by Pék et 
al. (2013), levels of bioactive compounds in Brassica oleracea were found to vary significantly 
with environmental conditions and water status [107].  
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1.7 Processing of bioactive phytocompounds 
1.7.1 Extraction of bioactive phytocompounds 
Extraction of bioactive phytocompounds from plants materials is the principal step in the 
utilization of phytochemicals in therapeutic concoction or pharmaceutical products [92]. 
Phytocompounds can be extracted from fresh, frozen or dried plant samples. It has been shown 
that the extraction conditions can influence the level and bioavailability of phytochemicals in 
the therapeutic concoction. For example, freeze-drying has been shown to retain higher levels 
of phenolics content in plant samples than air-drying [108, 109]. Methods of phytochemical 
extraction include: solvent extraction, ultrasound-assisted extraction (UAE), pressurized liquid 
extraction (PLE) or accelerated solvent extraction (ASE), and microwave-assisted extraction 
(MAE) [110].  
 
1.7.2 Solvent extraction 
Solvent extraction is the most widely used procedure to prepare extracts from plant. A variety 
of chemical extractants are used, based on their ease of use, efficiency, and wide applicability 
[92]. Solvents of varying polarity (hexane, carbon tetrachloride, di-isopropyl ether, ethyl ether, 
methylene dichloride, tetrahydrofuran, chloroform, acetone, ethanol, ethyl acetate, methanol, 
water or mixtures of different solvents) are used on the plant material [111]. The yield and 
composition of extracted phytocompounds in chemical extraction is dependent on the solvent 
polarity, extraction time and temperature, sample-to-solvent ratio, as well as the chemical 
composition and physical characteristics of the samples [92]. Similarly, the type of solvent 
used may have an effect on the nature of the compounds extracted, and the resulting bioactivity 
of the extract [111]. To evaluate each extractant, parameters including the rate of extraction, 
the quantity extracted, the diversity of compounds extracted, the ease of subsequent handling 
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of the extracts, toxicity of the solvent in the bioassay process and the potential health hazard of 
the extractant must be considered [112].  
 
1.7.3 Ultrasound assisted extraction (UAE) 
Ultrasound-assisted extraction (UAE) is a potentially useful and cost effective technology that 
does not require complex instruments. UAE can be used for both small and large-scale 
phytopharmaceutical extraction [113]. The mechanism of action of UAE involves the shear 
force generated by implosion of cavitation bubbles upon the propagation of acoustic waves in 
the kHz range [114]. Collapse of bubbles can produce physical, chemical and mechanical 
effects, resulting in the disruption of biological membranes, that enhances penetration of 
solvent into cellular materials to augment the release of extractable compounds [115]. UAE 
has been widely used in the extraction of various phenolic compounds from different parts of 
plants, including leaves [116], stalks, fruits [117, 118], and plant seeds [119]. In addition to 
time conservation, UAE has been shown to cause less degradation of phytocompounds 
compared to other methods of extraction [120].  
 
1.7.4 Pressurized liquid extraction (PLE) or accelerated solvent extraction (ASE) 
Pressurized liquid extraction (or ASE) is a relatively new method for phytochemical extraction 
that involves a high temperature and pressure. In PLE, applied pressure allows the use of 
extraction solvents at temperatures greater than their normal boiling point [92]. The combined 
use of high pressures (3.3-20.3 MPa) and temperatures (40-200°C) provides faster extraction 
processes that require small amounts of solvents (e.g. 20 min using 10–50 mL of solvent, 
compared to conventional extraction methods that require 10 – 48 hours and up to 200 mL of 
 
 
28 
 
solvent) [121]. High temperature and pressure improves analyte solubility and the desorption 
kinetics from the matrices [122]. Hence, extraction solvents including water which show low 
efficiency at low temperatures may be much more efficient at elevated PLE temperatures [92]. 
Another technique of compressed fluid extraction is the supercritical or subcritical fluid 
extraction (SFE) method that involves the use of compressed carbon dioxide as an extraction 
solvent. SFE is performed in the absence of both light and air; degradation and oxidation 
processes are significantly reduced in comparison with other extraction techniques [92].  
Taken together, compressed fluid-base extraction techniques are more environmentally 
friendly procedures than other methods, in that they reduce use of organic solvents and allow 
extraction performed with nonpolluting, nontoxic solvents (water and CO2). However, the 
complex instrumentation requirements and high cost often outweigh the technical benefits of 
these methods.  
 
1.7.5 Microwave-assisted extraction (MAE) 
Microwave-assisted extraction involves the use of microwave energy to facilitate partitioning 
of analytes from the sample matrix into the solvent. The main advantage of MAE is the reduced 
extraction time and solvent volume compared to conventional extraction methods [123]. MAE 
has been used for the extraction of  small-molecule phytocompounds such as ellagic acid [124], 
isoflavone [125], and quercetin [126], which were shown to be stable under microwave-
assisted heating conditions at temperature up to 100°C for 20 min [127].   
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1.8 Purification and fractionation of bioactive phytocompounds 
Crude plant extracts usually contain a mixture of large amounts of phytochemicals present at 
various concentrations. Hence, there is a need to separate the bioactive components from other 
co-extractives, once extracted from the plant. Purification steps may involve the use of 
techniques such as sequential extraction, liquid-liquid extraction, solid phase extraction (SPE), 
and/or chromatographic (column chromatography) methods in order to fractionate the 
compounds based on their acidity, polarity or molecular size.   
 
1.8.1 Liquid-liquid extraction (LLE) 
Liquid–liquid extraction is one of the most common purification method used, particularly for 
the separation of organic compounds from aqueous matrices. The principle of LLE is centered 
on the relative solubility of an analyte in two immiscible phases (a liquid stationary phase and 
a liquid mobile phase). Analyte are separated according to their partition coefficients between 
the two solvent phases based on their solubilizing power (polarity) [128, 129].   
 
1.8.2 Solid phase extraction (SPE) 
Solid phase extraction is a method of sample purification that separates and concentrates 
analytes from a solution of crude extracts (liquid phase) by adsorption onto an adsorbent (solid-
phase) cartridge. Post retention, analytes are subsequently recovered by elution with an 
appropriate solvent (mobile phase) [130]. SPE media include reverse phase, normal phase, and 
ion-exchange media. SPE is becoming popular since it is rapid, economical, and sensitive. 
Different cartridges and discs with a great variety of sorbents can be used, making it possible 
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to simultaneously extract analytes with an extremely wide range of polarities [130].  
 
1.8.3 Column chromatography (CC) 
Column chromatography has also been employed for the fractionation of analytes from a crude 
plant extract. Although often labor-intensive and solvent consuming, CC provides greater 
amounts of fractions for subsequent isolation and identification of pure substances. Commonly 
used column sorbents are toyopearl [131], RP-C18 [132], LH-20 [133] and, to a lesser extent, 
polyamide resin [134]. While ethanol, methanol, acetone, and water at various volume 
combinations are frequently used as eluents.  
 
1.9 Analysis and quantification of bioactive phytocompounds 
The selection of the appropriate analytical strategy for studying phytocompound constituents 
of crude plant extracts depends on the purpose of the study, nature of the sample and the analyte 
[135]. Quantification of compounds in plant extract is influenced by the presence of interfering 
substances, the chemical nature of the analyte, assay method and selection of standards [136]. 
In the phytochemical evaluation of plant extracts, different colorimetric and 
spectrophotometric methods have been used. Spectrophotometric assays provide simple and 
fast screening methods to quantify classes of phytocompounds in crude plant extracts. 
However, modern high-performance chromatographic techniques (liquid chromatography 
(LC), high performance liquid chromatography (HPLC), and gas chromatography (GC))  
combined with instrumental analysis are the “state of art” for analysis and quantification of 
bioactive compounds [92]. Furthermore, the recent approaches of applying chromatography 
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and mass spectrometry, such as liquid chromatography-mass spectrometry (LC-MS), high 
performance liquid chromatography–mass spectroscopy (HPLC–MS) and gas 
chromatography–mass spectroscopy (GC–MS) provide additional spectral information for 
qualitative analysis [137].  
 
1.10 Mechanism of action of bioactive phytocompounds  
Over the years, different mechanisms of action have been proposed for bioactive 
phytocompounds. Bioactive phytocompounds have been suggested to mediate their therapeutic 
effects by inhibiting microorganism growth (anti-microbial action), or modulating metabolic 
processes, gene expression and/or signal transduction pathways (anti-diabetic, anti-cancer 
action) [138-140]. In addition, in contrast to synthetic pharmaceuticals drugs, it has been 
suggested that many phytomedicines and herbal concoctions exert their therapeutic effects 
through the additive or synergistic action of several chemical compounds acting at single or 
multiple target sites associated with a physiological processes [141]. Studies on how synergistic 
interactions of phytochemicals augment their therapeutic potency have been documented [141, 
142]. In a study by Jamaluddin et al. (1994), the synergistic interaction between  β-Sitosterol 
and Stigmasterol in mediating hypoglycemia in alloxan-induced diabetic rats was confirmed 
when individual compounds showed no hypoglycemic effects when tested separately [143]. 
This synergistic or additive pharmacological effect of a complex mixtures could also be more 
toxic since they possibly contain more xenobiotic compounds [141].  
1.11 Anti-diabetic medicinal plants and anti-diabetic phytocompounds 
Diabetes Mellitus (DM) is a chronic debilitating metabolic disorder, associated with severe 
complications, that affect millions of people globally, irrespective of their socio-economic 
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profile and geographical location [144]. Considered the fourth leading cause of death by 
diseases, DM is a global health crisis with an estimated diagnosis and mortality frequency of 5 
seconds and 7 seconds, respectively [145, 146]. Management involves the use of conventional 
agents (oral hypoglycemic or insulin therapy) along with lifestyle modification [144]. 
However, despite the introduction and extensive utilization of hypoglycemic agents, diabetes 
and diabetes-related complications continue to increase globally, affecting nearly 10% of the 
world’s population [147]. According to WHO, DM related deaths will increase by more than 
50% in the next 10 years if the disease is not given urgent attention. Hence, research on DM 
treatment and discovery of new medications is gaining ground, as the world population of 
patients with diabetes increases from 382 million in 2013 to a projected 592 million by 2035 
[148, 149].  
Medicinal plants continue to be an important therapeutic aid for alleviating ailments of 
humankind, and because of their enormous therapeutic potential, medicinal plants are being 
extensively explored for their use in the management of DM [150]. This is  due in part to the 
high economic cost [151, 152] and undesirable side-effects associated with conventional anti-
diabetic drugs [153], leading WHO to support the utilization of herbal remedies for the 
management of diabetes [144]. Presently, numerous medicinal plants have been reported to be 
effective in diabetes therapy, however intensive research is still needed.  
 
1.12 Incidence and prevalence of DM 
According to the International Diabetes Federation (IDF) Atlas 2014, the global prevalence of 
diabetes is estimated to be 8.3%, representing 387 million people, and is expected to increase 
by an additional 205 million people by 2035 [146]. The occurrence of diabetes is higher in men 
than in women [144]. About 77-80% of people living with diabetes reside in the low and middle 
income countries [146, 154]. 
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In Africa, an estimated 22 million cases, with a prevalence of 5.1%, has been reported [155].  
In 2014, the Republic of South Africa was reported to have 2.713 million people within the age 
of 20-79 years living with DM [155]. 
 
1.13 Morbidity and mortality rate of DM 
In 2012, an estimated 1.5 million deaths were directly caused by diabetes globally [154]. In 
Africa, an estimated 481,000 deaths was projected in 2014, 75% of which will be < 60 years 
old [155]. 
 
1.14 Classification  
 Based on etiology, pathophysiology and clinical presentation, diabetes mellitus is divided into 
three main types: Gestational diabetes (pregnancy related diabetes), type 1 (insulin-dependent 
diabetes mellitus or IDDM or juvenile-onset diabetes) and type 2 (non-insulin-dependent 
diabetes mellitus or NIDDM).  
 
1.15 Pathogenesis of diabetes mellitus 
1.15.1 Gestational diabetes 
Gestational diabetes develops during pregnancy. Typically, it disappears after delivery, 
although the condition is associated with an increased risk of developing diabetes later in life 
[156]. 
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1.15.2 Type 1 DM 
1.15.2.1 Autoimmune factor 
Type 1 diabetes mellitus (T1DM) is categorized as an autoimmune-mediated (type IA) or 
idiopathic (type IB) form of the disease. It is more pronounced in children and young adults, 
and is characterized by the destruction of pancreatic β-cell islets resulting in absolute insulin 
deficiency, hence patients depend entirely on an exogenous supply of insulin [157]. About 80% 
of patients with T1DM have islet cell autoantibodies [158]. Autoantibodies to a variety of β-
cell constituents including insulin, isoforms of glutamic acid decarboxylase (GAD 65 and GAD 
67), and the secretory granule protein islet cell antigen (ICA) 512 or IA-2, have been 
recognized [158]. The concept of T1DM being a chronic autoimmune disease is supported by 
the fact that islet antigen-directed antibodies may be present in asymptomatic first-degree 
relatives of patients [159]. The chance of developing T1DM is greater than 50% if 
autoantibodies are present to more than one β-cell antigen (i.e., insulin, GAD 65, ICA 512); 
T1DM rarely develops in antibody-negative relatives [159]. β-cell destruction is mediated by 
a variety of cytokines or by direct T-lymphocyte activity [159]. As the disease progresses, the 
islets become completely devoid of β-cells while the α, δ, and pancreatic polypeptide cells are 
left intact, thus illustrating the exquisite specificity of the autoimmune attack [159]. However, 
in addition to autoimmune factors, genetics and environmental factors have also been 
implicated in type1 pathophysiology.  
 
1.15.2.2 Genetic factors 
The role of genetic factors in T1DM is underlined by data in identical twins showing 
concordance rates of 30 to 40%. The HLA (human leukocyte antigen) genes located on short 
arm of chromosome 6 (p6) (i.e., the IDDM1 locus) clearly play a dominant role in the genetic 
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susceptibility that leads to risk of T1DM [160]. Of the HLA types, HLA class II show the 
strongest association with T1DM, with haplotypes DRB1*0401-DQB1*0302 and DRB1*0301-
DQB1*0201 conferring the greatest susceptibility, while DRB1*1501 and DQA1*0102-
DQB1*0602 provide disease resistance [161]. Class I HLAs have also been implicated in the 
risk of T1DM, independent of class II molecules [160]. However, since concordance rates are 
not 100%, environmental factors must be important for disease expression.  
 
1.15.2.3 Environmental factors 
Although environmental factors such as diet and toxins have been proposed as triggers of 
T1DM, no environmental agent or agents have been proven to be a causative agent [158]. To 
date, scientific attention has focused on viral infections (e.g. coxsackievirus and 
cytomegalovirus) [162], early infant diet (e.g. breast feeding versus early introduction of cow's 
milk components) [163], and toxins (e.g., N-nitroso derivatives) [164].  
 
1.15.3 Type 2 Diabetes Mellitus (T2DM)  
Type 2 diabetes mellitus (T2DM or NIDDM) is the most common type of the disease 
characterized by a complex interaction between numerous genes, environmental and 
behavioural risk factors [165]. Onset of T2DM is generally in adulthood; largely occurring in 
people between the ages of 30-60 years. However early onset of the disease has recently been 
documented in children with an average age range of 10-20 years [165]. Prevalence is 
increasing rapidly throughout the world [166].  
Although the pathophysiology of T2DM is not entirely understood, T2DM is a multifactorial 
disease characterized by an initial peripheral insulin resistance in adipose tissue, liver, and 
skeletal muscle with subsequent pancreatic β-cell dysfunction resulting from an attempt to 
compensate for insulin resistance [167, 168]. The development of insulin resistance and T2DM 
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progression are often associated with obesity [168, 169]. Insulin resistance in T2DM refers to 
the failure of cells to respond to normal levels of circulating insulin with respect to glucose 
uptake, metabolism or storage [170].  
 
1.15.3.1 Insulin biosynthesis and secretion 
Insulin is primarily an anabolic hormone that promotes the storage and synthesis of lipids, 
proteins and carbohydrates, and inhibits their breakdown and release into circulation [171]. 
Insulin is a peptide hormone comprising of 2 polypeptide chains; A (21 amino acid residues) 
and B (30 amino acid residues) with a molecular weight of 5808Da. Chains A and B are linked 
by disulphide bridges. In addition the A-chain contains an intra-chain disulphide bridge linking 
residue 6 and 11. The C chain, which connects the A and B chains, is liberated along with 
insulin after breakdown of proinsulin. Insulin monomers aggregate to form dimers and 
hexamers [172]. 
 
1.15.3.2 Biosynthesis 
Insulin is synthesized in the beta (β) cells of the pancreas in the form of pre-proinsulin which 
is the ultimate precursor. Post synthesis pre-proinsulin is discharged into the cisternal space of 
the rough endoplasmic reticulum, where it is cleaved into proinsulin by proteolytic enzymes. 
Proinsulin with a C (connecting) chain linking the A and B chains is transported by 
microvesicles to the Golgi apparatus, with proinsulin then released in vesicles. Conversion of 
proinsulin to insulin then continues within maturing granules through the action of the 
prohormones convertase 2 and 3, and carboxypeptidase H [173]. Maturing granules are 
translocated to the β cell plasma membrane for secretion, with the help of microtubules and 
microﬁlaments.  
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1.15.3.3 Secretion 
Insulin is secreted from the pancreatic β-cells in response to various stimuli such as glucose 
(major physiological determinant), arginine, and sulphonylureas [174]. Similarly, various 
neural, endocrine and pharmacological agents can also exert a stimulatory effect. Glucose is 
taken up by β cells via glucose transporter (GLUT)-2 receptors. Once in the β-cells, glucose is 
oxidized by glucokinase, which acts as a glucose sensor. Glucose concentrations below 90 
mmol/L have been shown not to induce any insulin release [174]. At such sub-stimulatory 
glucose concentrations, K+ efﬂux through open KATP channels keeps the β cell membrane at a 
negative potential, hence causing the closure of the voltage-gated Ca2+ channels. However, in 
the presence of increased plasma glucose concentration, glucose uptake and metabolism by the 
β cells act as insulin secretogogues by closing KATP channels to induce insulin secretion [174].  
 
 
1.15.3.4 Insulin signaling 
Insulin action is mediated via its binding to, and activation of its cell-surface receptor. The 
insulin receptor belongs to a subfamily of receptor tyrosine kinases (RTK) that includes the 
insulin-like growth factor (IGF)-I receptor and the insulin receptor-related receptor (IRR) 
[175]. These receptors are tetrameric proteins consisting of two extracellular α subunits that 
bind insulin and two transmembrane β subunits with tyrosine kinase activity, linked by a 
disulphide bond into a α2β2 heterotetrameric complex. Binding of insulin to the α-subunit on 
the IRR subsequently triggers the transphosphorylation of one β subunit, resulting in the 
increased catalytic activity of the kinase [176].  
Once activated, the insulin receptor phosphorylates downstream signaling tyrosine molecules, 
including members of the insulin receptor substrate family (IRS1/2/3/4), the Shc adapter 
protein isoforms, SIRP family members, Gab-1, Cbl, and APS. Phosphorylation of the IRS 
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proteins create recognition sites for additional effector molecules containing Src homology 2 
(SH2) domains. These include the small adapter proteins Grb2 and Nck, the SHP2 protein 
tyrosine phosphatase and, most importantly, the regulatory subunit of the class 1a 
phosphatidylinositol-3-kinase (PI3-kinase) [177]. Upon phosphorylation, activated PI3-kinase 
enzyme translocates to the plasma membrane where it utilizes the lipid phosphatidylinositol-4, 
5-bisphosphate (PIP2) as a substrate to generate phosphatidylinositol-3, 4,5-trisphosphate 
(PIP3) [178]. PIP3 then mediates the recruitment and/or activation of pleckstrin homology (PH) 
domain–containing proteins, including various enzymes, their substrates, adapter molecules, 
and cytoskeletal proteins. Among these is the Ser/Thr kinase PDK1, which phosphorylates and 
activates several downstream kinases, including Akt1, Akt2, Akt3, protein kinase C (PKC)ζ/λ, 
and glucocorticoid-inducible kinase (SGK) [179]. PIP3 mediates the translocation of Akt to the 
plasma membrane, via its PH domain. Overexpression of a membrane-bound form of Akt 
(Akt1 and Akt2) in cells (adipocytes and myocytes) results in localization of glucose 
transporter (GLUT)-4 to the plasma membrane thus enhancing glucose transport into the cell 
[180] (Figure 1.17).  
However, it has been shown that activation of the cytoplasmic PI3-kinase pathway alone is not 
sufficient for increased glucose transport observed in response to insulin. Separate insulin 
signaling pathways localized within the lipid raft microdomains (specialized regions of the 
plasma membrane) [181] have also been implicated in GLUT-4 translocation and glucose 
transport. Activation of the insulin receptor within the lipid raft microdomains causes the 
phosphorylation of the substrates Cbl and APS. Cbl interacts with CAP (Cb1 associated 
protein), which can bind to the lipid raft protein flotillin. This interaction recruits 
phosphorylated Cbl into the lipid raft, resulting in the recruitment of the protein CrkII. CrkII 
binds constitutively to the exchange factor C3G, which can catalyze the exchange of GDP for 
GTP on the lipid-raft–associated protein TC10. Upon its activation, TC10 interacts with a 
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number of potential effector molecules, including CIP4, Exo70, and Par6/Par3/PKCλ, in a GTP 
dependent manner to mediate the docking of GLUT-4 vesicle to the plasma membrane [182] 
(Figure 1.17). 
 
 
 
Figure 1.17: Signaling pathways of insulin in adipocytes and myocytes. Two signaling 
pathways are required for the translocation of the glucose transporter GLUT4 by insulin in fat 
and muscle cells. Tyrosine phosphorylation of the IRS proteins after insulin stimulation leads 
to activation of PI3-kinase to produce PIP3, which in turn activates and localizes protein kinases 
such as PDK1. These kinases then initiate a cascade of phosphorylation events, resulting in the 
activation of Akt and/or atypical PKC. AS160, a substrate of Akt, plays an as yet undefined 
role in GLUT4 translocation through its Rab-GTPase activating domain.  Similarly, a separate 
pool of the insulin receptor can also phosphorylate the substrates Cbl and APS. Cbl interacts 
with CAP, which can bind to the lipid raft protein flotillin. This interaction recruits 
phosphorylated Cbl into the lipid raft, resulting in the recruitment of CrkII. CrkII binds 
constitutively to the exchange factor C3G, which can catalyze the exchange of GDP for GTP 
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on the lipid-raft–associated protein TC10. Upon its activation, TC10 interacts with a number 
of potential effector molecules, including CIP4, Exo70, and Par6/Par3/PKCλ, in a GTP 
dependent manner to mediate the docking of GLUT4 vesicle to the plasma membrane [182]. 
 
 
1.15.3.5 Role of insulin signaling in physiology of glucose metabolism, transport and storage  
In humans, glucose is necessary to ensure the proper function and survival of all organs. While 
hypoglycaemia (reduced blood glucose level) induces cellular death, chronic hyperglycaemia 
(persistent increased blood glucose level) also can result in organ damage. Therefore, the blood 
glucose level is maintained within a narrow range of about 5-7mmol/L, which is considered 
the physiological set point [167].  
Glucose homeostasis is regulated primarily by the liver and skeletal muscle. The balance 
between glucose metabolism and production is maintained at equilibrium by two opposing 
hormones, insulin and glucagon which are secreted by the β and α-cells of the pancreas 
respectively. Both β and α-cells are extremely sensitive to glucose concentrations and can 
regulate hormone synthesis and release in response to small changes in plasma glucose levels 
[172]. In response to an elevation in plasma glucose and amino acids, as seen after consumption 
of a meal, GLUT-2 facilitates the transport of glucose into β-cells, via a gradient-dependent 
manner, such that the rate of glucose transport changes with fluctuations in blood glucose 
concentration [183].   
Within the β-cells, phosphorylated glucose is oxidized and ATP is generated. The increased 
ATP/ADP ratio closes potassium channels, and the cell becomes depolarized [184] (Figure 18). 
This results in the opening of voltage-sensitive calcium channels, which increases intracellular 
calcium and thus stimulates the fusion of the insulin-containing secretory vesicles with the 
plasma membrane, resulting in the pulsatile release of insulin [184] (Figure 1.18). Insulin 
induces glucose uptake, utilization, and storage, while suppressing hepatic glucose production, 
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thus reducing plasma glucose levels. Conversely, in the presence of reduced plasma glucose 
level as seen during fasting or exercise, glucagon is secreted by the pancreatic-α cell. Glucagon 
then promotes the release of stored and newly synthesized glucose into the bloodstream (Figure 
1.19). These two hormones act in concert to ensure the maintenance of glucose homeostasis in 
a wide variety of physiological conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18: Glucose-mediated secretion of insulin from the pancreatic β-cell. Glucose entry 
and mitochondrial metabolism increases the intracellular ATP-to-ADP leading to closure of 
the KATP channels and membrane depolarization. This activates voltage–dependent calcium 
channels (VDCCs), allowing influx of Ca2+, which triggers exocytosis of insulin granules. Kv 
channels also activate upon depolarization to mediate action potential repolarization, limiting 
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Ca2+ entry and insulin secretion [184].  
 
The primary target organs/tissues for insulin are skeletal and cardiac muscle, adipose tissue 
and the liver. Glucose uptake is the rate-limiting step in glucose utilization and storage. Insulin 
binds to its receptor on the cell surface to stimulate the transport of glucose into muscle and fat 
cells via the translocation of the glucose transporter GLUT-4 from intracellular sites to the cell 
surface, thus increasing its concentration on the cell surface. About 75% of insulin-dependent 
glucose disposal occurs in skeletal muscle, while the adipocytes account for only a small 
fraction [185]. Once inside the muscle cell, glucose is rapidly phosphorylated by hexokinase 
and either subsequently stored as glycogen, due to the activation of glycogen synthase, or 
oxidized to generate ATP, via activation of enzymes such as pyruvate kinase (Figure 1.19).  
In the adipocytes, glucose is stored primarily as lipids, due to increased uptake of glucose and 
activation of lipid synthetic enzymes. Insulin also profoundly inhibits lipolysis in adipocytes, 
primarily through inhibition of the hormone sensitive enzyme lipase. Most, if not all, of these 
insulin-dependent changes in enzyme activities are mediated by attenuation of the 
phosphorylation state of the relevant enzyme, due to a combination of protein kinase inhibition 
and phophatase activation [185].  
Glucose homeostasis in the liver is maintained through a delicate balance between hepatic 
glucose uptake and utilization and hepatic glucose production [185]. In hepatic cells insulin 
inhibits the production and release of glucose by the liver, by blocking the processes of 
gluconeogenesis and glycogenolysis thus regulating fasting glucose levels. Hepatic GLUT-2 
facilitates the uptake of glucose into the hepatocytes when circulating levels of glucose are 
high, as well as the release of glucose out of hepatocytes into the plasma or bloodstream during 
the fasting state, via glycogenolysis and gluconeogenesis [185] (Figure 1.19). The direction is 
dictated by the glucose gradient across the plasma membrane.  
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Figure 1.19: Role of insulin signaling in glucose metabolism, transport and storage. (Left) 
After consumption of a meal (fed state), dietary carbohydrate (CHO) increases plasma glucose 
level and promotes insulin secretion from the pancreatic β-cells. In the myocytes, insulin 
increases glucose transport, permitting glucose entry and glycogen synthesis. In the hepatic 
cells, insulin promotes glycogen synthesis and de novo lipogenesis while also inhibiting 
gluconeogenesis. In the adipocytes, insulin suppresses lipolysis and promotes lipogenesis. 
(Right) In the fasting state, insulin secretion is decreased. The drop in insulin increases hepatic 
gluconeogenesis and promotes glycogenolysis. Hepatic lipid production diminishes while 
adipose lipolysis increases [172]. TG; Triglycerol; FA; fatty acid. 
 
 
1.15.3.6 Insulin signaling and T2DM 
Insulin signaling is altered in diabetic states. Three major metabolic abnormalities have been 
identified to impair insulin signaling and contribute to hyperglycemia in T2DM [186]. These 
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abnormalities are classified into:  (1) impaired insulin secretory responses to glucose, (2) 
elevated rates of hepatic glucose output (HGO), and (3) diminished ability of insulin to 
stimulate glucose uptake into peripheral tissues (insulin resistance). These functions involve 
cellular glucose transport in pancreatic β-cells, liver, adipose tissue, and skeletal muscle. In 
some instances, abnormalities in glucose transporter isoforms (GLUT) specifically expressed 
in these tissues may constitute key biochemical lesions underlying defective glucose 
homeostasis. Similarly, phosphorylation of the insulin receptor at the serine/threonine residue 
can inhibit the intrinsic tyrosine kinase activity of the receptor, thus altering the downstream 
signaling in a proportional manner [187]. It has been discovered that PKCs and MAPKs can 
phosphorylate the insulin receptor at this site, hence leading to decreased downstream signaling 
[188]. Furthermore, serine phosphorylation has also been found to be induced by the pro-
inflammatory cytokine TNF-α [188] (Figure 1.18). SOCS (suppressor of cytokine signaling), 
activated during inflammatory conditions has been found to compete with IRS1/2 for IR 
binding, thus attenuating tyrosine phosphorylation and downstream signaling of IR1/2, and is 
also capable of inducing IRS degradation [189]. In addition, free fatty acids (FFA) and FFA 
derivatives are also capable of increasing serine phosphorylation of IRS through the activation 
of several serine/threonine protein kinases, such as PKCs, JNK, and inhibitor of nuclear factor-
κB kinase β (IKKB), to decrease the insulin-insulin receptor signaling cascade [190] (Figures 
1.20). Furthermore, FFA also induces the stimulation of gluconeogenesis [172]. 
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Figure 1.20: Pathways involved in insulin resistance in myocytes (muscle). Insulin activates 
the insulin receptor (IR) tyrosine kinase, which subsequently phosphorylates IRS1. This leads 
to activation of Akt2. Akt2 activation then promotes the translocation of GLUT4-containing 
storage vesicles (GSVs) to the plasma membrane, permitting the entry of glucose into the cell, 
and promotes glycogen synthesis via glycogen synthase (GS). (1) Represent mechanisms of 
lipid induced insulin resistance, notably diacylglycerol (DAG)-mediated activation of PKCq 
and subsequent impairment of insulin signaling, as well as ceramide-mediated increases in 
PP2A and increased sequestration of Akt2 by PKCz. Impaired Akt2 activation limits 
translocation of GSVs to the plasma membrane, resulting in impaired glucose uptake. (2) 
Depict several intracellular inflammatory pathways—notably, the activation of IKK, which 
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may impact ceramide synthesis, and the activation of JNK1, which may impair insulin 
signaling via serine phosphorylation of IRS1. (3) Depicts activation of the unfolded protein 
response (UPR), which may lead to activation of ATF6 and a PGC1a-mediated adaptive 
response. CS, ceramide synthase; G3P, glycerol 3-phosphate; LPA, lysophosphatidic acid; 
SPT, serine palmitoyl transferase; TAG, triacylglycerol [172].  
 
1.16 Clinical manifestation 
Both T1DM and T2DM demonstrate common symptoms including hyperglycemia, polydipsia, 
polyphagia, polyuria, fatigue and blurred vision [191].   
 
1.17 Criteria for clinical diagnosis of DM  
To make a clinical diagnosis of DM one of the following criteria must be met: Glycosylated 
hemoglobin (HbA1c) ≥ 6.5%; or fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) 
(fasting is defined as no caloric intake for at least 8 hours); or Two-hour plasma glucose ≥ 200 
mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT) with75g of anhydrous 
glucose dissolved in water; or patient with classic symptoms of hyperglycemia or 
hyperglycemic crisis; or a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L). Excluding a 
state of hyperglycemic crisis, all other criteria must be repeated to confirm diagnosis [191]. 
 
 
1.18 Conventional treatment of T2DM and their complications  
T2DM is a multidimensional disorder characterized by a cluster of systemic pathologies, 
including obesity, hypertension, atherosclerosis, dyslipidaemia, hypercoagulation, impaired 
glucose tolerance and insulin resistance, collectively referred to as the “Metabolic syndrome” 
[192]. Hence, its management requires firm adherence to the prescribed treatment plan.  
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The existing treatment plan for T2DM is focused on suppressing and controlling blood glucose 
to a physiologic level, and lifestyle modification along with appropriate diet and weight control 
[193]. A number of medications are currently available, targeting numerous facets of the 
disease. Some of the first pharmacologic treatments for T2DM were aimed at increasing the 
insulin levels by using oral insulin secretagogues, such as sulfonylureas or meglitinides [194]. 
The insulin secretagogue binds to receptors on the pancreatic β cell to stimulate insulin 
secretion. In the event of failure of secretagogues, exogenous insulin can be administered. 
However both insulin secretagogues and exogenous insulin can induce hypoglycaemia [194]. 
Metformin (biguanide) is currently used as a first-line therapy in newly diagnosed T2DM 
patients [195]. Metformin acts by increasing the activation and phosphorylation 5’-AMP-
activated kinase (AMPK). In the liver AMPK activation decreases lipid and glucose synthesis 
and increases fatty acid oxidation [196]. In muscle AMPK activation stimulates GLUT4 
translocation [197]. However, the clinical limitation of metformin is that it is cleared through 
the kidneys, thus renal insufficiency/impairment could lead to toxic accumulation of the drug 
[194, 198]. 
Thiazolidinediones (TZDs) are relatively new class of drugs that were introduced in the late 
1990s [199]. TZDs are peroxisome proliferator-activated receptor-gamma (PPARγ) agonists 
that improve insulin sensitivity and glycemic control, with beneficial effects on lipid 
metabolism, blood pressure, vascular tone and endothelial function. However in clinical use 
TZDs have been shown to cause modest weight gain, increased risk of myocardial infarction, 
cardiovascular related death, and several cases of acute hepatitis and liver failure have also 
been reported [200, 201]. In addition to their individual debilitating side effects, anti-diabetic 
medication may sometimes involve polypharmacy (prescribing more than one drug at the same 
time), which can further augment the severity of these side effects. Hence, there is a need for 
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the development of novel anti-diabetic agents with more potent activity and lesser side effects 
than drugs currently in use in clinical practice.   
 
1.19 Anti-diabetic medicinal plant and anti-diabetic phytocompound: Potential source of 
alternative therapy 
Various herbal anti-diabetic remedies are used in traditional medical practices around the 
world. However, only a few of them have been scientifically assessed for their efficacy [144]. 
Anti-diabetic medicinal plants are widely distributed in six continental regions, and some 
specific regions around the world, such as in the Caribbean, Mediterranean and Middle East 
[150] (Figure 1.21). Asia (56%) and Africa (17%) dominate the global distribution of the anti-
diabetic plants (Figure 1.21) [150]. This is not surprising as the two continents are located in 
the tropic and sub-tropical regions with large coverage of tropical rain forests, with diverse 
species of plants. Moreover, these regions have long established their traditional medicine 
systems [150]. 
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Figure 1.21: Global distribution of anti-diabetic medicinal plants [150] 
 
In Africa, between 2000 and 2013, a total of 185 plant species from over 75 families were 
investigated for their anti-diabetic effects [29]. Of these, about 12.92% were reported from 
Southern Africa, with most (90%) of the studies originating from the Republic of South Africa 
[29]. Promising results were reported in several of these investigations, but only a few studies 
reported detailed characterization of bioactive principles [29] 
 
1.20 Sutherlandia frutescens 
1.20.1 Ethnobotany 
Sutherlandia frutescens (L.) R. BR., Family Fabaceae subsp. microphylla is a flowering shrub 
of the pea family (Fabaceae/Leguminaceae) found mainly in the Western Cape and Karoo 
regions of Southern Africa (Figure 1.22) [202].  
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Figure 1.22: Geographical distributions of S. frutescens in Southern Africa[202] 
S. frutescens grows to about 0.5-1 m in height and its leaves are pinnately compound. Each 
leaflet is about 4-10 mm long, greyish-green in color, giving the bush a silvery appearance 
(Figure 1.23) [203]. S. frutescens flowers are orange-red in color and can grow up to 35 mm 
long (Figure 1.23). The flowers appear in short clusters in the leaf axils at the tips of the 
branches in spring to mid-summer (September - December) [203]. Within the ethnic tribes of 
South Africa S. frutescens is known by different names including: cancer bush, balloon pea 
(English); umnwele (Xhosa); kankerbos, blaasbossie, blaas-ertjie, eendjies, gansiekeurtjie, 
klappers, hoenderbelletjie (Afrikaans); Unwele and Insiswa (Zulu); Musa-Pelo, Motlepelo an 
Phethola (Sotho) [204]. 
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including rue (Ruta graveolens) for a variety of ailments, camphor (Cinnamomum camphora) 
for fever, colds, antiseptic and mild analgesic activity, plus bluegum (Eucalyptus globulus) 
for its use in decongestant medicines (Van Wyk and Gericke, 2000). There are many other 
plants which have an important use in traditional medicines, but the main research focus of 
this study is on one of the above mentioned indigenous plants - Sutherlandia frutescens. 
 
1.3 SUTHERLANDIA FRUTESCENS 
The Sutherlandia plant occurs endemically in South Africa, being widely spread over the 
South Western and Northern Cape Provinces, essentially being found along road verges in the 
drier areas of the country, as indicated in Figure 1.1.  The  term  ‘sutherlandia’  refers  to  a  
shrubby plant that is known by many different names, including  cancer bush, balloon pea 
(English); umnwele (Xhosa); kankerbos, blaasbossie, blaas-ertjie, eendjies, gansiekeurtjie, 
klappers, hoenderbelletjie (Afrikaans); Unwele and Insiswa (Zulu); Musa-Pelo, Motlepelo 
and Phethola (Sotho) (Jackson, 1990). 
 
 
 
Figure 1.1 Geographical distributions of Sutherlandia species throughout South Africa 
(sahealthinfo.org). 
 
Sutherlandia belongs to the family Fabaceae (pea and bean or pod-bearing family) which is 
the second largest flowering plant family in the world. This family contains more than 600 
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Figure 1.23: Sutherlandia frutescens growing in the wild. 
 
1.20.2 Medicinal uses of Sutherlandia frutescens 
S. frutescens is one of the best known multi-purpose medicinal plants in Southern Africa, and 
has diverse medical uses [205]. Medicinal preparations are generally produced from the leaves, 
but the stems are often also included. Concoctions of various parts of the plant are used in the 
treatment of ailments such as; stomach problems, cancer, influenza, chicken pox, diabetes, 
varicose veins, piles, inflammation, liver problems, backache, heart failure, urinary tract 
infections, rheumatism, stress and anxiety [205, 206].  
In 2002, the South African Medical Research Council (MRC) launched a clinical research 
platform aimed at investigating the safety and efficacy of indigenous medicinal plants [207]. 
In the report of a test case, the first vervet monkey safety study of an indigenous plant, 
Matsabisa and colleagues reported that there was no indication of toxicity after feeding vervet 
monkeys with dried S. frutescens leaf powder for three months, at a dosage nine times the 
equivalent of the human dose [207]. Hence, the South African Ministry of Health concluded 
6 
 
 
Figure 1.2 S. frutescens growing in the wild at Goegap Nature Reaserve, Springbok, 
Northern Cape (photo taken by Nial Harding). 
 
1.3.1 A historical aspect of medicinal uses of Sutherlandia 
This plant has been used for hundreds of years by the original inhabitants of the Cape, being 
the Khoi San and Nama people, who used it mainly as a decoction for the washing of wounds 
and also take it internally to reduce fevers. For many hundreds of years, Zulu warriors 
returning from battle used the plant to relax themselves. Grieving widows used it as an anti-
depressant to help them through their loss. The old Zulu word of "insiswa" means "that which 
takes  away  the  dark”  refers  to  the  ability  of  the  plant  to  help  with  depression and sadness 
(www.plantzafrica.com - Sutherl ndia frutescens (L.) R. Br.; Van Wy  and Albrech , 2008).  
Sutherlandia has long been known and respected as a medicinal plant in southern Africa and 
is regarded as the African adaptogens par excellence. The early colonists regarded it as 
giving successful results in the treatment of chicken pox, stomach problems, internal cancers 
and eye troubles (Watt and Breyer-Brandwjik, 1962). It continues to be used to this day as a 
remedy for the above-mentioned ailments. According to Van Wyk and Gericke (2000), 
tinctures, infusions and decoctions of the l aves and young stems of Suther dia have been 
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that S. frutescens is safe for human consumption [208]. However, recent preclinical studies 
have indicated that concomitant administration of S. frutescens with prescription medicines 
(e.g. CYP3A4 substrates) could lead to therapeutic failure and adverse drug-herb interactions 
[209]. 
 
 
1.21 Pharmacological action of S. frutescens extracts  
Various pharmacological actions have been attributed to Sutherlandia frutescens extracts as 
discussed below. 
 
1.21.1 Immunomodulation   
Several studies have established a role for S. frutescens extracts in immune modulation [210-
212]. Using transcriptomic analyses, Lei et al. (2015) demonstrated the role of S. frutescens 
extract in regulating gene expression in an activated murine macrophage cell  line [211]. Lei 
and colleagues observed that treatment of cells with S. frutescens resulted in the differential 
expression of 547 genes (DEGs) [211]. Pathway analysis identified that many of these DEGs 
participate in inflammatory signaling pathways, such as NF-kB and MAPK [211]. Similarly, 
Kisten (2010), reported that S. frutescens extract regulated the expression of interleukin (IL) 6, 
IL-10 and IFNγ (inteferon-gamma) in lipopolysaccharide (LPS) or Phytohaemagglutinin 
(PHA) stimulated whole blood [212]. However, these effects were found to be donor dependent 
[212]. 
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1.21.2 Anti-oxidant 
Natural anti-oxidants play an important role in health maintenance and the prevention of 
chronic and degenerative diseases [213]. By scavenging free-oxygen radicals (superoxiode, 
peroxyl radicals, hydroxyl radicals and singlet oxygen) anti-oxidants protect cells against the 
damaging effects of these reactive oxygen species. Studies by Tai et al. (2004) and Fernandes 
et al. (2004), showed that S. frutescens extracts possess superoxide as well as hydrogen 
peroxide-scavenging activities at low concentrations [214, 215]. Tai and colleagues reported 
that an ethanolic extract of S. frutescens reduced free radical cations production in cancer cell 
lines, at an estimated volume of 0.5 μL of S. frutescens extract equivalent compared to 10 μM 
of Trolox [214]. While Fernandes and colleagues showed that hot aqueous extract of S. 
frutescens reduced the rate of superoxide and hydrogen peroxide generation in L-formyl-L-
methionyl-L-leucyl-L-phenylalanine (FMLP) stimulated neutrophils, at a concentration of 
10 µg/mL [215]. 
 
1.21.3 Anti-cancer 
Studies have shown that S. frutescens extracts have direct anti-cancer effects in some cancers. 
Chinkwo (2005) reported that crude aqueous extracts of S. frutescens induce apoptosis and 
cytotoxicity in cervical and ovarian neoplastic cells [216]. The pattern of S. frutescens-
mediated DNA fragmentation seen in these neoplastic cells was similar to that mediated by 
other inducers of apoptosis such as staurosporine and ceramide [216].  
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1.21.4 Anti-HIV 
S. frutescens has received international attention as a cheap herbal medicine that can improve 
the outcome of HIV infection. Clinical anecdotal evidence has shown that HIV-infected 
individuals on adjunct S. frutescens treatment have improved CD4 counts and decreased viral 
loads [217]. Similarly, Harnett et al. (2005) showed that both aqueous and organic extracts of 
S. frutescens contain inhibitory compounds active against HIV-1 reverse transcriptase (RT) 
enzyme [218]. In addition, Harnett and colleagues reported that a methylene dichloride extract 
of the S. frutescens leaves inhibited both α- and β-glucosidase enzymes, while no significant 
inhibitory activity was reported against HIV-II protease enzyme [218]. Consistent with this, 
the South African Ministry of Health recommended the use of S. frutescens as an adjunct 
therapy for HIV/AIDS treatment [219, 220].  
 
1.21.5 Anti-diabetic (Hypoglycemic) 
S. frutescens is among the most common and widely used herbal concoctions in Southern 
Africa for the treatment of T2DM. An aqueous extract of the shoots significantly prevented 
streptozotocin-induced hyperglycemia in mice when administered orally at various dosages 
(50–800 mg/kg) [221]. In a similar study by Chadwick et al. (2007) using rats fed a high fat 
diet to induce insulin resistance, a crude aqueous extract of S. frutescens leaves was shown to 
increase glucose uptake and utilization by peripheral tissues, with a decrease in intestinal 
glucose [222]. Furthermore, in a separate study, MacKenzie et al. (2009) showed that S. 
frutescens extracts reduced plasma free fatty acid levels in rats fed a high fat diet, subsequently 
preventing the development of insulin resistance in these rats [223]. In comparison to rats fed 
high fat diet only, levels of plasma free fatty acids (FFA) was significantly reduced after one 
week of S. frutescens treatment in the experimental group [223]. In addition, twelve weeks of 
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treatment with S. frutescens reduced the level of plasma free fatty acids below that of rats fed 
a normal diet [223]. 
 
1.22 Pre-isolated bioactive phytocompounds from Sutherlandia frutescens 
Over the years, several bioactive phytocompounds including L-canavanine, D-pinitol, and γ-
amino butyric acid (GABA) [35], triterpenoid glycoside (sutherlandioside B “SU1”) [206, 224, 
225], flavonol glycosides [226], amino acids and small amounts of saponins [35] have been 
isolated from S. frutescens extracts. Specific bioactive principle constituents have been linked 
to the therapeutic application of S. frutescens in folklore medicine, however each isolated 
compound alone does not have the full activity of the complete extract. Three purified 
compounds have been analyzed in some detail: 
 
1.22.1 Pinitol 
Pinitol is a type of sugar found in many species of legumes and is classified as chiro-inositol 
[212]. Pinitol (Figure 1.24) has also been shown to exert an insulin-like effect, resulting in 
lower blood sugar levels and increased availability of glucose for cell metabolism [227]. Thus, 
pinitol has been proposed as a bioactive compound underlying the anti-diabetic effect of S. 
frutescens. 
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Figure 1.24: Chemical structure of pinitol. 
 
1.22.2 Canavanine  
Canavanine (Figure 1.25) is a potent L-arginine competitor and the L-2-amino-4-guanidino-
oxy group, is a structural analogue of arginine [219]. It has been shown to possess both anti-
cancer as well as anti-viral activities [219, 228], justifying the traditional use of S. frutescens 
as an anti-cancer agent [206]. 
 
 
 
 
Figure 1.25: Chemical structure of canavanine 
 
 
1.22.3 Gamma Amino Butyric Acid (GABA) 
GABA (Figure 1.26) is a non-essential amino acid and the major inhibitory neurotransmitter 
9 
Bailey, 2000). It has also been shown to enhance the retention of creatinine by muscle cells 
(Greenwood et al., 2001), as well as  increasing the ability of the muscle cells to absorb 
glucose, resulting in benefits for sporting enthusiasts, who have concomitant requirements for 
strength and endurance, together with the added benefits of shortened physiological recovery 
times. Pinitol (see Figure 1.4), has also been shown to have a positive effect on muscles 
being able to store carbohydrates, thereby allowing for muscle growth, whilst permitting the 
burning of fat (www.sutherlandia.com). Overall, pinitol therefore seems to play a role in 
regulating cellular energy, resulting in increased energy levels and a reduction in fatigue (Van 
Wyk and Albrecht, 2008). This effect to increase muscle mass, thus has major applications in 
the treatment of wasting syndrome in cancer, HIV/AIDS and tuberculosis. It is not surprising 
therefore, that Sutherlandia has been used on the African continent for generations, to treat 
sufferers of tuberculosis, with impressive results (www.sutherlandia.com).  
It is not only the pinitol present in Sutherlandia that results in all its notable properties.  
Current research has indicated that there is strong evidence to support the interaction of 
pinitol with the other bio-active compounds (www.sutherlandia.com). 
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Figure 1.4 Compound 2: Pinitol. 
 
1.3.2.4 Gamma Amino Butyric Acid (GABA): is a non-essential amino acid and 
inhibitory neurotransmitter that is found in the leaves of Sutherlandia. It is primarily 
synthesized by decarboxylation of glutamate by the enzyme L-glutamic acid-1-decarboxylase 
(Ebadi, 2007). Together with niacinamide (vitamin B3) and inositol, GABA prevents anxiety 
and stress-related neuron messages from reaching the motor centres of the brain. It is thus 
essential for brain metabolism, where it also decreases neuron activity, thus preventing them 
from over-firing (www.vitamins-supplements.org). The presence of GABA also justifies the 
use of S. frut scens in treating anxiety and stress. According to Van Wyk and Gericke (2000), 
8 
L-arginine is important, because it acts as an antagonist of L-canavanine that attenuates the 
anti-proliferative activity of canavanine (Van Wyk and Albrecht, 2008). 
1.3.2.2 Canavanine: is frequently found in the seeds of Fabaceae and therefore its 
discovery at high concentrations in extracts from the leaves of Sutherlandia by Moshe 
(1998), was of considerable interest. Canavanine (see Figure 1.3), which is a potent L-
arginine competitor and the L-2-amino-4-guanidino-oxy, is a structural analogue of arginine 
(Mills, Cooper et al., 2005). It has also been shown to have anti-cancer as well as anti-viral 
activity, including inhibition of influenza virus and retroviruses (Green, 1988). As such, this 
finding justifies the traditional use of this plant against cancer; in addition, this also appears 
to be the first known case f a canavanine-containi g plant h v ng a well-recorded history of 
use against cancer ( Bence et al., 2002; Crooks and Rosenthal, 1994; Rosenthal, 1997; 
Swaffar, 1995; Van Wyk and Albrecht, 2008). Between 30-40 mg of canavanine can be 
found per dry gram of the leaves (Gericke et al., 2001). Canavanine is an inhibitor of nitric 
oxide synthase, which may be beneficial in certain forms of heart failure (Van Wyk and 
Gericke, 2000). 
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Figure 1.3 Compound 1: Canavanine. 
 
1.3.2.3 Pinitol: is a type of sugar found in many types of legumes and is classified as 
chiro-inositol. It was first found by Snyders (1965), as well as Viljoen (1969) and 
Brummerhoff (1969) in Sutherlandia microphylla leaves. It is also known as 3-O-methyl-D-
chiro-inositol, or 3-0-methyl-1,2,4 cis-3,5,6-trans-hexahydroxy-cyclohexanol (Mills, Cooper 
et al., 2005). The recorded bio-activities of pinitol make it a potentially important compound 
in the context of the traditional uses of Sutherlandia against diabetes and inflammation 
(Moshe, 1998). It has been used for the treatment of wasting in cancer as well as AIDS and is 
a known anti-diabetic agent (Narayanan et al., 1987; Ostlund and Sherman, 1996).  Pinitol 
has also been shown to exert an insulin-like effect (hypoglycaemic effect), resulting in lower 
blood sugar levels and increased availability of glucose for cell metabolism (Bates, Jones and 
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found in the mammalian nervous system [229]. The presence of GABA in the leaf extracts of 
S. frutescens justifies its use in treating anxiety and stress [35]. 
 
 
 
Figure 1.26: Chemical structure of GABA 
 
Identification and characterization of these aforementioned phytocompounds suggests that 
crude extracts of S. frutescens contain these bioactive principles and potentially other 
compounds not identified by previous studies, which can be explored for their anti-diabetic 
activity. Analytical approaches using Triple Time-of-Flight Liquid Chromatography with mass 
spectrometry (Triple TOF LC-MS/MS) are a more effective tool for qualitative exploration, 
rapid profiling, and high-resolution quantification of medicinal plants or herb medicinal 
products.   
 
 
 
 
 
 
 
 
 
10 
the seeds and leaves have been smoked by labourers and teenagers as a dagga substitute in 
Namaqualand, with the leaves invoking a strong GABA-induced sedative effect when 
smoked.  
According to Braveman and Pfeiffer (1987); Petty et al. (1993) and Petty (1995), GABA has 
been used in the treatment of depression, bipolar disorder, seizures, premenstrual dysphoric 
(feeling depressed) disorder, and anxiety. GABA (see Figure 1.5) also improves sleep cycles, 
as well as having a powerful stabilizing effect on blood pressure. It is a very effective 
analgesic, eliminating pain from chronic conditions such as arthritis and lower back pain. It 
has also been used to treat epilepsy and hypertension, where it is thought to induce 
tranquillity in individuals who have a high activity of manic behaviour and acute agitation 
(Denver Naturopathic Clinic
1
). 
GABA signals the pituitary gland to naturally release Human Growth Hormone (HGH), 
which is widely known for its powerful anabolic (muscle building) effects as well as its 
lipotropic (breakdown and utilization of body fat) effects (Di Luigi et al., 1999). GABA has 
also been found to inhibit tumour cell migration (Ortega, 2003). 
 
H2N
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Figure 1.5 Compound 3: GABA. 
 
1.3.2.5 Sutherlandiosides A to D: The major triterpene, in commercially produced 
Sutherlandia material, is a cycloartane-type triterpene glycoside called sutherlandioside B. At 
least 56 different triterpene glycosides have been detected. According to Van Wyk and 
Albrecht (2008), mixtures of cycloartane-type triterpenoid glycosides have extensive 
geographical variation in South Africa. A study done by Fu et al. (2008), found four 
cycloartane-type triperpenoids which have a bitter tonic activity that stimulates appetite and 
                                                          
1
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1.23 Statement of the problem  
In 2012, an estimated 1.5 million deaths were directly caused by diabetes globally [154]. Of 
these, T2DM accounted for about 90% of cases [230]. Presently, the global prevalence of 
diabetes is estimated to be 9% among adults aged 18+ years [231] with more than 80% occuring 
in low- and middle-income countries [154]. Although the pathophysiology of T2DM is not 
entirely understood, T2DM is a multifactorial disease characterized by initial peripheral insulin 
resistance in adipose tissue, liver, and skeletal muscle, and subsequent pancreatic β-cells 
dysfunction as a result of an attempt to compensate for insulin resistance [167, 168]. Presently, 
various pharmacological agents are available for the treatment of T2DM [232]. However, these 
conventional treatment modalities are expensive and could have short or long-term unpleasant 
side effects on the patients [233]. Hence there is a need to look for alternative and newer 
bioactive principles that will be cost effective and possess fewer side effects. 
Africa has an enormous number of potential plant resources that may contain these potent anti-
diabetic principles, thus Sutherlandia frutescens based on its folklore anti-diabetic usage can 
serve as a lead for the development of new treatments.  
Prior studies in our laboratory have demonstrated the role of an aqueous extract of S. frutescens 
in the regulation of T2DM in a rat model system and in the regulation of key genes; including 
Vesicle-associated protein (VAMP)-3 and N-ethylmaleimide sensitive fusion proteins (NSF) 
in liver cells made insulin resistant [234].  However, the detailed comparison of the potent anti-
diabetic phytocompounds present in the crude aqueous and organic extracts of the plant and 
the molecular mechanisms by which they mediate reversal of insulin resistance in hepatic cells 
in-vitro is yet to be elucidated.  
In this study, the molecular role of crude organic and aqueous extracts of S. frutescens in the 
regulation of gene expression and reversal of insulin resistance in hepatic cell lines was 
investigated and compared in-vitro. 
 
 
59 
 
Furthermore, several bioactive phytocompounds [35, 206, 224-226] have been isolated from S. 
frutescens extracts. However, no conclusive study of the phytocompounds isolated and purified 
from the plant material, has rigorously connected these compounds to anti-diabetic activities. 
Hence, the exact compounds mediating the anti-diabetic effects of S. frutescens is still a subject 
of debate.  
Using a more recent analytical approach (Triple TOF LC-MS/MS), qualitatively explore and 
profile the bioactive (anti-diabetic) principles present in crude and fractionated extracts of S. 
frutescens were qualitatively explored and profiled.  
 
1.24 Hypothesis 
I hypothesized that aqueous and organic extracts of S. frutescens contain anti-diabetic 
phytocompounds that can reverse insulin resistance in hepatic cells. Given the complexity of 
the extracts and their multiple activities, these extracts may display combinatorial or synergistic 
action, rather than containing a single active ingredient.  
 
1.25 Overall aims/objectives 
As a result of differences in activity reported between extracts from different plant samples and 
differing extraction procedures, the aim of this study was to investigate the phytochemical 
constituents and evaluate the relative anti-diabetic activities of aqueous and organic extracts of 
a single sample of plant material, as well as to identify potential active phytocompounds. These 
extracts will be used to analyze changes in expression of genes regulated by insulin resistance 
in hepatocyte cell lines in-vitro, following treatment with aqueous and organic extracts of S. 
frutescens. 
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1.26 Specific objectives. 
 
1. To prepare crude extracts and fractions of S. frutescens extracts. 
2. To elucidate the bioactive chemical compositions present in crude and fractionated 
extracts of S. frutescens. 
3. To evaluate and confirm the efficacy of aqueous and organic extracts of S. frutescens 
in treating insulin resistant human cell cultures. 
4.  To quantify changes in expression of selected genes regulated by insulin resistance in 
hepatocyte cell lines with and without S. frutescens treatment. 
5. To compare the molecular role and mechanism by which aqueous and organic extracts 
of S. frutescens mediate reversal of insulin resistance in hepatic cell in-vitro. 
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CHAPTER TWO 
PHYTOCHEMICAL ANALYSIS OF SUTHERLANDER FRUTESCENS EXTRACTS 
2.1 Introduction 
The effectiveness of medicinal plants and their pharmacotherapeutic action has been attributed 
to their complex diversity of chemical compounds [47]. Hence, the use of analytical 
phytochemical investigations to identify compounds with therapeutic properties is of utmost 
importance in ethnopharmacological studies to justify the usage of traditional medicinal plants 
[235]. Similarly, identification, isolation and analysis of the chemical profiles of plant extracts 
could play an important role in drug discovery [236]. 
In traditional medical practises, aqueous and alcohol (ethanol) infusions are the most widely 
used procedures to prepare extracts from plants [237, 238]. These solvents have been shown to 
extract multiple chemically complex principles or compounds. Thus, analytical methods for 
plant extracts must be capable of concurrently identifying multiple compound entities 
sensitively and accurately [239].  
In this study, using colorimetric and spectrophotomectric analysis I investigated and quantified 
the phytochemical constituents of crude aqueous (hot and cold) and organic (ethanol and 
methanol) extracts of S. frutescens. Furthermore, using Triple Time-of-Flight Liquid 
Chromatography coupled with Mass Spectrometry (Triple TOF LC-MS), with superior 
sensitivity and selectivity, I identified specific phytocompounds present in crude and solid 
phase extractions of aqueous (hot and cold) and organic (ethanol and methanol) extracts of S. 
frutescens. Analysis of these compounds using online databases of anti-diabetic compounds 
and a bioinformatics tool revealed possible anti-diabetic compounds present within each 
extract, and highlights possible similarities and variations within each extract.   
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2.2 Materials and Methods 
In traditional medicine, different parts (leaf, flower, stem and root) of medicinal plants have 
been utilized for the preparation of herbal mixtures [240]. S. frutescens leaves are the most 
widely used part of the plant in making infusions and decoctions [36]. In this study 
conventional methods of extraction and a range of solvents (hot aqueous, cold aqueous, 80% 
and 100% ethanol; 80% and 100% methanol) were used on air-dried S. frutescens leaves. These 
methods closely mimic the traditional medicine preparations. 
  
2.2.1 Chemicals and Reagents 
All chemicals used for this study were of high purity grade. Folin-Ciocalteu reagent, absolute 
(100%) ethanol and methanol, acetic acid, LC–MS grade methanol and trifluoroacetic acids 
(TFA) were purchased from Merck Chemicals (PTY) Limited (Gauteng, South Africa). 
Quercetins, tannic acid, sodium bicarbonate, LC-MS grade acetonitrile and aluminium chloride 
were purchased from Sigma Aldrich® (Cape Town, South Africa), while Whatman™ filter 
paper No 1 was purchased from GE Healthcare (UK). APCI negative calibration solutions, 
APCI positive calibration solutions and Phenomenex Strata™ X polymeric-based sorbent 
cartridges were purchased from Separations Scientific South Africa (PTY) Ltd. The LC–MS 
column and formic acid were purchased from Agilent (USA). Deionized water was used for all 
procedures. 
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2.2.2 Collection of Plant Material 
Sutherlandia frutescens (L.) R. BR., Family Fabaceae subsp. microphylla was identified by 
Professor E Campbell, Botany Department, Nelson Mandela Metropolitan University. A 
voucher specimen has been deposited in the University herbarium.  
Fresh S. frutescens plants were collected from a site in the Karoo region (Western Cape, South 
Africa) in August 2012 when the plants were in flower. The leaves of the plant material were 
removed from the stems and air dried at room temperature for two weeks away from direct 
sunlight. Then the dried leaves were ground to a fine powder using an electrical blender (Model 
BL-302, Pineware, South Africa), stored in clean labelled airtight bottles and extracted in six 
different solvents: hot water, cold water, 80% ethanol, 100% ethanol, 80% methanol and 100% 
methanol to extract potential bioactive constituents. 
  
2.2.3 Preparation of plant extracts 
2.2.3.1 Hot aqueous extracts 
The hot water extract was prepared following the procedure of Chadwick et al. (2007) [222] 
which imitates the traditional preparation. Briefly, powdered plant material (2.5 g) was mixed 
with 100 mL boiling deionized water in a 1L flask and allowed to brew overnight. The extract 
was filtered using a Buchner funnel and Whatman No 1 filter paper. The filtrate obtained was 
frozen at -80 °C and then dried under vacuum over 2 days using the Savant Freeze Drying 
System (Kansas City, MO, USA). The dried material obtained was placed in eppendorf 
microcapped tubes as 30 mg samples, sealed and kept in the dark at 4 oC in a desiccator until 
use. 
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2.2.3.2 Cold aqueous extracts 
The cold water extracts were prepared following the procedure of Harnett et al., 2004 [218]. 
Powdered plant material (25 g) was added to 200 mL of deionized water in a 1L bottle and then 
extracted in the dark at 4 °C for four days. Each day the extract was filtered using Whatman 
No 1 filter paper, the filtrate retained and 200 mL of fresh deionized water was added to the 
plant material. This process was repeated thrice to produce a total of four extractions 
(exhaustive extraction). The combined filtrates were freeze-dried under vacuum over two days 
in the Savant freeze dry system. Dried extract obtained was placed in eppendorf microcapped 
tubes as 30 mg samples, sealed and kept in the dark at 4 oC in a desiccator until use.  
 
2.2.3.3 Organic solvent extracts 
Extracts from the organic solvents (ethanol and methanol) were prepared following the method 
described by Harnett et al. (2005) [218] with slight modification. Powdered plant material (25 
g) was added to 200 mL of 80% or 100% ethanol, or 80% or 100% methanol. The material was 
allowed to soak for four days. Each day the extracts were filtered using Whatman No 1 paper 
and the appropriate 200 mL fresh solvent was added. This process was repeated thrice for a 
total of four extractions (exhaustive extraction) for each solvent system. The combined filtrates 
for each solvent were concentrated in a rotavapor (BUCHI R461, Switzerland) at a temperature 
not greater than 60°C. After rotary evaporation, a greasy residue was obtained for each of the 
organic extracts. The residues of the 80% organic extracts, were re-dissolved in 5 mL of 
relevant solvent and 45 mL of deionized water was added.  For the rotary evaporated 100% 
organic extracts, the residue extracts were transferred to labelled vials and air dried to permit 
full evaporation of residual solvent. All extracts were freeze-dried and a powder subsequently 
obtained.  Extracts were kept at 4 °C in the dark in a desiccator until use.  
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2.2.4 Determination of solvent extraction efficiency  
To determine the extraction efficiency of individual solvent extractants, 16 g of dried powdered 
plant material was immersed in 192 mL of extracting solvent (hot and cold water, 80% ethanol, 
100% ethanol, 80% methanol and 100% methanol) (single extraction). These were stirred, left 
on shaker overnight and then filtered. The aqueous extracts were frozen at    -80 o C and then 
freeze-dried, while the organic extracts were concentrated under vacuum at 60 °C using the 
rotary evaporator. The concentrated residue was freeze-dried and a powder subsequently 
obtained. The extracted mass for each solvent was measured and is presented in a bar chart, as 
mass of extract against solvent [241, 242].  
 
2.2.5 Phytochemical screening of crude S. frutescens extracts 
The screening procedure involves preliminary qualitative chemical tests to characterize the 
classes of compounds present in each extract and quantitative spectrophotometric methods to 
determine the concentration of phytocompounds within the extracts.  
 
2.2.5.1 Qualitative analysis 
Aqueous (hot & cold) and organic (ethanol & methanol) extracts (sections 2.2.3.1-2.2.3.3) were 
subjected to preliminary screening to determine the presence or absence of the following 
bioactive phytocompounds; tannins, phenol, flavonoids and flavonols using a standard 
procedure as described by Wintola et al. (2011) [243]. The presence or absence of bioactive 
phytocompounds was determined by the presence or absence of observable visual color change 
after the addition of the phytocompound specific reagents. These color changes were estimated 
as low (+), moderate (++) and high (+++).   
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2.2.5.2 Quantitative analysis  
2.2.5.2.1 Determination of total phenols 
The concentration of total phenolic compounds in crude S. frutescens extracts was evaluated 
spectrophotometrically with Folin-Ciocalteu’s phenol reagent as described by Otang et al. 
(2012) [244]. Individual solvent extracts (0.1 mg/mL) were mixed with 5 mL of Folin-
Ciocalteau reagent, previously diluted with deionized water (1:9 v/v), and incubated for 5 
minutes at room temperature. Post incubation, 4 mL of 7% sodium carbonate (Na2CO3) 
solution was added. The mixture was vortexed for 5 seconds and allowed to stand for 30 
minutes at 40 oC for color development. Absorbance at 765 nm was measured using a Bio-Tek 
KC4 Power Wave XS micro plate reader (Analytical and Diagnostic Products, South Africa). 
The concentrations of phenols in the test samples were calculated from the calibration plot and 
expressed as mg/g tannic acid equivalents. The experiment was conducted in triplicate and the 
results expressed as mean ± SD.  
 
2.2.5.2.2 Determination of tannin 
Tannin content in crude S. frutescens extracts was determined by the modified AOAC 
(Association of Official Analytical Chemists) method as described by Wintola et al. (2011) 
[243]. To 0.20 g of crude plant extracts, 20 mL of 50% methanol in distilled water was added. 
This was shaken thoroughly to ensure uniform mixing and placed in a water bath at 80 °C for 
1 hour. The mixture was filtered using Whatman filter paper No 1 and the filtrate collected into 
a 100 mL volumetric flask. To the filtrate, 20 mL of deionized water, 2.5 mL of Folin-Denis 
reagent and 10 mL of 17% Na2CO3 was added and then mixed thoroughly. The mixture was 
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made up to 100 mL with distilled water and allowed to stand for 20 minutes at room 
temperature. At the end of the reaction a bluish-green color developed of different 
concentrations ranging from 0 to 10 ppm. The absorbance at 760 nm was measured using a 
Bio-Tek KC4 Power Wave XS micro plate reader (Analytical and Diagnostic Products, South 
Africa). The tannic acid content in the standard solutions, as well as sample were expressed as 
mg/g of tannic acid equivalents using the calibration plot. The experiment was conducted in 
triplicate and the results expressed as the mean ± SD.  
 
2.2.5.2.3 Determination of total flavonoids  
Total flavonoid content in crude S. frutescens extracts was determined using a flavonoid-
aluminium chloride complex colorimetric method as, described by Ordonez et al. (2006) [245]. 
Briefly, 0.5 mL of individual solvent extract (0.1 mg/mL) was mixed with 0.5 mL of 2 % 
aluminium chloride (AlCl3) prepared in ethanol and incubated for 1 hour at room temperature. 
The absorbance was measured at 420 nm using a Bio-Tek KC4 Power Wave XS micro plate 
reader (Analytical and Diagnostic Products, South Africa). A yellow colour change indicates 
the presence of flavonoids. Total flavonoid content in the test samples were calculated from 
the calibration plot and expressed as mg/g of quercetin equivalents. The experiment was 
conducted in triplicate and the results expressed as the mean ± SD.  
 
 
2.2.5.2.4 Estimation of total flavonols 
Total flavonol content in crude S. frutescens extracts was determined using a modified 
Kumaran and Karunakaran method as described by Adedapo et al. (2008 ) [246]. The reaction 
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mixture consisted of 2.0 mL of the sample extract, 2.0 mL of 2% AlCl3 prepared in ethanol and 
3.0 mL of (50 g/L) sodium acetate solution. The absorbance at 440 nm was measured after 2.5 
h of incubation at 20°C using a Bio-Tek KC4 Power Wave XS micro plate reader (Analytical 
and Diagnostic Products, South Africa). The content of flavonols was calculated as mg/g of 
quercetin equivalents using a standard curve obtained from various concentrations of quercetin. 
The experiment was conducted in triplicate and the results expressed as the mean ± SD.  
 
2.2.6 Fractionation/Purification of crude extracts by Solid Phase Extraction Method 
Crude plant extracts contain multiple complex components. Hence, pre-concentration is needed 
to analyze targeted analytes by chromatographic methods. The use of SPE in the isolation and 
purification of bioactive compounds from crude plant extracts has been established by prior 
studies [247, 248]. SPE is a useful sample preparation technique that involves the use of a 
variety of media (sorbent) such as chemically bonded silica, usually with a C8 or C18 organic 
group and a porous polystyrene polymeric sorbent to trap analytes over a wide range of 
polarities [249]. The choice of SPE media (sorbent) is determined by the sample matrix 
composition, analyte properties and interaction mechanism between the analyte and the media 
during the extraction process[250, 251].  
For the purpose of this study, Strata - X polymeric reverse phase and ion exchange extraction 
methods were used to fractionate polar and non-polar groups of compounds from the crude 
plant extracts obtained in sections 2.2.3.1-2.2.3.3. Disposable Strata™ X polymer-based 
sorbent (200 mg/3 mL) mixed mode SPE syringe columns: Strata-X-C 33u polymeric strong 
cation, Strata-X-CW 33u polymeric weak cation, Strata-X-A 33u polymeric strong anion, 
Strata-X-AW 33u polymeric weak anion, and Strata-X 33u polymeric reversed phase 
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(Phenomenex, USA) were used to obtain a clean and concentrated target group of compounds 
prior to analysis by LC-MS.  
 
2.2.6.1 Steps in solid phase extraction 
The procedure of SPE generally consists of 5 main steps [252]. Step 1; conditioning (activation) 
of the sorbent with a suitable solvent to promote good surface contact between the sample and 
sorbent as well as to activate the functional groups on its surface to ensure a proper binding 
environment. Step 2; equilibration to remove the activation solvent. Step 3; passing of the 
sample through the sorbent bed by gravity, or application of vacuum such that the analyte will 
be retained by the sorbent. Step 4; washing away or removal of interfering 
compounds/impurities retained on the sorbent, while avoiding elution of analyte. Step 5; 
elution of the analyte retained on the sorbent using a suitable solvent or mixture of solvents, 
resulting in a highly purified extract (Figure 2.1). 
 
 
 
Figure 2.1: Steps in Solid Phase Extraction[252] 
2.2.6.2 Extraction of basic compounds with pKa ≤ 10.5 by Strata™ X-C cation exchange 
SPE   
A Strata-X-C 33u Polymeric Strong Cation cartridge (Phenomenex, USA) with a sorbent mass 
of 200 mg and sample volume of 3 mL was used to extract weak bases with pKa ≤ 10.5. The 
sorbent is composed of Strata X polymer with the surface modified with styrene divinylbenzene 
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and sulfonic acid functional group (highly selective for weakly basic compounds). This 
polymeric sorbent provides 3 mechanisms of retention; strong cation exchange (sulfonic acid 
ligand), π-π bonding, and hydrophobic interaction. This allows complete retention of basic 
compounds with pKa ≤ 10.5 and removal of matrix interferences such as phospholipids.  The 
SPE phase selected for this extraction used a mixed-mode reversed phase and strong cation 
exchange mechanism. The solid phase extraction procedure was carried out as described by the 
manufacturer’s instruction. The cartridge (sorbent) was conditioned with 1 mL methanol and 
equilibrated with 1 mL acidified water (1% trifluoroacetic acid in deionized H2O). Post 
conditioning, 3 mL of dissolved acidified sample extract (0.06 g) was loaded onto the 
conditioned cartridge and then washed with 1 mL 0.1N HCl in water to remove all polar 
neutrals. This was then followed by a second wash step with 1 mL 0.1N HCl in methanol to 
remove all neutrals/acids. The samples were eluted from the cartridge with 1 mL (2x 500 µl) 
of 5% NH4OH in methanol to strip the column of retained bases (i.e. weak bases). This fraction 
was collected for LC-MS analysis.  
 
 
 
2.2.6.3 Extraction of basic compounds with pKa > 8 by Strata™ X-CW anion exchange 
SPE 
A 200 mg/3 mL Strata-X-CW 33u Polymeric Weak Cation cartridge (Phenomenex, USA), was 
used to extract bases with pKa > 8 (strongly basic compounds). The sorbent has extremely tight 
retention of basic compounds with a pKa > 8 and is capable of removing matrix interferences. 
The sorbent is composed of Strata X polymer with the surface modified with styrene 
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divinylbenzene and carboxylic acid functional group (allows for reversible binding of strong 
bases and quaternary amines; highly selective for all basic compounds). This polymeric sorbent 
also provides 3 mechanisms of retention; weak cation exchange (Carboxylic acid ligand), π-π 
bonding, and hydrophobic interaction. The SPE phase selected for this extraction used a mixed-
mode reversed phase and weak cation exchange mechanism. The solid phase extraction 
procedure was carried out as described by the manufacturer’s instructions. The cartridge was 
conditioned with 1 mL methanol and equilibrated with 1 mL deionized water, pH 6.5. After 
the conditioning step, 3 mL of dissolved sample extract (0.06 g) pH 6.5, was loaded onto the 
conditioned cartridge and then washed with 1 mL water, pH 6.5. This was then followed by a 
second wash step with 1 mL methanol to remove all neutrals/acids. The samples were eluted 
from the cartridge with 1 mL (2x 500 µL) of 5% formic acid in methanol to strip the column 
of retained strong bases elution, (E) 1, and eluted again with 1 mL (2x 500 µL) of 5% NH4OH 
in methanol to elute weak bases, E2. Fractions were collected for Triple TOF LC-MS analysis.  
 
2.2.6.4 Extraction of Acidic Compounds with pKa > 2 by Strata-X-A ion-exchange SPE 
A Strata-X-A 33u Polymeric Strong Anion cartridge (Phenomenex, USA), 200 mg/3 mL was 
used to extract acids with pKa > 2 (weakly acidic compounds). The sorbent is composed of 
Strata X polymer with the surface modified with styrene divinylbenzene and dimethyl butyl 
quaternary amine functional group (provides strong retention of weakly acidic analytes). Like 
the previous sorbents, this polymeric sorbent provides 3 mechanisms of retention; strong anion 
exchange (di-methylbutyl quaternary amine ligand), π-π bonding, and hydrophobic interaction. 
The sorbent allows for complete retention of weakly acidic compounds with pKa > 2. The SPE 
phase selected for this extraction used a mixed-mode reversed phase and strong anion exchange 
mechanism. The solid phase extraction procedure was carried out as described by the 
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manufacturer’s instructions. The cartridge was conditioned with 1 mL Methanol and 
equilibrated with 1 mL deionized water. Next, 3 mL of dissolved sample extract (0.06 g) pH 
6.5 was loaded onto the conditioned cartridge and then washed with 1 mL 25 mM ammonium 
acetate buffered to pH 6.5. This was followed by a second wash step with 1 mL methanol to 
remove all neutrals/bases. The samples were eluted from the cartridge with 1 mL (2x 500 µL) 
of 5% formic acid in methanol to strip the column of retained strong acids. The fraction was 
collected for subsequent Triple TOF LC-MS analysis.  
 
2.2.6.5 Extraction of Acidic Compounds with pKa ≤ 5 by Strata X-AW ion exchange SPE 
A Strata-X-AW 33u Polymeric Weak Anion cartridge (Phenomenex, USA) with a sorbent mass 
of 200 mg and sample volume of 3 mL was used to extract any acids with pKa ≤ 5 (strongly 
acidic compounds). The sorbent is composed of Strata X polymer with the surface modified 
with styrene divinylbenzene and di-amino functional groups (highly selective for charged 
acidic compounds). Again this polymeric sorbent provides 3 mechanisms of retention; weak 
anion exchange (di-amino ligand), π-π bonding, and hydrophobic interaction. This cartridge 
allows for complete retention of acidic compounds with pKa ≤ 5. The SPE phase selected for 
this extraction uses a mixed-mode reversed phase and weak anion exchange mechanism. The 
solid phase extraction procedure was carried out following the manufacturer’s instructions. The 
cartridge was conditioned with 1 mL methanol and equilibrated with 1 mL deionized water 
(pH 6.5) after which 3 mL of dissolved sample extract (0.06 g), pH 6.5 was loaded onto the 
conditioned cartridge and then washed with 1 mL 25 mM ammonium acetate buffered to pH 
6.5. This was followed by a second wash step with 1 mL methanol. The samples were eluted 
from the cartridge with 1 mL (2x 500 µL) of 5% NH4OH in methanol to strip the column of 
retained strong acids, elution (E) 1, and eluted again with 1 mL (2x 500 µL) of 5% formic acid 
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in methanol to elute weak acids, E2. Fractions were collected for further Triple TOF LC-MS 
analysis.  
 
2.2.6.6 Extraction of Neutral Compounds by Strata X Reverse phase SPE 
A Strata-X 33u Polymeric reversed phase cartridge (Phenomenex, USA), 200 mg/3 mL was 
used to extract non-polar, hydrophobic and uncharged compounds (neutral and aromatic 
compounds). The cartridge is composed of Strata X polymer with a modified N-
vinylpyrrolidone functional group surface. This polymeric sorbent provides 3 mechanisms of 
retention; π-π bonding, hydrogen bonding (dipole-dipole interactions) and hydrophobic 
interaction. This cartridge has high retention of neutral compounds. The SPE phase selected 
for this extraction uses a reversed phase mechanism. The solid phase extraction procedure was 
carried out following the manufacturer’s instructions. The cartridge was conditioned with 1 mL 
methanol and equilibrated with 1 mL deionized water after which 3 mL of dissolved sample 
extract (0.06 g), was loaded onto the conditioned cartridge and then washed with 1 mL 60% 
methanol. The samples were eluted from the cartridge with 1 mL (2x 500 µL) of 2% formic 
acid in methanol to strip the column of retained neutral compounds. The fraction obtained was 
collected for further Triple TOF LC-MS analysis.  
 
2.2.7 Liquid Chromatography-Mass Spectrometry (LC-MS) analysis and identification 
of bioactive components 
The above preliminary analysis revealed the presence of bioactive phytocompound groups 
(flavonoids, flavonols, tannin, phenols) within the aqueous and organic crude S. frutescens 
extracts. Prior studies have successfully used the LC-MS technique for the separation and 
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identification of targeted bioactive compounds from S. frutescens [253, 254]. Using the new 
AB SCIEX TripleTOF™5600 LC/MS/MS system (Applied Bio systems Sciex, USA), I further 
identified possible bioactive daughter phytocompounds present within crude S. frutescens 
extracts. The new AB SCIEX TripleTOF™5600 LC/MS/MS system is the next generation in 
quadrupole TOF technology. This instrument adds high resolution at the speed and sensitivity 
needed to give percentage of coefficient variations (%CVs) and limits of quantitation (LOQ) 
equivalent to those of high-end triple quadrupoles. 
Mass spectrometry measures the mass-to-charge ratio of ions to identify unknown compounds 
and provide information about the structural and chemical properties of molecules. The 
TripleTOF®5600/5600+ system has a series of quadrupole filters that transmit ions according 
to their mass-to-charge (m/z) value. The QJet®ion guide is the first quadrupole in this series. 
The QJet ion guide does not filter ions, but focuses them before they enter the 
Q0 region. By prefocusing the larger ion flux created by the wider orifice, the QJet ion guide 
increases instrument sensitivity and improves the signal-to-noise ratio. The ions are again 
focused in the Q0 region before passing into the Q1 quadrupole. 
In the Q1 quadrupole, the ions are sorted before they enter the Q2 collision cell. In the Q2 
collision cell, the internal energy of the ions is increased through collisions with gas molecules 
to the point that molecular bonds break, creating product ions. This technique enables the 
design of experiments that measure the m/z of product ions to determine the composition of 
the parent ions.  
After passing through the Q2 collision cell, the ions enter the TOF region for additional mass 
analysis, and then enter the detector. In the detector, the ions create a current that is converted 
into a voltage pulse. These voltage pulses are counted, and the number of pulses leaving the 
detector is directly proportional to the quantity of ions entering the detector. The instrument 
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monitors the voltage pulses and converts the information into a signal. The signal represents 
the ion intensity for a particular m/z value and the instrument displays this formation as a mass. 
For the purpose of this study, a non-targeted (without a preceding selection of compounds of 
interest) screening technique was employed to identify new or previously unrecognized 
bioactive compounds in the sample extracts.  
 
2.2.7.1 Sample preparation 
Both crude aqueous and organic extracts were weighed and reconstituted in deionized 
water/acetonitrile 50:50 (v/v) and methanol respectively to produce individual stock solutions 
(0.1 mg/mL). The mixture was then vortexed and centrifuged at 13000 rpm for 1 min, and the 
supernatant was filtered through a 0.2 µm acrodisc filter (PALL, USA) and then placed into 2 
mL LC-MS vials ready for analysis. Each SPE fraction was injected directly as an LC-MS 
sample. 
 
 
2.2.7.2 Instrumentation and chromatographic conditions 
LC-MS Triple-TOF qualitative analyses of extracts and fractions were performed with a high 
performance Agilent 1260 infinity liquid chromatography system coupled with the 5600 AB 
SCIEX Triple TOF hybrid mass spectrometer (Applied Bio systems Sciex, USA) and operated 
in both the positive and negative turbo ion spray (ESI) mode. The individual sample extracts 
(200 µL) were separated/analyzed using a reverse phase Poroshell 120; EC-C18 column (7 µm, 
4.6 mm x 50 mm, Agilent Technologies) or ZORBAX SB-C18 column (5 µm, 4.6 mm x 250 
mm). The mobile phase used was 0.1% (v/v) formic acid in deionized water (Solvent A), and 
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0.1% (v/v) formic acid in acetonitrile (Solvent B). Extraction/elution of bound compounds was 
achieved using a flow rate of 0.5 mL/min with the following gradient: 95% A: 5% B to 5% A: 
95% B for 10 min, kept constant for 1 minute. Finally, it was returned to the initial conditions 
in 0.5 min and kept constant for 5 minutes, giving a total run time of 17 min. The sample 
injection volume was 200 µL. The column was equilibrated with deionized water/0.1% formic 
acid at a flow rate of 5 mL/min for 5 minutes. TOF MS parameter settings were as follows: the 
declustering potential (DP) was 60 V and Collision Energy (CE) was 35V with collision energy 
spread (CES) of ± 35V. Product ion parameters were as follows: the IonSpray Voltage Floating 
parameter (ISVF) 5500, the Ion Source Gas 1 (GS1) parameter was 50 psi, the Ion Source Gas 
2(GS2) parameter was 50 psi and Temperature (TEM) was 6000 C. An Agilent 1260 High 
Performance Auto sampler, with a 100 µL syringe was used, with an injection volume of 200 
µL, to draw and inject the samples at a speed of 200 µL/min. The Agilent column oven was set 
at 40°C for both right and left temperatures with a temperature tolerance of +/- 2°C. 
 
 
2.2.7.3 LC-MS Data analysis 
2.2.7.3.1 Generation of total ion chromatograms of untargeted analytes 
Full scan acquisition to obtain total ion chromatograms (TICs) of untargeted analytes was 
performed with the aid of the PeakView Analyst software v1.1.1 (Absciex) (Figure 2.2) 
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Figure 2.2: Total Ion Chromatograms obtained from crude extracts of S. frutescens   
 
2.2.7.3.2 Identification of the elementary composition of untargeted analytes  
The elementary composition of the untargeted compounds in crude S. frutescens extracts was 
obtained using the XIC manager/IDA (independent data acquisition) (Absciex). The XIC 
Manager is an add-in for the PeakView™ software. It allows the management of large lists of 
compounds and performs automatic extracted ion chromatogram (XIC) calculations from a 
table of defined list of masses or formulae. The XIC manager also has the ability to review the 
results of the XIC including any library search results.  
 
2.2.7.3.2.1 Generation of XIC list 
For the purpose of this study, the XIC list was generated from the Plant Metabolic Network 
(PMN) database (http://pmn.plantcyc.org/PLANT/class-instances?object=Compounds). 
PlantCyc database contains pathways and their catalytic enzymes and genes, as well as 
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compounds from over 350 plant species (2982 compounds) [255].  
 
2.2.7.3.2.2 Defining an XIC list 
The XIC table contains columns with values that can be edited, including Name, Formula, and 
Retention Time. To define an XIC, either a chemical formula or a mass must be defined. All 
other columns are either optional or contain default values [256].  
 
2.2.7.3.2.3 XIC list column descriptions 
The description of the columns in the XIC list is as seen in Table 2.1 
Table 2.1: Descriptions of the columns in the XIC list [256] 
Column Name Description 
# The line number of the XIC when it was entered in the table. 
Used for reverting the list to its original order. 
 
Used to set which XICs will be calculated or have a specific 
action performed on them. See Exporting to MultiQuant™ 
Software for an example. 
 
A visual representation of the quality of an XIC. This includes 
how well: 
 the detected mass spectral peak matches the defined 
extraction mass. 
 the detected retention time matches the expected retention 
time. 
 the isotope pattern from the detected mass spectral peak 
matches the theoretical isotope pattern from the defined 
chemical formula. 
 the purity score from the best library search hit. 
The traffic lights for each of these values are displayed as red, 
yellow, or green. The criteria for this are set using the Options 
dialog. 
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Column Name Description 
If a value was not calculated then the traffic light is disabled. 
Name A name to represent the XIC. Used to label the XIC in the 
PeakView chromatogram panel. 
Formula Any valid chemical formula. The mass of this formula is 
calculated and then automatically entered in the Mass column. 
If the Name column is empty, then this formula is also used as 
the Name for the XIC. 
Isotope By default, the monoisotopic value for a formula is used to 
calculate the mass. For some formulae (for example, highly 
chlorinated and brominated compounds) it is preferable to use 
the second, third, or higher isotope. Use this column to define 
which isotope to use. 
Mass (Da) The neutral mass (not m/z) of the compound this XIC defines. 
This mass can be entered directly or it can be calculated 
automatically when a Formula is entered. 
Adduct / Modification Use this column to enter any ionization, adduct, or modification 
chemical formula. The mass of this formula is added to the 
value in the Mass column to determine the actual Extract Mass 
used for generating the XIC. For most positive mode XIC, this 
column will be +H, to indicate protonation. A doubly-charged 
molecule is indicated using +2H. 
This value will default to the last Adduct / Modification value 
entered. 
Extraction Mass (Da) This is a non-editable value that is calculated from the Mass 
(Da) and the Adduct / Modification values. This value is used 
for calculating the XIC. 
Width (Da) The total width of the XIC window.  
This value will default to the last value entered. 
Found At Mass (Da) The mass calculated from the mass spectral peak detected 
during the XIC. Spectral peak detection is performed at the 
apex of the XIC, at the rising portion of the XIC, and at the 
falling portion of the XIC. The spectral peak with an intensity 
greater than 300 and closest to the expected Extraction Mass is 
used. If no peak has an intensity greater than 300, then the peak 
detected at the apex of the XIC is used. 
Error (ppm) The mass error, in parts per million, of the Found At Mass 
compared with the Extraction Mass. 
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Column Name Description 
Error (mDa) The mass error, in milliDaltons, of the Found At Mass 
compared with the Extraction Mass. 
Expected RT (min) If the retention time of the compound is known, enter the value 
here. This limits the XIC to only calculate the XIC in this 
region, greatly improving the calculation time. 
RT Width (min) The total width of the retention time window that is used to 
calculate the XIC. Only used if a non-zero Expected RT is 
specified. 
Found At RT (min) The largest peak in an XIC is automatically detected when an 
XIC is calculated. The actual retention time of the detected peak 
is displayed here.  
Intensity The intensity at the apex of the detected XIC peak. 
Library Hit The name of the compound with a matching library spectrum. 
Purity Score The purity score of the matching library spectrum compared 
with the acquired spectrum. 
 
2.2.7.3.2.4 Confidence Settings 
The thresholds for displaying green, yellow, or red for the traffic lights in the confidence 
column are defined in Figure 2.3. 
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Figure 2.3: XIC manager confidence Settings 
 
2.2.7.3.2.5 Displaying Results   
The XIC is calculated from the mass spectra and the results are displayed in the XIC table, 
including found mass, mass error, found retention time, and library search results (Figure 2.4). 
The confidence in results is visualized using traffic lights. Each column of the result table can 
be used to sort generated results for each parameter. In addition, the filter XIC list function 
searches for specific information. 
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Figure 2.4: XIC manager showing automatically extracted ion chromatograms displayed in 
chromatographic pane obtained from crude extracts of S. frutescens.  
The retention time chromatogram, TOF-MS and product ion of identified compounds from 
crude S. frutescens extracts were obtained by selecting the identified compound in the XIC 
manager and obtaining the associated MS spectra. The results are displayed as shown in figure 
2.5. The TOF-MS pane displays the mother peak and its mass found at a specific retention 
!
!
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time, whilst the product ion pane displays broken down fragments of the mother peak. 
 
 
Figure 2.5: Result table obtained from non-targeted screening from organic crude extracts of 
S. frutescens  
 
2.2.8 Identification of bioactive (anti-diabetics) compounds from generated XIC results 
Having identified the compounds present in crude S. frutescens extracts, the next procedure 
was to identify possible bioactive (anti-diabetic) compounds present in the XIC results 
generated for each solvent extract. In doing this, the XIC results of individual extracts with two 
online databases of anti-diabetic phytocompounds were compared: DIACAN: Integrated 
Database for Anti-diabetic and Anti-cancer Medicinal Plants (http://www.kaubic.in/diacan) 
[257] and Phyto diab care: Phytoremedial database for anti- diabetics  
Retention time pane 
Automatic extracted ion chromatogram results 
TOF MS pane Product ion pane 
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(http://www.gbpuatcbsh.ac.in/departments/bi/database/phytodiabcare/HOME%20PAGE/Ho
me%20page.html) [258].   
 
2.2.9 Chemical structures of identified possible anti-diabetic compounds 
The chemical structures of identified anti-diabetic phytocompounds were obtained from ChEBI 
(Chemical Entities of Biological Interest) (https://www.ebi.ac.uk/chebi/), which is a freely 
available online dictionary of molecular entities, focused on chemical entities. Nomenclature, 
symbols and terminology used by ChEBI are endorsed by the International Union of Pure and 
Applied Chemistry (IUPAC) and the Nomenclature Committee of the International Union of 
Biochemistry and Molecular Biology (NC-IUBMB) [259].  
 
2.2.10 Comparison of anti-diabetic phytocompounds between extracts 
An online bioinformatics tool (Bioinformatics & Evolutionary Genomics) 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to identify possible anti-
diabetics phytocompounds common within groups of extracts.  
 
2.2.11 Statistical analysis 
The experimental results were expressed as the mean ± standard deviation (SD) of three 
replicates. For the phytochemical analysis, One Way Analysis of Variance (ANOVA) was used 
to determine the significance of the difference in the extracts used. 
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2.3 Results  
2.3.1 Extractant efficiency 
 Based on their extracting power and the technique of extraction (i.e. application of heat and/or 
mixing), different solvent extractants have been shown to exhibit remarkable differences in 
their extraction yield [242, 260]. In this study, using a single step extraction process, the 
extraction yield of hot aqueous, cold aqueous, 80% ethanol, 100% ethanol 80% methanol and 
100% methanol from 16 g of fresh powdered S. frutescens plant material was evaluated. The 
results obtained, as shown in figure 2.6 revealed, that the hot aqueous extractant was 
quantitatively the best extractant, extracting 1.99 g of plant material compared to 80% ethanol 
(1.403 g), 100% methanol (1.37 g), cold aqueous (1.09 g) and 80% methanol (1.05 g), while 
100% ethanol has the lowest mass extracted (0.52 g) (Figure 2.6). Thus suggesting that the 
application of heat (hot aqueous) could play a vital role in extraction of bioactive compounds 
from S. frutescens. Thus justifying the traditional use of a tea infusion of S. frutescens [261]. 
 
Figure 2.6: Mass of samples extracted by different solvents with varying polarity from 16 g 
of powdered S. frutescens. 
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2.3.2 Qualitative phytochemical analysis of S. frutescens extracts 
Using colorimetric and spectrophotometric techniques, the levels of flavonoids, flavonols, 
tannins, and phenols present in aqueous and organic S. frutescens extracts were qualitatively 
and quantitatively investigated. Furthermore, using statistical tools (One-Way Analysis of 
Variance), the concentrations of these compounds in individual extracts were compared.  
All extracts showed the presence of flavonoids (greenish yellow color), flavonols (pale yellow 
color), tannins (bluish green color), and phenols (bluish green color) with varying intensity. 
They all exhibited a moderate color intensity (++) for tannins and phenols (Table 2.2), while 
the organic extracts 100% methanol, 80% and 100% ethanol exhibited high color intensity 
(+++) for flavonoids and flavonols respectively (Table 2.2). 
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Table 2.2: Qualitative phytochemical analysis of flavonoids, flavonols, tannins and phenols in 
aqueous and organic extracts of S. frutescens. 
 
Solvents Flavonoids Flavonols Tannins Phenols 
 
Hot aqueous 
 
++ 
 
++ 
 
++ 
 
++ 
 
Cold aqueous 
 
++ 
 
++ 
 
++ 
 
++ 
 
80% Ethanol 
 
++ 
 
+++ 
 
++ 
 
++ 
 
100% Ethanol 
 
++ 
 
+++ 
 
++ 
 
++ 
 
80% Methanol 
 
++ 
 
++ 
 
++ 
 
++ 
 
100% Methanol 
 
+++ 
 
++ 
 
++ 
 
++ 
  
+; Low intensity 
++; Moderate intensity 
+++; High intensity 
 
2.3.3 Quantitative phytochemical analysis of S. frutescens extracts 
Spectrophotometric analysis of S. frutescens extracts revealed that all the organic extracts 
contained a statistically significant higher concentration (in mg/g of extract) of flavonols when 
compared to the aqueous extracts (0.79 mg/g, 0.62 mg/g, 0.495 mg/g and 0.42 mg/g for 100% 
ethanol, 80% ethanol, 100% methanol and 80% methanol, respectively vs 0.36 mg/g and 0.30 
mg/g for hot and cold aqueous; P < 0.001 in all cases)  (Figure 2.7 ii). Similarly, higher 
concentrations of tannins were found in the organic extracts, when compared to both aqueous 
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extracts (0.095 mg/g, 0.090 mg/g and 0.089 mg/g for 100% methanol, 80% methanol and 100% 
ethanol, respectively vs 0.074 mg/g and 0.073 mg/g for both hot and cold aqueous; P < 0.001 
in all cases) (Figure 2.7 iii). With the exception of 100% methanol (0.028 mg/g), both aqueous 
extracts contained a slightly higher concentration of flavonoids compared to the remaining 
organic extracts. However this was not found to be statistically significant (0.027 mg/g and 
0.028 mg/g for hot and cold aqueous vs 0.024 mg/g, 0.026 mg/g, 0.026 mg/g for 80% ethanol, 
100% ethanol and 80% methanol, respectively) (Figure 2.7 i). All extracts contained 
approximately equal levels of phenols (Figure 2.7 iv). Taken together, these data confirm the 
presence of all four groups of bioactive phytocompounds in the S. frutescens extracts used in 
this study, and also confirm that different solvent extractants possess the capability to 
differentially extract specific groups of phytocompounds. 
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Figure 2.7: Concentrations of (i) flavonoids, (ii) flavonols, (iii) tannins and (iv) phenols 
found in aqueous and organic extracts of S. frutescens. *; P < 0.05, **; P < 0.01, ***; P < 
0.001. 
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2.3.4 LC-MS analysis of crude and SPE fractions of S. frutescens extracts 
It is well established that plant mixtures contain hundreds of chemical constituents, but only a 
few components are bioactive [262]. Therefore, it is essential to identify and measure all of the 
bioactive constituents of medicinal plants [263]. However, the inherent complexity and 
variability of plant extracts has presented significant challenges for separation, detection and 
analysis of their chemical composition [264]. From the perspective of separation, modern 
chromatographic methods have been shown to be highly efficient in the analysis of natural 
products including plant extracts [265]. Hence, using the new AB SCIEX TripleTOF™5600 
LC/MS/MS system, untargeted compound constituents present in crude and SPE fractionated 
S. frutescens extracts were identified. 
Application of Triple TOF LC/MS/MS enables the separation of compounds in crude and SPE 
fractions of S. frutescens extracts by their ionic masses (ion chromatograms) and retention time. 
Further analysis with PeakView Analyst software v1.1.1 and XIC manager identified numerous 
compounds within each extract. List of some compounds identified are shown in Appendix I 
(Table I-XXII).  
 
2.3.4.1 Identification of bioactive (anti-diabetics) compounds in crude aqueous and 
organic extracts of S. frutescens 
Initially, the crude aqueous (hot and cold) and organic extracts of S. frutescens were screened 
for bioactive phytocompounds. To detect possible bioactive compounds in the identified list of 
compounds from crude extracts of S. frutescens, compounds identified by Triple TOF 
LC/MS/MS in each of the individual crude aqueous and organic extracts with a list of already 
identified anti-diabetic phytocompounds (327 compounds) obtained from the online databases 
DIACAN [257] and Phyto diab care [258] (Appendix II) were compared. 
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2.3.4.1.1 Anti-diabetic compounds in crude aqueous (Hot and Cold) extracts of S. 
frutescens  
As shown in Figure 2.8 a and c, 3 anti-diabetic compounds common to the crude aqueous (hot 
and cold) extracts of S. frutescens were identified namely; α-pinene, Limonene and Sabinene. 
Stigmasterol and Myricetin, a hydroxyflavone, were found in the cold aqueous extracts alone 
(Figure 2.8 b and c). Compounds were found at retention times (RT) ranging from 4.90 minutes 
- 14.49 minutes (Table 2.3).  Of these compounds, α-pinene had good confidence parameters 
(mass error (ppm) ≤ 5.0 and isotope ratio % difference ≤ 10.0) (Figure 2.9), while Sabinene 
and Limonene had fair confidence parameters (mass error (ppm) ≤ 5.0 and isotope ratio % 
difference ≤ 20.0) (Figure 2.10 – 2.11). Stigmasterol and Myricetin had poor confidence 
parameters (mass error (ppm) ≤ 10 and isotope ratio % difference ≤ 20.0), and therefore 
Myricetin (the poorest) is not shown. Further comparison between hot and cold aqueous 
extracts showed that both extracts had 21 other non-anti-diabetic compounds in common, 74 
compounds were specific for the crude cold extract alone, whilst 20 compounds were specific 
for the crude hot extract (Figure 2.8 c).    
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Figure 2.8: Anti-diabetic compounds identified in crude (a) Hot, (b) cold aqueous and (c) 
comparison of both aqueous extracts of S. frutescens 
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Table 2.3: Anti-diabetic compounds identified in crude aqueous (hot and cold) extracts of S. 
frutescens 
Name  Formula Mass (Da) Found at mass 
(Da)  
Found at RT 
(min) 
 
α-Pinene 
 
C10H16 
 
136.1252 
 
137.13229 
 
10.63 
 
Limonene 
 
C10H16 
 
136.1252 
 
137.13192 
 
13.04 
 
Myricetin 
 
C15H10O8  
 
318.23510 
 
318.23510 
 
4.99 
 
Sabinene 
 
C10H16 
 
136.1252 
 
137.13248 
 
9.43 
 
Stigmasterol 
 
C29H48O  
 
412.69082  
 
412.69082  
 
14.49 
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Figure 2.9:  Chromatogram of α-pinene identified in crude aqueous (hot and cold) extracts of 
S. frutescens 
RT = 10.63 min 
Found at mass (Da) = 137.13229 
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Figure 2.10:  Chromatogram of Sabinene identified in crude aqueous (hot and cold) extracts 
of S. frutescens 
RT = 9.43 min 
Found at mass (Da) = 137.13248 
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Figure 2.11:  Chromatogram of Limonene identified in crude aqueous (hot and cold) extracts 
of S. frutescens 
RT = 13.04 min 
Found at mass (Da) = 137.13192 
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Figure 2.12:  Chromatogram of Stigmasterol identified in crude aqueous cold extract of S. 
frutescens 
RT = 14.49 min 
Found at mass (Da) = 412.69082  
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2.3.4.1.2 Anti-diabetic compounds in crude organic extracts of S. frutescens  
Analysis of the crude organic (80% and 100% ethanol) extracts of S. frutescens identified 2 
anti-diabetic compounds (Rutin and Carvone) common to both the 80% and 100% ethanolic 
extracts of S. frutescens (Figure 2.13 b and c) whilst Emodin and Limonene were found in the 
80% ethanol extract alone (Figure 2.13a). Compounds were found at RT ranging between 8.35 
minutes – 14.30 minutes (Table 2.4). Data from the XIC manger showed that Rutin and Emodin 
had fair confidence parameters (mass error (ppm) ≤ 10 and isotope ratio % difference ≤ 10) 
(Figure 2.14 and 2.15), whilst both Carvone and Limonene had poor confidence parameters 
(mass error (ppm) > 10 and isotope ratio % difference ≤ 20) (Figure 2.16 and 2.17). Further 
comparison between the two extracts (80% and 100% ethanol extracts) as seen in figure 2.13 
c showed that 146 and 86 non-diabetic compounds were specific for 80% and 100% crude 
methanol extract while both extracts shared a total of 74 non-diabetic compounds. 
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Figure 2.13: Anti-diabetic compounds identified in crude (a) 80% (b) 100% and (c) 
comparison of both ethanolic extracts of S. frutescens 
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Figure 2.14: Chromatogram of Rutin identified in crude ethanolic extracts of S. frutescens 
RT = 8.35 min 
 Found at mass (da) =610.517 
610610.51750  610.51750  
MS/MS  
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Figure 2.15: Chromatogram of Emodin identified in crude 80% ethanol extracts of S. 
frutescens 
 RT = 8.73min 
 Found at mass (da) = 270.23690 
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Figure 2.16: Chromatogram of Carvone identified in crude ethanol extracts of S. frutescens 
 
 
 RT = 14.3 min 
 Found at mass (da) = 151.11702 
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Figure 2.17: Chromatogram of Limonene identified in crude 80% ethanol extract of S. 
frutescens 
 
 
 RT = 11.44 min 
Found at mass (da) = 137.13621 
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Table 2.4: Anti-diabetics compounds identified in crude ethanolic (80% and 100%) extracts of 
S. frutescens 
Name  Formula Mass (Da) Found at mass 
(Da)  
Found at RT 
(min) 
Rutin C27H30O16 610.51750 610.51750 8.35 
Emodin C15H10O5 270.23690  270.23690  8.73 
Carvone C10H14O1 150.10447 151.11702 14.3 
Limonene C10H16 136.1252 137.13621 11.44 
 
Analysis of the S. frutescens methanolic extracts identified Hypoglycin B and Stigmasterol in 
both the 80% and 100% methanol extracts (2.18 c), whilst Sarpagine was identified in the 80% 
extract alone (Figure 2.18 a),  and Limonene was found in the 100% (Figure 2.18 b) methanolic 
S. frutescens extract alone. The retention time (RT) for these compounds was within the range 
9.69 min – 16.15 min (Table 2.5). As seen in figures 2.19-2.22, the confidence parameter of 
individual compounds was as follows; Hypoglycin B (Mass error (ppm) > 10 and isotope ratio 
% difference ≤ 10); Stigmasterol (Mass error (ppm) ≤ 5 and isotope ratio % difference >20); 
Sarpagine (Mass error (ppm) ≤ 5 and isotope ratio % difference ≤ 20) and Limonene (Mass 
error (ppm) ≤ 5 and isotope ratio % difference ≤ 20). Both methanolic extracts shared 76 non-
diabetic compounds, whilst 120 non-diabetic compounds were specific for the 80% and 118 
for the 100% methanol extract.  
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Figure 2.18: Anti-diabetic compounds identified in crude (a) 80% (b) 100% and (c) 
comparison of both methanolic extracts of S. frutescens 
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Figure 2.19: Chromatogram of Hypoglycin B identified in crude methanolic extracts of S. 
frutescens 
 
 
 RT = 16.15 min 
Found at mass (da) = 270.281 
 MS/MS 
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Figure 2.20:  Chromatogram of Stigmasterol identified in crude methanolic extracts of S. 
frutescens 
 
Found at mass (da) = 412.960 
 RT = 13.23 min 
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Figure 2.21: Chromatogram of Sarpagine identified in crude 80% methanol extract of S. 
frutescens 
 
 
 RT = 9.69 min 
Found at mass (da) = 310.390 
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Figure 2.22: Chromatogram of Limonene identified in crude 100% methanol extract of S. 
frutescens 
 
Found at mass (da) = 137.1331 
 RT = 13.9 min 
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Table 2.5: Anti-diabetic compounds identified in crude methanolic (80% and 100%) extracts 
of S. frutescens 
Name  Formula Mass (Da) Found at mass 
(Da)  
Found at RT 
(min) 
Hypoglycin B C12H18N2O5 270.28172 270.28172 16.15 
Stigmasterol C29H48O 412.69082 412.69082 13.23 
Sarpagine C19H22N2O2 310.390 310.390 9.69 
Limonene C10H16 136.1252 137.1331 13.9 
 
2.3.4.1.3 Anti-diabetic compounds in both crude aqueous and organic extracts of S. 
frutescens  
Comparison analysis between individual extracts revealed anti-diabetic compounds identified 
in each individual extract. Results obtained showed that no single compound was found in all 
the extracts. However, Limonene was found in all the extracts except 100% ethanol and 80% 
methanol extracts (Table 2.6). 
 
Table 2.6: Comparison of anti-diabetic compounds identified in individual aqueous and 
organic extracts of S. frutescens 
 
Cold aqueous Hot aqueous  80% Ethanol 100%  
Ethanol 
80% Methanol 100% Methanol 
α-Pinene α-Pinene Rutin Rutin Hypoglycin B Hypoglycin B 
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Limonene Limonene Limonene Carvone Stigmasterol Limonene 
Myricetin Sabinene Carvone  Sarpagine Stigmasterol 
Sabinene  Emodin    
Stigmasterol      
 
Taken together, the data obtained from this preliminary untargeted LCM-MS screening of 
crude aqueous and organic extracts of S. frutescens suggest that S. frutescens extracts contain 
several anti-diabetic compounds that may work in synergy, or alone at a single specific site, or 
multiple sites in a cell to mediate their biological effects.  
 
2.3.4.1.4 Anti-diabetic compounds in SPE fractions of S. frutescens 
Analysis of ion chromatograms obtained from SPE fractions of S. frutescens aqueous, 100% 
ethanol and 100% methanol extracts, acquired in positive [H+] ion spray (ESI) mode revealed 
similar anti-diabetic compounds as seen in the individual crude extracts. However, compounds 
were found separated by their individual ionic charges as seen in table 2.7. Other non anti-
diabetic compounds identified in individual SPE fractions are listed in Appendix I.  
 
2.3.4.1.5 Comparison of compounds in crude and SPE fractions of S. frutescens acquired 
in both the positive and negative ion spray (ESI) mode. 
Further comparison of ion chromatograms obtained from crude and SPE fractions of S. 
frutescens acquired in both the positive [H+] and negative [H-] ion spray showed the presence 
of similar compounds in each extract, found at the specific ionic spray i.e. [H+] or [H-] (data 
not shown). 
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Table 2.7: Anti-diabetic compounds identified in SPE fractions of crude aqueous and organic 
extracts of S. frutescens 
-; no anti-diabetic compound found 
 
 
 
Extracts SPE fractions 
 Strong anions Weak anions Strong cations Weak cations Reverse Phase 
 
Cold 
aqueous 
 
- 
 
- 
Limonene 
α-pinene 
Sabinene 
Stigmasterol 
 
 
 
Stigmasterol 
 
Limonene 
α-pinene 
 
 
 
Hot aqueous 
 
- 
 
- 
α-pinene 
Limonene 
Sabinene 
 
 
- 
 
- 
 
100% 
Methanol 
 
- 
 
- 
 
Limonene 
Stigmasterol 
 
- 
 
 
Hypoglycin B 
 
 
 
100% 
Ethanol 
 
- 
 
 
Rutin 
 
 
 
Carvone 
 
 
- 
 
 
Emodin 
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2.4 Discussion  
For many decades, the use of synthetic chemicals as drugs has been effective in the treatment 
of diseases. However, the increased rates of resistance, rising costs and the possible toxicity of 
some synthetic drugs has led to the search for new therapeutics particularly from 
ethnopharmacology and traditional herbal medicine. Hence, over the past 20 years interest in 
traditional medicines has increased considerably in many parts of the world [266]. Many plant 
based (herbal) medicines have been shown to play an important role in health care [267].  
Medicinal plant species are reservoirs of natural products with remarkably high biodiversity, 
which can serve as a source of novel chemical entities with potential as drug treatments [236]. 
Phytochemicals are natural bioactive compounds found in medicinal plants, usually in leaves, 
flowers and roots. They act as plant defense system to combat against diseases. More than 1000 
different phytochemicals have already been shown to possess interesting therapeutic activities 
[268]. Phytochemicals comprises of a diverse range of chemical entities, such as polyphenols 
(tannins), flavonoids, flavonols, phenols, steroidal saponins, organosulphur compounds and 
vitamins [267].  
Sutherlandia frutescens (L.) R. BR., Family Fabaceae subsp. microphylla, is a multipurpose 
medicinal plant widely used in the Western Cape province of South Africa [269, 270]. Crude 
extracts of the plant have been shown to possesses anticancer [271], antidiabetic [222], 
antibacterial and antioxidant  properties, as well as inhibitory activity against HIV target 
enzymes [272]. However, despite extensive biological and pharmacological studies, few 
analyses exist of the chemical constituents of this medicinally important herbal plant [273], 
and no Triple TOF LC/MS/MS analysis has been performed. 
Based on their extracting power, different solvents exhibit remarkable differences in their 
extraction yield [242, 260]. However, in traditional medical practices, water is the chief solvent 
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and major extractant used in preparing herbal mixtures and extracting bioactive compounds 
from medicinal plants [242]. Moreover, water is not harmful to humans and is generally cheap 
and easily acquired. In South Africa, the use of S. frutescens tea infusion as a herbal mixture is 
a common practice [274]. 
In this study, crude aqueous (hot and cold) and organic (80% and 100% methanol and 80% and 
100% ethanol) extracts of S. frutescens were qualitatively and quantitatively investigated for 
the presence of phytocompounds tannins, flavonoids, flavonols, and phenols. Furthermore, 
using the Triple TOF LC-MS/MS, a preliminary phytochemical screening was performed to 
identify possible bioactive (anti-diabetic) chemical constituents of these extracts.  
The hot aqueous extractant was quantitatively the best extractant, extracting 1.99 g of extract 
from 16 g starting plant material, while the organic solvent (100% ethanol) was a poor 
extractant yielding 0.52 g of extract from 16 g starting plant material. It is therefore very 
plausible that the biological effects mediated by hot aqueous extract of S. frutescens are a 
consequence of its greater extracting power leading to extraction of more bioactive compounds 
from a given amount of plant material. 
Plant phenols range from simple low-molecular-weight phenolic glycosides to polymeric 
compounds [275]. Phenols and their metabolites are believed to play important roles in plant 
defense mechanisms [276]. However, in human medicinal therapy, phenols and phenolic 
compounds have been explored for their anti-cancer [277], anti-oxidant, anti-atherosclerotic, 
anti-bacterial, anti-inflammatory, and anti-viral properties [278, 279]. In this present study, 
aqueous and organic extracts of S. frutescens were investigated for their total phenolic content. 
All extracts contained approximately equal concentration of phenol. However, further analysis 
showed differences in the concentration of polyphenolic compounds: flavonoids, flavonol and 
tannins in each individual extract. 
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Flavonoids are polyphenolic compounds distributed widely in the plant kingdom and include 
several subclasses, such as flavones, flavanols, flavanones, isoflavones and anthocyanins 
[280]. Flavonoids are found in several medicinal plants and plant mixtures containing 
flavonoids have been used in folk medicine around the world [281]. Flavonoids display a 
number of biological activities including antiallergic, anti-inflammatory, antioxidant, 
anticarcinogenic, and modulation of enzymatic activities [282-285]. The enzyme modulatory 
action of flavonoids was demonstrated in a study by Zhang et al. (2013). Zhang and colleagues 
showed that total flavonoids obtained from Rosa laevigata michx fruit significantly decreased 
serum liver enzymes: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 
activities in non-alcoholic fatty liver diseased rats [286]. In addition, emerging studies have 
established a neuroprotective and neuromodulatory role for plant-derived flavonoids. By 
interacting within ERK and PI3-kinase/Akt signaling pathways, medicinal plant flavonoids 
was shown to increase the expression of neuroprotective and neuromodulatory proteins and 
increase the number and strength of connections between neurons [287]. Furthermore, 
Zayachkivska et al. (2005) demonstrated the gastroprotective properties of plant-derived 
flavonoids on ethanol-induced gut damage in male Wistar rats [288]. Data presented herein 
revealed that both aqueous and organic extracts of S. frutescens contained flavonoids and in 
particular flavanols. The presence of flavonoids and flavonols in these extracts thus support the 
folklore use of herbal mixture of S. frutescens as an anxiolytics, anti-inflammatory and in the 
treatment of stomach problems [206] 
 
Spectrophometric quantitative analysis showed that all extracts had approximately equal 
concentration of flavonoids while the organic extracts had a significantly higher concentration 
of flavonols than both aqueous extracts, with the 80% and 100% ethanolic extracts having the 
highest concentration (0.62 mg/g and 0.79 mg/g).  This is in agreement with similar findings 
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by Brandao et al. (1997) [289] and Hufford et al. (1993) [290] reviewed in Cowan et al. (1999) 
[291] where it was shown that ethanol is a major extractant of  flavonol compounds. Similarly, 
all S. frutescens extracts in this study contained tannins. Tannins are polymeric phenolic 
compounds with molecular weights ranging from 500 - 3,000 Da [292] found in almost every 
plant part: bark, wood, leaves, fruits, and roots [293]. Tannins are divided into two groups, 
hydrolysable and condensed tannins [293]. Over the years, tannins have received a great deal 
of attention owing to their health benefits. The consumption of tannin-rich beverages, 
particularly green teas and red wines have been suggested to cure or prevent human ailments 
including, cancer and cardiovascular diseases [294].  
The anti-cancer properties of tannins have been heavily linked to their beneficial physiological 
role as a scavenger of reactive oxygen intermediates (ROI) [295]. Labieniec and colleagues 
demonstrated this in a study where tannins was shown to significantly decrease H2O2 mediated 
DNA damage at low concentration in fresh water bivalve mollusc (mussel Unio tumidus) [296]. 
In addition, using disc diffusion method Langer et al. (2013), demonstrated the anti-bacterial  
(gram positive and gram negative) properties of tannins [297]. Furthermore, in an experiment 
to elucidate the anti-inflammatory properties of tannins, Yoshimura and colleagues discovered 
that oenothein B a unique macrocyclic ellagitannin found in several medicinal plants inhibited 
dendritic cell (DC) differentiation. In addition, this compound also inhibited the production of 
inflammatory cytokines such as IL-1β and IL-6 in a dose-dependent manner [298]. Taken 
together, the identification of tannins in S. frutecsens extracts as seen herein may, in part, 
explain the traditional use of S. frutescens herbal mixture in the treatment of a variety of 
inflammatory diseases including inflammatory bowel disease, celiac disease, and rheumatoid 
arthritis [206] and as an anti-cancer agent [216].  
Analysis of the ion chromatograms generated from crude aqueous and organic S. frutescens 
extracts, using untargeted Triple TOF LC-MS/MS separation technique in positive ionic mode, 
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revealed the presence of multiple compounds in individual extract. Further comparison of these 
compounds with online databases of anti-diabetic phytocompounds led to the preliminary 
identification of 10 possible anti-diabetic compounds in crude aqueous and organic extracts of 
S. frutesecens. These compounds include: α-Pinene, Limonene, Sabinene, Carvone, Myricetin, 
Rutin, Stigmasterol, Emodin, Sarpagine and Hypoglycin B.   
Pinenes and bicyclic terpenes are the major chemical constituents found in the essential oils of 
coniferous trees (pine) [299]. Pinenes have two active constitutional isomers: - and β-pinene 
both having enantiomers known in nature as (−)--pinene, (+)--pinene, (−)-β-pinene and (+)-
β-pinene [299]. Alpha-pinene (α-pinene) is a monoterpene (Figure 2.23) [300] that has been 
suggested to possess a variety of interesting pharmacological properties including anti-
inflammatory [301], ant-ibacterial [299, 302], and anti-fungal [303] properties. Diaz et al. 
(2008) demonstrated the cytotoxic effect of α-pinene a major constituent (97.2%) of Schinus 
molle essential oil on breast cancer and leukemic cell lines [304]. In addition, Pinheiro et al. 
(2015) demonstrated the gastroprotective and anti-ulcerogenic effect of α-pinene. In their 
study, Pinheiro and colleagues showed that α-pinene pre-treatment inhibited ethanol-induced 
gastric lesions, reduced volume and acidity of the gastric juice and increased gastric wall mucus 
in male Swiss mice [300]. The anti-diabetic effect of α-pinene has been demonstrated by 
various in vitro and in vivo studies showing the hypoglycaemic and insulin-like effects of α-
pinene-rich extracts or oil of medicinal plants [305, 306]. In an in-vivo study,  Bakirel et al 
(2007) showed that ethanol extracts (100 and 200 mg/kg) of Rosmarinus officinalis, a plant 
highly rich in α-pinene [307, 308], significantly lowered blood glucose level and increased 
serum insulin concentration in alloxan-diabetic rabbits [305]. In an in- vitro study sought to 
investigate the inhibitory potential of rosemary extracts on key enzymes related to diabetes 
such as α-amylase and pancreatic lipase activities, Ben Ali et al. (2014) demonstrated that α-
pinene-rich essential oil of Rosmarinus officinalis inhibited α-amylase and pancreatic lipase 
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activities with an IC50 ranging from 28.36 - 34.07 µg/mL, suggesting strong anti-diabetic and 
anti-obesity effects of Rosmarinus officinalis [309]. Furthermore, ethanol extracts of Nigella 
sativa L. seed, a plant containing α-pinene [310] was shown to significantly reduce the elevated 
levels of blood glucose, lipids and improved altered levels of lipid peroxidation products in 
streptozotocin (STZ) induced diabetic rats [309].   
In this present study, (+)--pinene was identified in crude aqueous (hot and cold) extracts of 
S. frutescens. It is therefore very plausible that aqueous extracts of S. frutescens can act in 
similar ways to mediate anti-diabetic effects.  
 
Figure 2.23: Chemical ontology of α-pinene [311]. 
Limonene is also a monocyclic monoterpene (Figure 2.24), that has been isolated from a 
number of medicinal plants such as Citrullus colocynthis, Adansonnia digitata and Finger 
citron fruits [312-314]. Limonene, has been shown to have both chemopreventive and 
therapeutic effect against several human cancers [315]. Haag et al. (1992), showed that 
Limonene mediated regression of mammary gland cancer in Wistar-Furth female rats [316]. 
Similarly, recent clinical trial data have shown a promising therapeutic effect of Limonene in 
human breast carcinoma [317, 318]. To demonstrate the anti-inflammatory properties of 
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Limonene, d'Alessio and colleagues showed that Limonene significantly reduced intestinal 
inflammation in TNBS-colitis rats. This was associated with lowered serum concentrations of 
TNF-α compared to the untreated TNBS-colitis rats [319]. Furthermore, the anti-diabetic 
properties of Limonene has been documented in a study by Murali et al. (2012) in which orally 
administered Limonene (100 mg/kg) was found to decrease plasma glucose and glycosylated 
haemoglobin, down regulate activities of gluconeogenic enzymes such as, glucose 6-
phosphatase and fructose 1, 6-bisphosphatase and up-regulate the activity of glycolytic 
enzyme, glucokinase in streptozotocin-induced diabetic rats [320]. Identification of Limonene 
in aqueous (cold and hot) and organic (80% ethanol and 100% methanol) extracts in this present 
study suggests that cold aqueous, hot aqueous, 80% ethanol and 100% methanol extracts of S. 
frutescens  could serve as a potent anti-cancer and anti-diabetic agents.  
 
 
Figure 2.24: Chemical ontology of Limonene [311] 
 
Sabinene is a natural bicyclic monoterpene (Figure 2.25), isolated from essential oils of plants 
including Quercus ilex and Picea abies [321, 322]. To date, several medicinal plant extracts 
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rich in Sabinene have been used as anti-pyretic [323], anti-microbial [324], anti-hypertensive, 
anti-convulsant and anti-asthma [323] therapeutic agent. The anti-inflammatory effect of 
Sabinene was demonstrated in a study by Min-Jin et al. (2013) where it was shown that hydro-
distilled essential oils (HEOs) of Citrus unshiu Marcov, rich in Sabinene (34.7%), supressed 
lipopolysaccharide (LPS)-mediated cyclooxygenase-2 (COX-2) protein synthesis via the 
inhibition of  nitric oxide (NO) and prostaglandin E2 (PGE2) secretion in LPS-stimulated 
macrophage cells [325]. In addition, HEOs of Citrus unshiu Marcov downregulated the 
production of inflammatory cytokines, tumour necrosis factor (TNF)-α, Interleukin (IL)-6, and 
IL-1β in these cells [325]. Similarly, Sabinene has been suggested to be a potent anti-diabetic 
compound in a study by Saini et al. (2013). Saini and colleagues showed that oral 
administration of ethanolic extract (250-500 mg/kg) of Sabinene-rich seed of Helianthus 
annuus L. reduced blood glucose level, restored lipid profile, showed improvement in body 
weight, liver glycogen content, glycosylated haemoglobin, plasma malondialdehyde, 
glutathione level and serum insulin levels in streptozotocin-nicotinamide induced diabetic rats 
[326]. Hence, it is likely that Sabinene present in aqueous extracts of S. frutescens as seen in 
this study, can as an anti-inflammatory and anti-diabetic therapeutic agent. 
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Figure 2.25: Chemical ontology of Sabinene [311] 
 
Carvone is a monoterpene ketone (Figure 2.26) found as the active component of several 
essential oils [327]. Well-known sources of Carvone include spearmint oil and Carum carvi 
(caraway) oils [328]. Carvone has been proposed to have depressant and consequently 
anticonvulsant-like activity in the central nervous system (CNS) [328]. The anti-diabetic 
properties of Carvone was suggested in a study by Eddouks et al. (2004) where oral 
administration of aqueous of Carum carvi (20 mg/kg) decreased blood glucose levels in STZ- 
diabetic rats [329]. Similarly, Sadiq et al. (2010) showed that aqueous extracts of Carum carvi 
(60 mg/kg) decreased diabetic-mediated systemic and renal changes (increase in the serum 
levels of glucose, urea, creatinine, total urinary protein and microalbuminuric levels) in male 
Wistar rats [330]. Thus, confirming the reno-protective properties of Carvone in diabetic 
nephropathy state. It can then be suggested that Carvone found in ethanolic extracts of S. 
frutescens can reduce elevated glucose level and confer reno-protective function in diabetic 
patients. 
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Figure 2.26: Chemical ontology of Carvone [311] 
 
Myricetin is a member of the flavonoid class of polyphenolic compounds (Figure 2.27). 
Myricetin is present in several medicinal plants and edible fruits [331, 332]. The therapeutic 
potentials of Myricetin include, as an anti-inflammatory [333], anti-carcinogenic [334], anti-
microbial [335] and anti-viral agent [336].  
Phillips et al. (2011) demonstrated the anti-carcinogenic effect of Myricetin in a study, in which 
Myricetin was shown to mediate pancreatic cancer cell death in vitro. Furthermore, Phillips 
and colleagues demonstrated that in vivo treatment of orthotopic pancreatic tumors with 
Myricetin resulted in tumor regression and decreased metastatic spread in female nude mice 
[337]. In a similar study, Iyer et al. (2105), showed that Myricetin inhibited 
PAK1/Ras/Wnt/Erk/Akt/Bcl-2 signaling to mediate intrinsic caspase-mediated mitochondrial 
apoptosis in hepatocellular carcinoma cells [338]. In addition to its anti-carcinogenic effect, 
Myricetin has also been shown to be a potent anti-diabetic agent. In a study by Ong et al. 
(2000), 12 hourly intraperitoneal injection of Myricetin (3 mg) reduced hyperglycaemia by 
50% and normalized associated hypertriglyceridemia in diabetic male Wistar Rats. These was 
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associated with increased hepatic glycogen and glucose-6-phosphate content and increased 
hepatic glycogen synthase I activity [339]. Ong and colleagues reported no indication of serious 
hepatotoxicity with Myricetin treatment in the experimental group of rat [339]. Similar findings 
was reported by IM et al. (2005) where bolus intravenous injection (1.0 mg/kg) of Myricetin 
decreased plasma glucose concentrations in a dose-dependent manner in STZ-diabetic rats 
[340]. In this present study, Myricetin was found in cold aqueous extracts of S. frutescens with 
poor confidence parameter, thus suggesting that it could be present in  minimal quantity in this 
extract. However, it is probable that nominal Myricetin found in the cold aqueous extract of S. 
frutescens can mediate anti-cancer and anti-diabetic activity.  
 
Figure 2.27: Chemical ontology of Myricetin [311]  
Rutin is a flavonoid (Figure 2.28) found in many plants, fruits, and vegetables [341, 342], and 
has been suggested to possess a wide range of biological activities. Rutin exhibit broad 
biochemical and pharmacological activities including anti-carcinogenic, vasoprotective, anti-
thrombic, and cardioprotective activities [343]. In addition, Rutin possess anti-oxidant, anti-
inflammatory, anti-allergic, and anti-viral activities [344, 345]. In a study aimed at 
investigating the oral anti-diabetic activity and anti-hyperlipidemic activity of four flavonoids 
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including Rutin in STZ-nicotinamide induced diabetic rats, Jadhav et al. (2012) showed that 
Rutin significantly diminished total cholesterol, triglyceride compared with the control group 
[346]. This was associated with significant increase in glucose uptake and decrease glucose 
transport activity observed in the rat hemi-diaphragm [346]. In addition, Jadhav and colleagues 
reported that Rutin was the most active compound of all four flavonoids in both experiments 
[346]. This in agreement by prior study by Prince et al. (2006) where it was reported that Rutin 
improves glucose homeostasis in STZ-diabetic tissues by altering glycolytic and gluconeogenic 
enzymes [347]. Hence, it is likely that Rutin found in ethanolic (80% and 100%) extracts of S. 
frutescens as seen in this present study, can act in similar manner to mediate glucose 
homeostasis and therapeutic anti-diabetic function. 
 
 
Figure 2.28: Chemical ontology of Rutin [311] 
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Stigmasterol belongs to the family of phytosterols (Figure 2.29) that include β sitosterol, 
campesterol, brassicasterol, delta-7 Stigmasterol, and delta-7-avenasterol, that are chemically 
similar to animal cholesterol [348]. Phytosterols are insoluble in water but soluble in most 
organic solvents. Thus agreeing with findings in this present study, as Stigmasterol was found 
only in organic (80 and 100% methanol) extracts of S. frutesecens. Thiers (1953) proposed the 
first therapeutic role of Stigmasterol as an anti-stiffness factor in the therapy of rheumatic 
disease, as shown in an in vivo experiment using guinea pigs [349]. Hence, Stigmasterol is also 
known as Wulzen anti-stiffness factor [349]. Similarly, using new born mouse chondrocytes 
and human osteoarthritis (OA) chondrocytes in primary culture, Gabay and colleagues 
demonstrated that Stigmasterol (20 µg/mL) downregulated the expression of pro-inflammatory 
gene IL-6 and genes involved in cartilage turn-over: MMP-3, MMP-13, ADAMTS-4,-5, type 
II collagen, and aggrecan in  IL-1β-stimulated cells [348]. Thus, confirming the anti-
inflammatory and anti-osteoarthritic properties of Stigmasterol. Stigmasterol has been reported 
to reduce plasma cholesterol levels and inhibit hepatic synthesis and intestinal absorption of 
cholesterol in the rat [350]. Furthermore, oral administration of chloroform extracts of Parkia 
speciosa seeds, containing Stigmasterol (34%), significantly reduce blood glucose levels in 
alloxan-induced diabetic rats [143]. Data presented herein showed the presence of Stigmasterol 
in methanolic extracts of S. frutescens thus suggesting a therapeutic role for S. frutescens 
methanol extracts in the treatment of inflammatory conditions and diabetes.   
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Figure 2.29: Chemical ontology of Stigmasterol [311] 
 
Emodin is a natural occurring phytocompound that belong to the class of 
hydroxyanthraquinones (Figure 2.30) [351]. Emodin has been reported to exhibit anti-bacterial 
[352], anti-inflammatory [353], immunosuppressive [354], anti-ulcerogenic [355], and anti-
cancer [356, 357] activites. In an in vivo experiment aimed at investigating the anti-diabetic 
properties of Emodin, Xue et al. (2010) demonstrated that three weeks intraperitoneal injection 
of Emodin into STZ-induced diabetic mice resulted in significant decrease in the level of blood 
glucose, triglyceride and total serum cholesterol [358]. These was also associated with 
improved glucose tolerance and insulin sensitivity in Emodin-treated mice. Furthermore, Xue 
and colleagues suggested that Emodin mediates its anti-diabetic action via the activation of 
Peroxisome proliferator-activated receptor-γ (PPARγ) and the modulation of systemic 
metabolism-related genes [358]. It is therefore very likely that the ethanolic (80%) extracts of 
S. frutescens can mediate anti-diabetic function consequent of the presence of Emodin. 
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Figure 2.30: Chemical ontology of Emodin [311] 
 
Sarpagine is an indole alkaloid (Figure 2.31), that have structural similarity to the essential 
amino acid tryptophan and related metabolites, such as the neurotransmitter serotonin [359]. 
Sarpagine has been isolated from various plant species most importantly genus Rauwolfia, 
Corynanthe, Alstonia, and Strychnos [359]. Extracts of Rauwolfia has been shown to possess 
potent anti-cancer [360] and anti-hypertensive [361] properties. Similarly, the anti-bacterial 
and anti-oxidant properties of Rauwolfia ethanolic extract has been reported [362]. In 2009, 
Qureshi and colleagues demonstrated that methanolic root extract of Rauwolfia can mediate 
hypoglycaemic, hypolipidemic and hepato-protective function in alloxan-induced diabetic rats 
[363]. In addition to this, Ganugapati et al. (2012) discovered that alkaloids present in 
Rauwolfia serpentine act as potential activators of insulin receptor [364]. The presence of 
Sarpagine alkaloid in 80% methanolic extract of S. frutescens as presented herein thus suggests 
a similar anti-diabetic role for S. frutescens. 
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Figure 2.31: Chemical ontology of Sarpagine [311] 
 
Hypoglycin B is a naturally occurring organic compound in the species Blighia sapida [365]. 
Hypoglycin B has been proposed to have anti-diabetic activities [366]. Hypoglycin B, of the 
fruit of Blighia sapida, have been shown to induce hypoglycemia in rabbits, monkeys, rats and 
mice [367]. Thus suggesting that the Hypoglycin B in the methanolic extract of S frutescens 
can mediate anti-diabetic function. 
Taken together, preliminary identification of bioactive (anti-diabetic) phytocompounds in 
crude aqueous and organic extracts of S. frutescens investigated in this present study, does in 
part support the folklore use of herbal mixture of S. frutescens as an anti-diabetic agent. 
Furthermore, the identification of multiple bioactive compounds in individual extracts suggests 
a possible synergistic effect. Having found the presence of these bioactive compounds in 
individual S. frutescens extract, the anti-diabetic properties of individual crude extract using an 
in-vitro biological assay was then investigated. 
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CHAPTER THREE 
SUTHERLANDIA FRUTESCENS PREVENTS DIABETIC METABOLIC CHANGES 
IN INSULIN RESISTANT HEPATIC CELLS. 
3.1 Introduction 
Globally, the incidence and prevalence of chronic non-communicable diseases including 
chronic respiratory diseases, cardiovascular diseases, neoplasia and T2DM have reached 
epidemic proportions affecting people of all ages, nationalities and ethnicity [368-370].  
Though the exact pathophysiology of T2DM is not entirely understood, initial peripheral 
insulin resistance in adipose tissue, liver, and skeletal muscle with subsequent pancreatic β-cell 
dysfunction resulting from an attempt to compensate for insulin resistance is a common feature 
of the disease [167, 168]. Thus, the classical clinical features of T2DM include peripheral 
hyperglycemia with underlying dyslipidaemia, including  increased free fatty acid flux, 
elevated triglyceride levels and reciprocally low levels of high-density lipoprotein (HDL) [371, 
372]. Altered liver metabolism disrupts normal maintenance of glucose homeostasis [373], 
through impaired suppression of hepatic glucose production [374]. In addition, accumulation 
of lipids within the liver can interfere with insulin signalling and cause insulin resistance [375]. 
Dyslipidaemia is a major risk factors for premature cardiovascular morbidity and mortality in 
T2DM patients [376, 377]. Hence, multiple anti-hyperglycaemic and anti-hyperlipidaemia 
drugs are often needed for effective management of T2DM [378, 379]. Over the years, 
conventional anti-T2DM  drugs have been shown to have limited efficacies and serious adverse 
effects [371]. Hence, the need for newer, more efficacious and safer anti-T2DM agents [380, 
381]. Medicinal plants offer great potential for the development of natural effective anti-T2DM 
agents, often with minimal or no side effects [29]. 
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In my previous chapter, preliminary Triple TOF LC-MS/MS analysis revealed the presence of 
several potential anti-diabetic phytocompounds in crude aqueous and organic extracts of S. 
frutescens. Hence, the aim of this part of my present study was to investigate and compare the 
anti-T2DM properties of crude aqueous and organic extracts of S. frutescens using two cell 
lines (Chang and HepG2) as an in-vitro model system, in which glucose uptake, 
gluconeogenesis and lipid accumulation were analyzed. 
Furthermore, using a multiplex gene array,  prior research from our laboratory has shown that 
an aqueous extract of S. frutescens can regulate diabetes related genes in IR hepatic cells [382]. 
Hence, using quantitative real-time RT-PCR, the inter-extract variability in the regulation of 
expression in IR hepatic cells of three diabetes-associated genes previously shown to be 
regulated by S. frutescens: Vesicle-associated membrane protein 3 (VAMP3), a transporter 
gene; Mitogen-activated protein kinase 8 (MAPK8), a signal transducer; and Insulin receptor 
substrate 1 (IRS1) were investigated. 
 
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents 
All chemicals used for this study were of molecular biology grade. Cell culture media (EMEM) 
was purchased from Lonza, South Africa. Fetal bovine serum (FBS) and non-essential amino 
acids (NEAA) were purchased from HyClone, South Africa. DMSO, absolute ethanol and 
methanol were purchased from Merck Chemicals (PTY) Limited (Gauteng, South Africa). 
Tissue culture plates and flasks (TTP) were purchased from Separations, South Africa. Fatty 
acid-free BSA (FAF-BSA), MCDB-201 medium, Palmitate, D-fructose, MTT, Sodium lactate, 
Sodium pyruvate, Oil-Red-O, Nile Red, 2-deoxy glucose, Silica gel TLC plates, HEPES, L-
carnithine transferase, L-carnithine, Aldrithiol and Acetyl CoA were purchased from Sigma 
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Aldrich, Cape Town, South Africa. Insulin was obtained from Roche, South Africa. Glucinet 
reagent, 2-DOG (0.2μCi/ml 2-[3H]-DOG was purchased from New England Chemicals, UK. 
Optiphase Supermix scintillation cocktail was purchased from PerkinElmer, USA. Aurum™ 
RNA extraction kit, iScript cDNA synthesis kit, SoFast™ Evergreen Supermix were purchased 
from Bio-Rad and PCR primers synthesised by Inqaba Biotech, Johannesburg,South Africa. 
All reagents were prepared according to manufacturers’ instructions.  
 
3.2.2 Collection of Plant Material 
Collection of S. frutescens was as described in section 2.2.2  
 
3.2.3 Preparation of plant extracts 
3.2.3.1 Hot aqueous extract 
A hot aqueous extract of S. frutescens was prepared as described previously in section 2.2.3.1  
 
3.2.3.2 Cold aqueous extract 
A cold aqueous extract of S. frutescens was prepared as described previously in section 2.2.3.2  
 
3.2.3.3 Organic solvent extracts 
Organic solvent extracts were prepared as described previously in section 2.2.3.3.  
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3.2.3.4 Preparation of extracts for cell culture 
Each dry S. frutescens extract was dissolved in 1 mL 50% (v/v) dimethyl sulfoxide (DMSO) 
in deionized water, vortexed for 5 min and further diluted in MCDB-201 medium (Sigma). The 
extract suspension was filter sterilised using 0.2 µm acrodiscs (Pall), in a laminar flow hood 
using aseptic techniques. All extracts were used at a final concentration of 12.5 µg/mL. The 
concentration of S. frutescens used in this study was based on previous dose response studies 
on C2C12, 3T3-L1, and Chang cells [383-385]. The DMSO serves to sterilize the extract and 
once diluted (0.25%) has no effect on the biological assays or cell viability [386].  
 
3. 2.4 Cell lines 
3.2.4.1 Chang liver cell  
 The human hepatoma Chang cells were purchased from Highveld Biological, South Africa. 
These are adherent epithelial-like cells that grow as monolayers of small aggregates. Chang 
cells were originally derived from a normal human liver tissue, but were subsequently found 
to have been contaminated by HeLa cell based on isoenzyme analysis, HeLa marker 
chromosomes and DNA fingerprinting [387-390]. Although HeLa markers have been 
identified in this cell line, published work done in our laboratory [384] and studies from other 
laboratories [391, 392] have provided evidence of hepatocyte functions of these cells.   
 
3.2.4.2 HepG2 cell 
The HepG2 cell was purchased from Highveld Biological, South Africa. HepG2 cells are 
adherent, epithelial-like cells similar to liver parenchymal cells, which are mostly responsible 
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for the synthesis and secretion of plasma proteins characteristic of normal human liver cells 
[393].  
These two human liver cell cultures were used to strengthen the significance of the results 
obtained in the experiments and determine whether the results were cell line-related or 
hepatocyte-related.   
 
3.2.5 Cell culture. 
Cells were routinely maintained in Eagle’s minimum essential medium (EMEM) cell culture 
medium, containing 25 mM HEPES and 2 mM L-glutamine (Fisher, Philadelphia, USA) 
supplemented with 10%  fetal bovine serum (FBS) (HyClone, Cape Town, South Africa) and 
1% non-essential amino acids (NEAA) (HyClone, Cape Town, South Africa) at 37 0C and 5% 
CO2. The medium was stored at 4 
0C, and was warmed to 37 0C before use. Monolayer cultures 
of hepatic cells were grown in 10 cm  diameter tissue culture (TC) dishes  (TPP, UK) and kept 
in a humidified incubator (37 0C , 95% relative humidity and 5% CO2). Cellular growth was 
monitored every 48 hours using an inverted microscope and cells were passaged when 70-80% 
confluent. To passage, cell cultures were placed in a laminar flow cabinet and the culture 
medium aspirated using a sterilized Pasteur pipette attached to a pump. The cells were then 
washed twice in pre heated (37 0C) sterile phosphate buffered saline (PBS) (8 g/L NaCl, 0.2 
g/L KH2PO4, 2.9 g/L Na2HPO4, and 0.2 g/L KCl, pH 7.4) and detached from the TC dish with 
1 mL sterile 1x trypsin (HyClone, South Africa) and incubated for 5 min at 37°C. The culture 
was viewed under an inverted microscope to confirm cell detachment. The cells were then 
transferred into a new culture dish with complete medium at a ratio of 1 in 3. Alternatively 
cells were seeded onto culture dishes/plates for experimentation, or frozen in liquid nitrogen for 
later use. Early passage cells were frozen by re-suspending the trypsinized cells (1×106 cells/mL) in 
 
 
134 
 
FBS containing 10% DMSO and transferred into sterile cryogenic vials. The vials containing 
cell aliquots (1mL each) were placed upright in a -80 0C freezer for 24hrs and later transferred 
to liquid nitrogen for long term storage.  
 
3.2.6 Preparation of Metformin 
Metformin (Sigma Aldrich, South Africa), an established first line medication for the treatment 
of insulin-resistance (IR) and T2DM, was used as a positive control for the treatment of IR. 
Metformin was prepared as a 1 mM stock solution in 90% DMSO (Merck, South Africa) and 
filter sterilized with 0.2 μM acrodisc filters. Aliquots of 100 μL were stored at -200C. Before 
use, the stock solution was diluted to 20 µM/mL with MCDB-201 medium and used at a final 
concentration of 1 µM/mL. Diluted stock solutions were stored at 40C and discarded after one 
week.  
 
3.2.7 Conjugation of Palmitate to Fatty Acid Free-BSA 
Palmitate-BSA complex was prepared following the method described by Pappas and Ruddock 
[394, 395]. Palmitate is a saturated fatty acid with low solubility in aqueous solutions.  This 
becomes a challenge in cell-based assays since it is not readily available to the cells. In order 
to create an aqueous-soluble reagent, palmitate was conjugated to a stabilizing agent for 
insoluble fatty acids (e.g. fatty acid free-BSA). Briefly, sodium palmitate (100 mM) solution 
was added to 0.1 M sodium hydroxide and heated to 65 °C with stirring until dissolved. A 0.1 
mL aliquot of the resulting fatty acid solution was added, with stirring, into 1.3 mL 10% (w/v) 
fatty acid free-BSA (FAF-BSA) solution (Sigma Aldrich, South Africa) at 50 °C. After 15 min 
of slow stirring to allow clarification of the solution, 0.6 mL sterile deionized water (dH2O) 
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was added to bring the final concentration to 5 mM fatty acid. The solution was filter sterilised 
using an acrodisc (0.2 µm pore size) and stored in aliquots at -20 °C for up to 6 months.  
 
3.2.8 Cellular investigations 
3.2.8.1 Generation of Insulin-Resistance in Hepatic cells 
3.2.8.1.1 Cell treatment with Insulin and Fructose 
Separate Chang and HepG2 cell cultures were each seeded at a density of 2.5 × 104 cells/mL 
and grown for 48 hours in EMEM containing 10% FBS and 1% non-essential amino acids in a 
humidified incubator at 37 °C and 5% CO2. After 48 hours, the culture medium was aspirated 
and replaced with either serum-free MCDB-201 (Sigma Aldrich, South Africa) medium 
(control) or serum free MCDB-201 supplemented with 0.1 µM insulin (Roche, South Africa) 
and 1 mM fructose (Sigma Aldrich, South Africa) (MIF) to induce insulin-resistance, as 
described by Williams (2010) [384]. In addition, cells were exposed to MIF induction medium 
supplemented with either a 12 µg/mL (final concentration) aqueous or organic extract of S. 
frutescens (MIF+SF) or 1 µM metformin (MIF+MET) (positive control for treatment) for 24 
hours [384].  
 
3.2.8.1.2 Treatment with Palmitate-BSA  
Separate Chang and HepG2 cell cultures were each grown in complete culture medium at a 
density of 2.5 × 104 cells/mL for 48 hours, after which the culture medium was aspirated and 
replaced with either serum-free MCDB-201 medium (control) or serum-free MCDB-201 
supplemented with palmitate-BSA (0.25 mM) (PMB) to induce insulin-resistance. Parallel 
cultures were exposed to PMB-induction medium supplemented with either 12 µg/mL (final 
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concentration) aqueous or organic extract of S. frutescens (PMB+SF) or 1 µM metformin 
(PMB+MET) (positive control for treatment) for 24 hours [395].  
 
3.2.9 Cell Viability Testing 
The viable cell number was determined in parallel experimental plates using the 4,5- 
dimethylthiazol-2,5-diphenyltetrazolium bromide MTT assay (Sigma, South Africa) [396]. A 
stock solution of MTT (5 mg/mL) was made in PBS and filter sterilized with a 0.2μm filter. A 
working solution (10%) was made from the stock solution in EMEM containing 10% FBS. An 
aliquot of 200 μL of the working solution was added to three parallel wells for each medium 
condition tested. The MTT assay was based on the metabolic reduction of the yellow 
tetrazolium salt (4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT), by 
dehydrogenase enzymes present in viable cells, to a water-insoluble, purple formazan product. 
The MTT was removed after a 4hr incubation at 37oC and the formazan product (purple 
crystals) extracted from the cells by the addition of DMSO. Absorbance was measured 
spectrophotometrically against a DMSO blank at 540 nm. The amount of purple formazan 
extracted from the cells is proportional to the number of viable cells in the culture [397].  
 
3.2.10 Verification of insulin resistance 
3.2.10.1 Glucose Production Assay 
Chang and HepG2 cell cultures were each grown in complete medium. After 48 hours of 
growth, the medium was aspirated and replaced with the various treatments as described in 
section 3.2.8.1.2 and the cultures incubated for a further 24 hours. The glucose content of each 
culture medium after treatment with the insulin resistance inducing agents was analysed using 
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a glucose oxidase colorimetric method, as described by Gao et al. (2010) [398]. Briefly, the 
medium was aspirated and cells washed twice with PBS to remove any residual glucose 
contained in the culture media. The cells were then incubated for 16 hours in glucose 
production medium (glucose- and phenol red-free EMEM containing gluconeogenic substrates, 
20 mM sodium lactate and 2 mM sodium pyruvate) (Sigma) with the addition of 0.1 µM insulin 
during the last 3 hours. The glucose content of medium from each sample was analysed by 
glucose oxidase colorimetric determination using a Gluci-net reagent kit (Bayer, France). 
Glucose oxidase in the Gluci-net reagent, oxidises the D-glucose to gluconic acid producing 
hydrogen peroxide. This causes the oxidation of sodium hydroxyl-benzoate-aminophenazone 
to form stable quinine complexes varying in color according to the concentration of glucose in 
the medium from each sample. To each aliquot in the 96-well plates, 200 µL of Gluci-net 
reagent was added and incubated for 15 minutes in a humidified 5% CO2 incubator at 37
0C. 
The optical density was read at 510 nm using a Bio-Tek KC4 Power Wave XS micro plate 
reader (Analytical and Diagnostic Products, South Africa) The viable cell population was 
measured with the MTT method described in section 3.2.9 and used to normalize assay results.   
 
3.2.10.2 Deoxy-glucose uptake assay 
Glucose uptake by Chang and HepG2 cell cultures was measured using tritium labelled 2-
Deoxy-D-glucose ([2-[3H]-DOG), adopting the method of Ralser et al. (2008) [399] as 
described by Williams et al. (2013) [384] with slight modification. 2-Deoxy-D-glucose (2-
DOG) is a stable analogue of glucose that can be taken up and phosphorylated, but cannot be 
fully metabolized by the cell; consequently 2-DOG-6-phosphate accumulates in the cell [399]. 
Briefly, Chang and HepG2 liver cell cultures were seeded into 96-well cell culture plates at 5 
x 103 cells per well in 200 µL of growth medium. After 48 hours, growth medium was removed 
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from the cells and replaced with plant extract or metformin treated media, or control media 
described in section 3.2.8.1.2. The cells were chronically exposed to these conditions for 24 
hours. The following day, cells were washed twice with 200 µL Krebs-Ringer phosphate (KRP) 
buffer (10mM phosphate (pH 7.2), 136mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 1.25mM 
MgSO4). After washing with KRP-buffer, cells were stimulated with 1μM insulin in KRP-
buffer without glucose (starvation buffer) for 15 min. After stimulation, starvation buffer was 
removed and 200 µL 2-DOG (0.2μCi/ml 2-[3H]-DOG (New England Chemicals) in 1μM 
unlabelled 2-deoxyglucose) was added and cells were incubated for 15 minutes. Cells were 
then washed thrice with ice cold PBS and solubilized in 100 μL 0.1N NaOH. A PerkinElmer 
optiphase supermix scintallation cocktail (100 μL) was added to each cell suspension, the 
solution was vortexed until it was clear, and thereafter each of the samples was counted for 15 
minutes in a PerkinElmer MicroBeta2 2450 microplate counter (PerkinElmer, USA).   
3.2.11 Lipid Accumulation Assays 
Two lipid stains, Oil-Red-O and Nile Red, were used to determine lipid accumulation in the 
Chang and HepG2 cell cultures after exposure to the treatment conditions. The Oil-Red-O 
assay detects cellular neutral lipids, while Nile Red staining is used for the detection of neutral 
lipids (yielding a yellow-gold fluorescent colour) and phospholipids (yielding an orange-red 
fluorescence).  
 
3.2.11.1 Oil-Red-O Assay 
Chang and HepG2 liver cell cultures were seeded into 96-well cell culture plates at 5x103 cells 
per well in 200 µl of growth medium. After 48 hours, growth medium was removed from the 
cells and replaced with the same media described in section 3.2.5-2. The cells were chronically 
exposed to these conditions for 24 hours. The next day, the medium was removed and cells 
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fixed in 10% (v/v) formaldehyde in PBS (pH 7.4) for 10 min. Cells were rinsed with deionized 
H2O followed by 70% (v/v) ethanol, and stained with 200 µL of 3% (v/v) Oil-red-O solution 
(Sigma, South Africa) (6 parts Oil-Red-O stock in isopropyl alcohol: 4 parts water) for 15 min. 
The stain was removed and cells washed with 70% (v/v) ethanol and finally deionized water. 
The stain was then extracted by addition of isopropyl alcohol and the absorbance measured at 
520 nm [398]. After the Oil-Red-O assay was completed, cell viability was determined with 
the MTT assay, as described in section 3.2.9.  
 
3.2.11.2 Nile Red Assay 
Chang and HepG2 liver cell cultures were seeded into 96-well cell culture plates at 5x103 cells 
per well in 200 µL of growth medium. After 48 hours growth medium was removed from the 
cells and replaced with the same media described in section 3.2.5. The cells were chronically 
exposed to these conditions for 24 h, after which, the medium was removed and  cells were 
washed with Hanks Balanced Salts Solution (HBSS; pH 7.4), and background fluorescence 
determined (535nm excitation, 580nm emission) in a Fluoroskan Ascent FL (Thermo 
Labsystems) plate reader. A 1mM stock solution of Nile red dye (Sigma, South Africa) was 
prepared in DMSO and stored in the dark at -20oC. The 1mM Nile red stock solution was 
freshly diluted in DMSO with 1% Pluronic F127 (Sigma, South Africa) in HBSS to form a 1 
μM working solution, 100 μL of the working solution was then added to each culture well. 
After 4 hour incubation at room temperature in the dark, Nile Red was removed and cells were 
washed once with HBSS. After a further incubation for sixteen hours in HBSS at room 
temperature in the dark, fluorescence was again determined as above and background 
subtracted to obtain bound Nile Red fluorescence [384]. After the Nile red assay was 
completed, cell viability was determined with the MTT assay as described in section 3.2.9.   
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3.2.12 Thin Layer Chromatography Analysis for Lipids Classes  
Thin Layer Chromatography (TLC) on silica gel was used to separate and determine lipid 
components in the Chang and HepG2 cell cultures after exposure to the treatment conditions. 
After 24 hour exposure to the conditions indicated in section 3.2.5, the culture medium was 
aspirated and cells gently scraped into 1 mL growth medium. Cells were then transferred to 2 
mL microcentrifuge tubes and centrifuged for 5 min at 400 ×g. The supernatant was removed 
and the cell pellet re-suspended in 0.75 mL chloroform-methanol (1:2, v/v) to extract total 
lipids. Lipids and polar contaminant phases were separated by the addition of 0.25 mL 
deionized H2O and 0.25 mL chloroform, followed by centrifugation at 1000 ×g for 5 min. The 
lower phase containing neutral lipids (e.g., triacylglycerides, free fatty acids, diacylglycerides, 
monoacylglycerides, waxes and sterol esters) and polar lipids (mainly phospholipid) was dried 
and re-dissolved in 50 µL chloroform and spotted on silica gel TLC plates (Sigma, South 
Africa). The total lipid extract in the lower phase was separated using diethylether-heptane-
acetic acid (75:25:1, v/v/v). The solvent used to resolve the TLC plates causes the separation 
of the neutral lipid class. Thus, waxes and sterol esters migrate most quickly, followed 
by triacylglycerides (TAGs), free fatty acids (FFAs), diacylglycerides (DAG), and 
monoacylglycerides MAG, while polar lipids remain at the sample origin. Once the solvent 
had run to approximately ¾ of the length of the TLC plate, the TLC plates were stained using 
0.003% (w/v) Coomassie blue in 100 mM NaCl in 30% (v/v) methanol for 30 min. The plates 
were de-stained in the dye-free 100mM NaCl in 30% (v/v) methanol solution for 5 min [400]. 
Developed TLC plates were imaged using an AlphaImagerTM 3400 (Alpha Innotech). 
Densitometry on visualized lipid bands was done using ImageJ version IJ 1.46r 
(imagej.nih.gov/ij/) [401].  
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3.2.13 Quantification of changes in gene expression 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyse levels of 
mRNA expression of VAMP3, MAPK8 and IRS1 in Chang and HepG2 cell cultures after 
exposure to various induction media or treatments as indicated in section 3.2.8.1.1. qRT-PCR 
allows for accurate and reproducible measurement of mRNA present within the tissue sample 
[402]. In the qRT-PCR technique data are collected throughout the PCR process as it occurs, 
therefore combining amplification and detection into a single step. This is achieved using a 
variety of different fluorescent chemistries that correlate PCR product concentration to 
fluorescence intensity [403]. The qPCR technique combines PCR amplification of the gene 
sequence of interest, with fluorescent probe detection of the amplified product. Fluorescence 
intensity is recorded during every cycle. The cycle in which target amplification is first detected 
as significantly above a defined background threshold is referred to as the threshold 
quantification cycle (Cq). The greater the quantity of target cDNA in the starting material, the 
smaller the number of PCR amplification cycles required to increase the fluorescent signal 
above the background threshold, yielding a low Cq value [404]. 
In order to evaluate the level of gene expression, mRNA must first be extracted from the 
samples and reverse transcribed to cDNA, which is quantified in the qPCR experiment. Reverse 
transcription and PCR may be performed in a one-step reaction where both occur in the same 
tube or in a two-step process, where these occur in two separate tubes. This study employed 
the two-step procedure. 
The PCR process involves 3 steps: (i) denaturation at 94-96ºC: where double stranded DNA 
(dsDNA) is denatured into single stranded DNA (ssDNA); (ii) annealing: where the forward 
and reverse primers bind with their complimentary ssDNA sequences on either side of the 
sequence to be amplified at lower temperatures, generally of 50-65ºC; (iii) elongation or 
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extension: where the Taq polymerase extends the DNA sequence from the primers in the 5’to 
3’ direction at 72ºC. This process is repeated for 40 cycles. Amplification curves are generated 
from the PCR reactions to determine the Cq value, which is inversely proportional to the 
amount of specific nucleic acid sequence in the original sample [405]. Comparison of PCR 
template quantity can be performed in two ways: (1) Relative quantification: where changes in 
the steady-state mRNA levels of a gene of interest are measured following normalization with 
one or more reference genes, and (2) Absolute quantification: which requires a sample of 
known quantity (copy number) of the gene of interest diluted to generate a standard curve. The 
unknown samples are compared to this standard curve for absolute quantification [405].  
In this study, the relative quantification procedure was used. This procedure relies on the use 
of control genes or sequences (referred to as reference or housekeeping genes) and a 
normalization procedure. During the analysis of gene expression, several variables need to be 
controlled, such as the amount of starting material, enzymatic activity, and differences between 
the overall transcription activities of the experimental cells [406]. One strategy to normalize 
for these variations is the use of reference or housekeeping genes which should not vary in any 
of the experimental and control cells.  
 
3.2.13.1 Quantitative real-time PCR detection Chemistries 
During qPCR, the accumulation of amplified DNA product is detected and measured as the 
reaction progresses. Two types of detection methods can be employed. The first is a non-
specific detection method using an intercalating dye such as SYBR green that binds to any 
dsDNA. The second method consists of specific fluorogenic probes which are activated during 
the amplification process [40]. The signal from a single fluorophore is observed for each 
amplified molecule synthesized. It has high specificity, but probe production is expensive. 
Specialized thermal cyclers equipped with fluorescence detection modules are used to monitor 
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the fluorescence in each cycle as amplification occurs. The measured fluorescence reflects the 
amount of amplified product in each cycle (Bio-Rad laboratories Inc, USA).  
 In this study, SYBR Green dye was used to detect PCR products. SYBR Green dye chemistry 
uses the SYBR Green dye to detect polymerase chain reaction (PCR) products by binding to 
double-stranded DNA formed during PCR. As the double-stranded PCR products accumulate 
during cycling, more dye can bind and emit fluorescence. Thus, the fluorescence intensity is 
directly proportional to synthesized dsDNA concentration [407]. Advantages of this method 
include: (a) it can be incorporated into optimized and previously established PCR protocols 
simply by adding the dye as a reagent to the PCR reaction cocktail of standard reactions and 
(b) it is significantly cheaper than using specific probes. Disadvantages of the non-specific 
SYBR Green dye technique include: indiscriminate binding to any dsDNA, which can result 
in fluorescence readings in the “no template controls” (NTC) due to dye molecules binding to 
primer dimers. This problem can be addressed by using software capable of melt curve 
analysis. This method makes use of plotting fluorescence as a function of temperature to 
generate a melting curve. This is done by slowly increasing the temperature above the melting 
temperature (Tm) of the amplicon and measuring fluorescence. A single characteristic melting 
peak at the Tm of the amplicon distinguishes it from the shorter primer-dimers that melt at 
lower temperatures with broader peaks [404]. A qPCR plot shows two phases: an exponential 
phase and a plateau phase. DNA replication in the exponential phase doubles with each cycle. 
As the reaction progresses, one or more reagents are used up and become limiting. At this point 
the reaction will slow and enter the plateau phase where no more amplification will take place. 
Therefore, for quantification purposes, the Cq value, representing the cycle in which the target 
amplification is first detected as significantly above a background threshold and the reaction is 
in the early exponential phase, is used.  
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3.2.13.2 RNA Extraction 
After exposure to the various induction media or treatments as described in section 3.2.8.1.1  
the cells were exposed to either an equal volume of 1× PBS (pH 7.4) or 0.1 µM insulin for 30 
minutes. Thereafter, the medium was removed and cells were washed twice with PBS before 
RNA was extracted using Bio-Rad Aurum™ Total RNA extraction kit (Bio-Rad Laboratories 
Inc, USA) following the manufacturer’s instructions. Throughout the RNA extraction, a 
ribonuclease (RNase) free environment was maintained by wiping all the surfaces with RNase-
ZAP® (Sigma). Briefly, lysis buffer contained in the extraction kit, was added directly to the 
culture wells at 350 μL per 2 × 106 cells. A cell scraper was used to loosen the cells off the 
plate, and the scraped cells were then transferred to a sterile 2 mL Eppendorf capped 
microcentrifuge tube. The lysed cells were homogenized with a 2 mL syringe and 21 gauge 
needle for one minute. 350 μL volume of 70% ethanol was added to the sample and mixed 
thoroughly by pipetting up and down. 700 μL of the RNA lysate was transferred onto a RNA 
binding column and centrifuged for 30 seconds at 13400 xg in an Eppendorf minispin 
microfuge. The filtrate was discarded leaving the RNA bound to the column. 700 μL low-
stringency wash solution was added to the RNA binding column, centrifuged for 30 seconds at 
13400 xg and the filtrate discarded. Any contaminating genomic DNA was removed from the 
RNA by the addition of 70 μL chilled diluted DNase 1 (Bio-Rad Laboratories Inc, USA) to 
each column. The DNase I digest was incubated for 15 minutes at room temperature. Once 
digestion was complete, the columns were centrifuged for 30 seconds at 13400 xg and the 
digestion buffer discarded from the wash tube. 700 μL high stringency wash solution was added 
to the RNA binding column to wash off the DNase 1, centrifuged for 30 seconds at 13400 xg 
and then discarded. 700 μL low-stringency wash solution was added to the RNA binding 
column, centrifuged for 1 minute at 13400 xg and discarded. The sample was centrifuged for 
an additional 2 minutes at 13400 xg to remove any residual wash solution. The RNA binding 
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column was transferred to a new sterile 1.5 ml capped microcentrifuge tube. 30 μL of elution 
solution was pipetted onto the RNA binding column. The sample was incubated for 1 minute 
to allow complete soaking and saturation of the membrane. The sample was then centrifuged 
for 2 minutes at 13400 xg to elute the total RNA, which was stored at -80 ºC for later use.  
The yield and quality of the extracted RNA was assessed with RNA 6000 Nano chips in the 
Agilent 2100 Bioanalyer (Agilent Technologies, Germany). The Agilent 2100 Bioanalyzer 
uses a fluorescent assay involving electrophoretic separation to evaluate RNA samples 
qualitatively and quantitatively. The amount of fluorescence is measured as the RNA sample 
is pulsed through a microchannel and the Agilent Bioanalyzer software creates an 
electropherogram. The electropherogram is a diagram showing the fluorescence changes over 
time. For each sample the software creates a gel image to accompany the graph. It also displays 
the sample concentration and the ratios of the 18S and 28S ribosomal subunits. By determining 
the quantity of RNA in the sample, the volume needed to reverse transcribe the RNA to cDNA 
can be calculated. 
In order to standardize the process of RNA integrity interpretation, Agilent Technologies has 
developed the RNA Integrity Number (RIN) to remove individual interpretation in RNA 
quality control. RIN is based on a software algorithm that works with the Agilent 2100 
Bioanalyzer and the RNA 6000 LabChip kit. The algorithm was developed from a large 
database of eukaryote total RNA samples (mainly human, mouse and rat) to enable the 
classification of eukaryotic total RNA, based on a numbering system from one to ten, with one 
being the most degraded profile and ten being the most intact. In the present study only samples 
with a RIN value > 8 were used. 
A RNA ladder (Agilent technologies, Germany) was used for the quantitation and quality 
testing. The ladder was reconstituted according to the manufacturer’s instructions. The Agilent 
RNA 6000 Nano Gel Matrix was prepared according to manufacturer’s instructions. Prior to 
 
 
146 
 
analysis, the electrodes of the Agilent RNA 6000 BioAnalyzer were cleaned according to the 
manufacturer’s instructions. The gel, dye concentrate and marker were allowed to equilibrate 
at room temperature for 30 minutes before use. The RNA 6000 Nano dye concentrate was 
protected against light, vortexed for 10 seconds and pulse spun down in an Eppendorf minispin 
microfuge to allow proper mixing. 1μL of dye concentrate was pipetted into a 65μL aliquot of 
the gel, vortexed thoroughly and visibly inspected to ensure proper mixing. Immediately before 
use, the tube was spun for 10 minutes at room temperature at 13400 xg in an Eppendorf 
minispin microfuge (Eppendorf, Germany). A new RNA Nano chip was placed on the chip 
priming station with 9.  of the gel-dye mix. Two further 9.0 μl aliquots of the gel-dye mix were 
pipetted into the chip. The fluorescent marker was vortexed and 5 μL pipetted into each of the 
12 sample wells and the RNA ladder well. 2 μL of each RNA sample was pipetted into a 
microcentrifuge tube and heated at 70 °C for 2 minutes and placed on ice. 2 μL RNA ladder 
was also heated at 70°C for 2 minutes and placed on ice. The mixtures were pulsed down for 
15 seconds before use. 1 μl of the ladder was pipetted into the ladder well and 1 μl of each 
sample was pipetted into each of the 12 sample wells. The Nano chip was vortexed for 60 
seconds at 2000 xg using the IKA vortex mixer (IKA Works, Inc, USA). The Nano chip was 
inserted into the Agilent BioAnalyzer and run according to the manufacturer’s instructions. 
Extracted RNA was stored at -80 °C until reverse transcribed. 
 
3.2.13.3 Reverse transcription (cDNA synthesis) 
 RNA samples were thawed on ice and reverse transcribed to cDNA using the reverse 
transcription BioRad iScript® cDNA synthesis kit (Bio-Rad Laboratories Inc, USA.) according 
to the manufacturer’s instructions. The volume of RNA template added was dependent on the 
concentration of RNA obtained from the Agilent BioAnalyzer results. The volume of RNA 
used was calculated to provide 1 μg of RNA. The total reaction volume was 20 μL. Each reverse 
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transcriptase reaction was set up as indicated in Table 3.1. The reaction mixture was incubated 
for 5 minutes at 25 ºC to allow RNA unfolding, 30 minutes at 42 ºC for the reverse transcription 
to occur and finally incubated for 5 minutes at 85 ºC to degrade the enzyme and stop the 
reaction. The samples were then frozen at -80 °C until the qPCR experiment. 
 
 
Table 3.1: Reverse Transcription Reaction Mix. Relative amounts of each component from the 
iScript cDNA synthesis kit added per reaction. 
 
Components Volume per Reaction 
5× iScript Reaction Mix 4 μl 
iScript Reverse Transcriptase 1 μl 
Nuclease-free water x μl 
RNA template (1µg of total RNA) x μl 
Total Volume 20 μl 
 
 
3.2.13.4 Quantitative real-time PCR reaction analysis 
Quantitative real-time PCR was performed on the samples using a SoFast™ Evergreen 
Supermix ((Bio-Rad Laboratories Inc, USA) in a 20 µL reaction under sterile conditions 
according to the manufacturer’s instructions. Briefly, a master mix (Table 3.2) containing a 
final concentration of 1× SoFastTM Evergreen Supermix, 500 mM final concentration forward 
and reverse primers, and nuclease-free PCR-grade water (Ambion), was prepared. The mixture 
was vortexed, pulse spun and then placed on ice until needed. Prior to performing qPCR, the 
total number of reactions in each experiment was calculated (plus one extra reaction per 10 
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reactions to accommodate pipetting error and residual reagents left in the tube) in order to 
accurately prepare a qPCR master mix. Each cDNA sample was diluted 1 in 10 in nuclease-
free PCR grade water (Ambion, USA) and placed on ice. The mixtures were vortexed and pulse 
spun prior to use. 10 μL of the above diluted cDNA was mixed together with 30 μL of the 
master mix. 10 μL of nuclease-free PCR grade water (Ambion, USA) was used in place of the 
cDNA sample in no template controls (NTC). All tubes were vortexed, pulse spun and placed 
on ice. A 96 well PCR plate was placed on a chilled IsoFreeze plate holder to ensure all 
reactions remained cold while transferring the reactions to the plate and 20 μL of the 
appropriate master mix-cDNA sample was added to each of the wells, with NTC included in 2 
wells. Each sample and NTC was run in duplicate. The plate was sealed with optical tape, (Bio-
Rad Laboratories Inc, USA), centrifuged at 1500 xg for 2 minutes at  4 °C on an Eppendorf 
centrifuge 5804 R (Eppendorf, Germany), and run in a CFX96™ qRT-PCR detection system 
(BioRad, South Africa). A reference positive control was also added in duplicate. To normalize 
the gene of interest, a reaction mix containing ALUSx primers and corresponding cDNA 
samples was included in the experiment to serve as an internal reference control. ALUSx 
sequence was provided by Jan Hellemans. Ferdricks et al. 2013 [408] showed that ALUSx was 
one of the most stable reference genes analyzed for human colon tissue when the average 
expression stability value M was calculated using geNorm in qbase+ 2.5.1 software 
(Biogazelle, Belgium). 
The protocol for all qPCR runs comprised of 3 minute Taq polymerase activation at 95 ºC and 
40 cycles of denaturing at 95 ºC for 30 seconds, 30 seconds at appropriate annealing 
temperature (see Table 3.2) and extension at 72 ºC for 30 seconds. The quantification cycle 
(Cq) defined as the number of qPCR cycles to reach a fluorescence threshold was determined 
for each sample. Cq was measured at the start of the exponential phase of PCR amplification 
where the reagents are not limited; hence qPCR can be reliably and accurately used to calculate 
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the initial amount of template present in the reaction (Bio-Rad Labarotories Inc, USA). Once 
the 40 cycle amplification reaction was completed, a melt curve was generated to verify the 
specificity of the reaction. The plate was heated to 95 ºC, and then cooled to 2°C below the 
annealing temperature for each primer pair to ensure that the entire DNA was double stranded. 
The temperature was increased in increments of 0.5 ºC for 30 seconds up to 95 ºC to melt the 
double stranded DNA. The Cq values for the reference genes were transformed into relative 
quantification data using the 2-ΔΔCt method [409]. All the relevant genes used in the analyses 
in this study are listed in Table 3.2, with their respective forward and reverse sequences as well 
as melting or annealing temperature. 
The Ta for each primer pair was determined by performing a temperature gradient experiment. 
This involves the preparation of a qPCR reaction as described above, but using a cocktail of 
the cDNA samples. This cocktail was set up by mixing equal volumes of each cDNA sample 
in a single tube from which 2 µL was used per qPCR reaction. For each primer pair, a 
theoretical Ta was reported by the supplier (Inqaba Biotech, South Africa) which was used as 
a guideline for the temperature gradient experiment. The CFX was programmed to run a 
temperature gradient ranging from ~2 °C below the theoretical Ta to ~65 °C, providing 8 
temperatures for testing. Once the PCR reaction was completed, the highest Ta at which the 
amplification efficiency was still as high as the most-efficient lower Ta was chosen as the 
experimental Ta to be used. The melt curve was checked to ensure that no non-specific reaction 
occurred. The qPCR data was recorded on the CFX software, and the Cq values were exported 
for analysis. Relative changes in gene expression were compared. 
 
Table 3.2: qPCR conditions used for each of the reference and target genes. The annealing 
temperature for each primer pair varied between genes (designated Tm) as listed in Table 3.3. 
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Step Number of Cycles Temperature (°C) Time 
Denaturation 1 95 3 minutes 
Denaturation  
40 
95 30 seconds 
Annealing Ta 30 seconds 
Extension 72 30 seconds 
Denaturation 1 95 30 seconds 
Melt Curve 1 Variable 30 seconds 
Hold 1 18 ∞ 
 
 
Table 3.3: Primers used for the reference genes or sequences and genes of interest. Primer 
sequences and respective annealing temperatures of each primer pair were determined using a 
temperature gradient of which the highest, most efficient temperature was chosen to be used. 
 
 
3.2.14 Calculation of relative mRNA expression using the comparative Cq method 
The comparative Cq method is a mathematical model that calculates changes in gene 
expression as a relative fold difference between an experimental and calibrator sample [402] 
Target Primer Sequences Ta 
(°) 
Sense Anti-sense  
IRS1 5’-TCTGTAAGTCTGTCTCCTA-3’ 5’-CCTAATGTGATGCTCTGT-3’ 59 
MAPK8 5’-ATGTCCTACCTTCTCTATCA-3’ 5-’TTACTACTATATTACTGGGCTTTA-3’ 56 
VAMP3 5’-TCCAACTTATGCCTTCCA -3’ 5’-CGAGAGTCAGTAGTGCTTA -3’ 59 
ALUsx 5’-TGGTGAAACCCCGTCTCTACTAA-3’ 5’CCTCAGCCTCCCGAGTAGCT-3’ 60 
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In this study, the ΔΔCq method, also known as the Livak method [409] was used to determine 
relative mRNA expression of genes assayed. This method normalizes the expression of the 
target genes relative to a single reference gene and expressed relative to the reference sample 
[409]. Calculations adapted from Livak et al. (2001) are summarized below;  
ΔCq = Average Cq (target assay) - Average Cq (Reference assay) 
 ΔΔCq = ΔCq (Test sample) - ΔCq (Reference sample)  
Relative quantification (RQ) = 2-ΔΔCq 
 
3.2.15 Data Analysis 
All cell assay data in this study were normalised to cell number as determined by the MTT 
assay and expressed as a percentage of the control (MCDB-201). All experiments were 
performed in triplicate and each experiment contained three replicate cultures for each 
treatment. Statistical analysis was performed by one-way analysis of variance (ANOVA) using 
Graph Pad Prism 5.0 software (GraphPad Software Inc., San Diego, CA) to determine the 
significant difference between treatments and control IR cultures, followed by Newman-Keuls 
post-tests with p < 0.05 considered significant. 
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3.3 Results 
3.3.1 Cell Viability 
Data obtained revealed that S.frutescens extracts were not toxic to the cells at the concentration 
used in this study.  
 
3.3.2 Crude aqueous and organic extracts of S. frutescens decrease gluconeogenesis 
production in IR Chang and HepG2 liver cells 
 In the physiologic state, insulin inhibits gluconeogenesis and glycogenolysis, thus blocking 
the production and release of glucose by the liver [185]. This occurs via the direct effect of 
insulin on the liver cells [410]. However, in IR hepatic cells, there is an increase in 
gluconeogenesis and consequently an increase in glucose production, in an attempt to 
compensate for IR. In this present study, the glucose content of the culture medium of IR Chang 
and HepG2 cell cultures was measured using the oxidase assay. Result as presented in Figures 
3.1a and b show that there was significantly more glucose in the medium after culture in MIF 
than in the control MCDB culture medium (Figures 3.1a and b; ***; P < 0.001). Thus indicating 
that these cells were IR. Further analysis using One-way ANOVA followed by Newman-Keuls 
post-test indicated that simultaneous treatment of IR Chang and HepG2 cells with crude 
aqueous or organic extracts significantly decreased glucose production by these cells (Figures 
3.1a and b; P < 0.001 in all cases) and maintained glucose at the same level as the control 
(MCBD) (no significant difference was observed between control and S. frutescens extract 
treated MIF cultures) (Figures 3.1a and b). Data obtained from the IR Chang cell culture 
showed that the hot aqueous extract gave a better reduction in glucose production when 
compared to the other extracts, although this was not found to be statistically significant 
(108.53% for hot vs 138.78%, 154.53%, 134.07%, 159.75%, and 136.83% for cold aqueous, 
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80% ethanol, 100% ethanol, 80% methanol and 100% methanolic extracts, respectively) 
(Figure 3.1a). Similarly, treatment with metformin also maintained the glucose content of the 
culture medium at the level of the control culture (Figures 3.1a and b). 
 
 
Figure 3.1: Hepatic glucose production in IR (a) Chang and (b) HepG2 liver cells as measured 
by the glucose oxidase assay, is expressed as a % of the control MCDB culture. Chang and 
HepG2 cells were cultured in MCDB-201 medium containing insulin and fructose (MIF) for 
24 hrs, with S. frutescens extracts or metformin as positive control. The 
effect of S. frutescens extracts or metformin on net glucose concentration in the 
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culture medium is shown. Data are represented as mean ± SEM from 3 independent 
experiments of 3 wells per experiment for all  analysed conditions. One-way ANOVA was 
conducted on the means of the replicates between MIF and MCDB (control) and, MIF and cells 
treated with Sutherlandia frutescens extracts or metformin.* or #, ** or # # and *** or  # # # 
indicates significance at P < 0.05, P < 0.01, and P < 0.001, respectively.  
 
3.3.3 Crude S. frutescens extracts increased glucose uptake in IR Chang and HepG2 liver 
cells 
The 2-[3H]–DOG taken up by the experimental or control Chang and HepG2 liver cells, was 
calculated relative to the untreated control culture of Chang and HepG2 liver cells in MCDB-
201 medium (MCDB). Compared to the control culture (MCDB), Chang and HepG2 liver cells 
made IR, by treatment with 0.1 mM insulin and 1 mM fructose in MCDB-201 medium (MIF) 
for 24 h, took up significantly less 2-[3H]–DOG (Figures 3.2a and b; P < 0.001), thus indicating 
the IR state in these cells. Treatment of IR Chang and HepG2 liver cells with metformin 
significantly reversed the effect of IR-mediated changes on glucose uptake in these cells, 
returning 2-[3H]–DOG uptake to that of the control culture (Figures 3.2a and b; P < 0.001 and 
P < 0.05, respectively).  In the IR Chang cell culture, simultaneous treatment of cells with 
aqueous or organic extracts of S. frutescens significantly increased 2-[3H]–DOG uptake,  
returning it to the control level, with the hot aqueous extract displaying the highest activity 
(100% for hot aqueous vs 80%, 84%, 77%, 78.33% and 84.33% for 80% ethanol, 100% 
ethanol, 80% methanol and 100% methanolic extracts, respectively; P < 0.001 for hot aqeous, 
80% and 100% ethanolic extracts and P < 0.01 for cold aqeous 80% and 100% methanolic 
extracts, respectively) (Figure 3.2a). However, in the IR HepG2 culture, hot aqueous, cold 
aqeous and 80% ethanolic extracts were the only extracts found to significantly return 2-[3H]–
DOG uptake to that of the control culture (Figure 3.2b; P < 0.001 for hot aqeous and P < 0.05 
for cold aqeous and 80% ethanolic extracts, respectively). 
 
 
155 
 
 
 
Figure 3.2: Glucose uptake (2-[3H]-deoxyglucose) in (a) IR Chang, (b) HepG2 liver cells. 
Chang and HepG2 cells were cultured in MCDB-201 medium containing insulin and fructose 
(MIF) for 24 hrs, with S. frutescens extracts, or metformin as positive control. 2-[3H]–DOG 
uptake measured relative to the control MCDB culture. Data are represented as mean ± SEM 
from 3 independent experiments of 3 wells per experiment for all analysed conditions. One 
way analysis of variance (ANOVA) was conducted on the means of the replicates between 
MIF and MCDB (control) (*) and, MIF and cells treated with Sutherlandia frutescens or    
metformin (#). * or #, ** or # # and *** or # # # indicates significance at P < 0.05, P < 0.01, 
and P < 0.001, respectively. 
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3.3.4 Aqueous and organic extracts of S. frutescens regulates lipid accumulation in IR 
Chang and HepG2 liver cells 
In addition to changes in glucose metabolism, altered lipid metabolism has been observed in 
IR state [382]. In this present study, lipid accumulation following insulin and fructose (MIF) 
or palmitate (PMB) treatment of Chang and HepG2 liver cells was determined using the Oil-
red-O stain to detect neutral triacylglycerols and cholesteryl esters [411, 412], and the 
fluorescent Nile Red stain to detect cytoplasmic phospholipids and neutral lipid droplets [413]. 
One-way ANOVA indicated that there was significant variation between the groups. Newman-
Keuls post-test showed that Chang and HepG2 liver cells treated with MIF or PMB 
accumulated significantly higher levels of neutral triacylglycerols and cholesteryl esters than 
the control cell culture (MCDB) as determined by the Oil-red-O stain  (Figures 3.3a I-II and b 
I-II; P < 0.001, P < 0.05, P < 0.01 and P < 0.001, respectively). Similarly, data obtained from 
the fluorescent Nile Red stain showed that both cells accumulated higher levels of cytoplasmic 
phospholipids and neutral lipid droplets than the control cell culture, though this was not 
significant in the HepG2 cell cultures (Figures 3.3c I-II; P < 0.001). The presence of S. 
frutescens extracts or metformin significantly reduced the amount of lipid accumulation in cells 
cultured in MIF or PMB, compared to the MIF or PMB treatment alone, returning lipid 
accumulation to a similar level to that observed in cells cultured in MCDB alone (Figures 3.3a 
I-II and b I-II; P < 0.05 in all cases). In the Chang cells cultured in MIF or PMB and HepG2 
cells cultured in PMB, the hot aqueous extract of S. frutescens displayed a greater activity when 
compared to the other extracts (101.66% for hot aqueous extract vs 111.33%, 111%, 107%, 
122.33% and 108.33% for cold aqueous, 80% ethanol, 100% ethanol, 80% methanol and 100% 
methanolic extracts, respectively) (Figure 3.3a I), (102 % for hot aqueous extract vs  108.5%, 
104.5%, 109%, 110.5%, 105.5% for cold aqueous, 80% ethanol, 100% ethanol, 80% methanol 
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and 100% methanolic extracts, respectively) (Figure 3.3a II) and (100.33 for hot aqueous 
extract vs 115.33%, 115.66%, 117,66%, 114.33%, 105.33% for cold aqueous, 80% ethanol, 
100% ethanol, 80% methanol and 100% methanolic extracts, respectively) (Figure 3.3b II). 
Furthermore, aqueous and organic extracts of S. frutescens were also found to significantly 
decrease the levels of cytoplasmic phospholipids and neutral lipids droplets in MIF treated 
Chang liver cells, as determined by the Nile Red stain (Figures 3.3c I-II; P < 0.001 in all cases). 
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Figure 3.3: Lipid content in (a) Chang, (b) HepG2 liver cells determined using Oil-red-O 
staining and (c) Chang and HepG2 liver cells determined by Nile Red stain. Chang and HepG2 
cells cultured in MCDB-201 medium containing MIF (aI, bI and cI-II) or palmitate (PMB) (aII 
and bII) are compared to the control MCDB culture, S. frutescens or metformin. Data are 
represented as mean ± SEM from 3 independent experiments of 3 wells per experiment for all 
analysed conditions. One way analysis of variance (ANOVA) was conducted on the means of 
the replicates between MIF and MCDB (control) (*) and, MIF and cells treated with S. 
frutescens or metformin (#). * or #, ** or # # and *** or # # # indicates significance at P < 
0.05, P < 0.01, and P < 0.001, respectively. 
 
 
3.3.5  Thin Layer Chromatography Analysis for Lipids Classes  
Thin Layer Chromatography was used to separate and determine lipid components in the Chang 
and HepG2 cell cultures after exposure to MIF treatment in the presence or absence of 
metformin or extracts of S. frutescens. In the Chang cell culture, treatment with MIF increased 
the levels of triacylglycerol (TAG), diacylglycerol (DAG) and monoacylglycerol (MAG) by 
2.25, 14.47 and 37.81 fold above the control (MCDB), respectively (P < 0.001) (Figures 3.4a 
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I and II). Subsequent treatment with metformin or extracts of S. frutescens significantly 
decreased the accumulation of these classes of lipid in comparison to the MIF-treated Chang 
cells (Figures 3.4a I and II) (P < 0.05), although MAG and DAG levels remained significantly 
higher than those of the control (MCDB) (p < 0.05) (Figure 3.4a II). Similarly, treatment of 
HepG2 cells with MIF increased the levels of TAG, DAG and MAG by 1.47, 1.74 and 2.48 
fold above the control (Figure 3.4b I and II; P < 0.01). The presence of S. frutescens extracts 
or metformin was found to significantly reduce the levels of these classes of lipids compared 
to the MIF-treated HepG2 cells alone (Figure 3.4b I and II; P < 0.01 in all cases for DAG and 
MAG). 
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Figure 3.4: Thin layer chromatography of lipid fractions in (a) Chang and (b) HepG2 liver 
cells. The cellular lipid profile of Chang and HepG2 cells grown for 24 hours in MCDB or MIF 
or MIF together with metformin or extracts of S. frurtescens extract was analysed by (I) 
representative thin layer chromatograph and (II) subsequent densitometry.  In the 
chromatograph, lanes represent the samples as 1) MCDB, 2) MIF, 3) MIF+Metformin, 4) 
MIF+hot aqueous extract, 5) MIF+cod aqeous extract, 6) MIF+80% Ethanolic extract, 7) 
MIF+100% Ethanolic extract, 8) MIF+80% Methanolic extract, and 9) MIF+100% Methanolic 
extract of S. frutescens. Data are represented as fold increase compared to the control (MCDB) 
TAG 
DAG 
MAG 
Other unidentified 
classes of lipids 
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± S.D.  Statistical analysis was performed using two-way ANOVA (n = 2).  * or #, ** or # # 
and *** or # # # indicates significance at P < 0.05, P < 0.01, and P < 0.001, respectively. MAG 
= monoacylglycerol, DAG = diacylglycerol, TAG = triacylglycerol. 
  
3.3.6 S. frutescens regulates the expression of VAMP3, MAPK8, and IRS1 in IR hepatic 
cells.  
Data obtained from the quantitative real-time RT-PCR analysis showed that IR state induced 
by treatment with insulin and fructose (MIF) downregulated the expression of VAMP3, IRS1 
and MAPK8 in the HepG2 cultures when compared to the control MCDB culture (Figures 3.5a 
I-III; P  < 0.001 for MAPK8 expression). However, this downward regulation was reversed in 
the presence of metformin and S. frutescens extracts. For VAMP3 expression, the 100% 
ethanolic extract of S. frutescens had the highest activity, significantly increasing the 
expression of VAMP3 by 11.81 fold above the control (Figures 3.5a I; P < 0.001).  In addition, 
it was observed that the presence of insulin augmented the activity of the aqueous extracts and 
metformin while a reduction in the level of gene expression was observed in the organic 
extracts in the presence of insulin (3.79 fold increase compared to control  vs 2.73 for 
hot+insulin vs hot+pbs, 5.182 fold increase vs 3.25 for cold+insulin vs cold+pbs, 2.06 fold 
increase vs 11.81 for 100% ethanol+pbs vs 100% ethanol+insulin, and 0.17 fold expression 
(decrease) vs 2.76 for 100% methanol+insulin vs 100% methanol+pbs). Similarly, for IRS1 
expression, the 100% ethanolic extract significantly up-regulated the expression of IRS1 gene 
by a 2.31 fold increase above the control (Figure 3.5a II; P < 0.001). This was also associated 
with a reduction in gene expression in the presence of insulin (Figure 3.5a II). With the 
exception of 100% methanolic extracts, all other extracts were not able to reverse IR-mediated 
downregulation of MAPK8 in IR HepG2 hepatic cells ( Figure 3.5a III; P < 0.001).  
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Interestingly, in the Chang cell cultures, the IR state had no downregulatory effect on the 
expression of all three genes when compared to the control MCDB (Figures 3.5b I-III). 
Nonetheless, in the presence of insulin, metformin and the cold aqueous extract of S. frutescens 
were observed to significantly up-regulate the expression of VAMP3 above the MIF insulin 
resistant culture or MCDB control (Figure 3.5b I; P < 0.05). While the hot aqueous extract in 
absence of insulin and the methanolic extracts with or without insulin augmentation, 
maintained VAMP3 gene expression at the level of the MCDB control in IR Chang hepatic 
cells (Figure 3.5b I). As seen in Figure 3.5b II,  metformin with insulin and 100% methanolic 
extracts without insulin up-regulated IRS1 expression above the MCDB control, but this was 
significantly less than the MIF-mediated IRS1 expression in these cells. In addition, a 
combination of metformin and insulin was found to significantly up-regulate MAPK8 
expression above the MIF or MCDB control cultures (Figure 3.5b III; P < 0.01). Although, the 
hot aqueous extract without insulin and cold aqueous extract with insulin up-regulated MAPK8 
expression, this was not found to be significant (Figure 3.5b III). 
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Figure 3.5: Relative mRNA expression of VAMP3, IRS1, and MAPK8 in (a) IR HepG2 cells 
and (b) IR Chang cells. Chang and HepG2 cells were cultured in MIF for 24 hr in the presence 
or absence of metformin or extracts of S. frutescens with or without insulin augmentation. The 
relative mRNA expression of VAMP3, IRS1, and MAPK8 was determined by quantitative 
real-time RT-PCR, with fold changes in expression calculated by the ΔΔCq Livak method 
[409]. Data are represented as fold increase above control (MCDB) ± S.D.  Statistical analysis 
was performed using One-Way ANOVA (n = 3).  * or #, ** or # # and *** or # # # indicates 
significance at P < 0.05, P < 0.01, and P < 0.001. 
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3.4 Discussion 
It is estimated that by the year 2020, approximately 250 million people will be affected with 
T2DM [414]. Though the primary etiological factor for this disease remain unknown, it is 
accepted that IR plays a key role in the development of T2DM [415]. This is supported by 
findings from longitudinal and cross sectional studies that show the presence of IR 10–20 years 
before the onset of T2DM [416, 417] and prospective studies demonstrating that IR is the best 
predictor of whether or not an individual will become diabetic later in life [416, 417]. The 
current approach to treating T2DM is the use of oral anti-diabetic agents (OAAs), insulin, and 
incretin-based drugs in an attempt to achieve glycemic control and maintain glucose 
homeostasis [418]. But current anti-diabetic agents lack efficacy and also possess undesirable 
side effects [419].  
Extracts of S. frutescens have been shown to contain a number of potential anti-diabetic 
phytocompounds [420, 421]. Prior studies by Chadwick et al. (2007) and Mackinzie et al. (2009 
and 2012) have demonstrated the anti-diabetic potential of both a laboratory prepared aqueous 
extract and a commercial aqueous preparation of S. frutescens in the treatment and prevention 
of IR in rats fed with high fat diet [261, 422, 423].  
Solvent extraction is the most widely used procedure to prepare extracts from plants. The type 
of solvent used may have an effect on the nature and the groups of compounds extracted, 
affecting the resulting bioactivity of the extract [111]. It is therefore very plausible that different 
solvent extracts of S. frutescens may posses varying biological activity consequent on the 
groups of compounds extracted. In this present study, six different solvent extracts; hot 
aqueous, cold aqueous, 80% ethanol, 100% ethanol, 80% methanol and 100% methanol 
extracts of S. frutescens were investigated for their anti-diabetic activity and the ability to 
prevent IR-mediated metabolic changes in IR Chang and HePG2 liver cell lines. Futhermore, 
the activity of individual extracts was compared with each other, MIF treated cells and the 
 
 
167 
 
MCDB control. In-vitro insulin resistance was established in Chang and HepG2 cells by 
treating cultures with 0.1 mM insulin and 1 mM fructose (MIF), or 0.25 mM palmitate (PMB) 
for 24 hours. Characteristic metabolic changes found in the IR state include reduced glucose 
uptake, increased hepatic glucose production and the accumulation of circulating lipids and 
ectopic fat deposits [382].  
De novo synthesis of glucose in the liver is a central mechanism to provide the organism with 
glucose in times of starvation [424, 425]. However, when glucose is directly available from 
external sources,  hepatic gluconeogenesis becomes dispensable and consequently needs to be 
shut off [426]. Insulin is the most important hormone that inhibits gluconeogenesis [426]. It 
acts predominantly by suppressing key gluconeogenic enzymes including 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase) [425, 
426]. However, in the diabetic state, the occurrence of IR, leads to the inability of insulin to 
regulate the activity of glucogenic enzymes, thereby causing an increase in hepatic glucose 
output and elevated blood glucose levels [426]. In patients with T2DM, the rate of hepatic 
gluconeogenesis has been found to be considerably elevated compared to healthy subject [425]. 
Similarly, an increased hepatic glucose production with elevated levels of  G-6-Pase and 
PEPCK was reported in mice with an organ-specific insulin receptor knockout in the liver 
[410]. 
In this study, treatment of Chang and HepG2 cells with MIF resulted in a significant increase 
in glucose production and accumulation within the culture medium (Figures 3.1a and b) 
compared to the control. Simultaneous treatment of these cells with  S.  frutescens extracts or 
metformin, prevented IR-mediated gluconeogenesis by significantly decreasing the percentage 
glucose production in IR Chang and HepG2 cells (Figure 3.1a and b; P < 0.001) and 
maintaining it at the same level as the control (MCBD). Futhermore, in the Chang cell culture, 
the hot aqueous extract was found to be most active, decreasing the percentage glucose 
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production levels by 79.7% when compared to metformin (71.2%) and all the other solvent 
extracts, Figure 3.1a although this was not statistically significant. Several studies on anti-
diabetic medicinal plants have suggested that extracts of these plants mimic insulin in 
downregulating hepatic gluconeogensis. In a study by Pari et al. (2004), 4 weeks oral 
administration of 200 mg/kg aqueous extract of Boerhaavia diffusa L. leaf to diabetic albino 
rats was found to significantly increase the activity of hepatic hexokinase while downregulating 
the activity of hepatic G-6-Pase glucose and fructose-1,6-bisphosphatase in normal and 
diabetic rats [427]. G-6-Pase catalyzes the final step of gluconeogenesis, the production of free 
glucose from glucose 6-phosphate [426]. It is therefore very likely that extracts of S. frutescens 
act in a similar manner to prevent IR-mediated gluconeogenesis in Chang and HepG2 liver 
cells.  
Futhermore, S. frutescens-mediated prevention of glucose production in IR-hepatic cells seen 
herein is in agreement with findings by Williams et al. (2013), where an aqueous extract of S. 
frutescens was found to prevent the development of IR-mediated glucose production in Chang 
liver cells [382]. This was associated with up-regulation of the phosphatidylinositol 3-kinase 
(PI3-kinase)-protein kinase B (PKB/Akt) and the mitogen-activated protein kinase (MAP 
kinase) signaling pathways [382], required for insulin-mediated regualtion of glucogenic 
enzymes [428]. Likewise, in this present study, both aqueous and methanolic extracts of S. 
frutecsens up-regulated MAPK8 expression in IR Chang hepatic cells, while the methanolic 
extract alone regulated MAPK8 expression in the HepG2 cell cultures. Futhermore, the 
inability of metformin alone (Met+pbs) to significantly up-regaulate MAPK8 expression does 
partialy support the theory that metformin inhibits hepatic gluconeogenesis  via other pathways, 
in particular the AMPK-activated protein kinase [429]. However, a recent finding has 
suggested metformin can act via other non-AMPK dependent pathways [430]. 
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Insulin receptor substrate (IRS) 1 and 2 are abundantly expressed in the liver and are thought 
to be responsible for transmitting insulin signaling from the insulin receptor to the intracellular 
effectors in the regulation of glucose and lipid homeostasis [431]. The binding of insulin to its 
receptor on the hepato-cellular membrane, promotes the autophosphorylation of regulatory 
loop tyrosine residues, removing the inhibition of the insulin receptor tyrosine kinase activity 
toward IRS [432]. Tyrosine phosphorylation of IRS1 by the insulin receptor generates binding 
sites for Src homology 2 (SH2) domain proteins, including the regulatory subunits of class 1A 
phosphatidylinositol 3-kinase (PI3K) [433]. Up-regulation of IRS1 expression by aqueous and 
organic extracts of S. frutesecens in IR HepG2 seen in this present study suggests that use of 
S. frutescens herbal mixture can reverse the IR state, possibly as a result of increased IRS1 
expression. This is in agreement with similar findings by Williams et al. (2013) where extracts 
of S. frutescens up-regulated IRS1 expression in IR Chang cells [382]. However, in contrast to 
their findings, the S. frutescens extracts used in this present study did not induce IRS1 
expression in IR Chang cells. Thus suggesting that further work is needed to determine the 
roles S. frutescens in the regulation of IRS1 expression.  
Activation of PI3-kinase leads to downstream phosphorylation and activation of protein kinase 
B (PKB/Akt) [434, 435]. PKB has shown to be partially responsible for the regulation of G-6-
Pase gene transcription via the insulin-response unit (IRU) within the G-6-Pase promoter [436]. 
In addition, overt expression of PKB in hepatoma cells and primary hepatocyte cultures has 
been shown to downregulate PEPCK and G-6-Pase gene transcription [437]. Similarly,  
activation of mitogen-activated protein kinase by phorbol ester has been shown to mediate the 
suppression of PEPCK and G-6-Pase gene transcription [437, 438]. Hence, it is plausible that 
extracts of S. frutescens used in this present study act via the PI3-kinase-Akt and MAP kinase 
signaling pathways to inhibit PEPCK and G-6-Pase gene transcription and prevent 
gluconeogenesis. However, reduced extract-mediated expression of MAPK8 in the presence of 
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significant biological activity seen herein suggests that these extracts might be acting on 
multiple intracellular target pathways to significantly decrease glucose production in IR hepatic 
cells. Thus corroborating the hypothesis that a herbal mixture has a significant advantage over 
conventional pharmaceuticals synthesised from a single chemical [439].  
In the post-prandial state, peripheral blood glucose is taken up by the hepatocyte via the hepatic 
glucose transporter type 2 (GLUT2), a membrane bound transporter with high capacity and 
low affinity for glucose [440]. The expression and activity of GLUT2 is independent of insulin 
signaling [440], but dependent on the concentration gradient of glucose across the hepatocyte 
plasma membrane [441]. GLUT2 maintains intracellular glucose in equilibrium with 
extracellular glucose [441]. Thus, the generally accepted role of GLUT2 is to take up glucose 
during the absorptive phase and to release it in the blood during fasting [442]. Hepatic insulin 
resistance, created by exposing hepatic cells Chang [382] and HepG2 [443] to high doses of 
fructose or glucose and insulin has been shown to down-regulate the expression of GLUT2 and 
reduce glucose uptake [443]. The significant reduction in uptake of 2-[3H]–DOG by Chang 
and HepG2 cells treated with 0.1 mM insulin and 1 mM fructose seen herein thus suggest that 
IR inhibits hepatic GLUT2 in these IR hepatic cells. This reduction in glucose uptake was 
prevented by simultaneous treatment with 12.5 µg/mL S. frutescens extracts or 1 µM 
metformin (Figure 3.2a and b; P < 0.05). In the Chang cell culture, both aqueous and organic 
extracts of S. frutesecens were found to significantly induce 2-[3H]–DOG uptake above the 
MIF treated cells while the hot aqueous, cold aqueous and 80% ethanolic extracts of S. 
frutescens were found to significantly induce 2-[3H]–DOG uptake in the HepG2 culture. 
Futhermore, in both cell cultures, the hot aqueous extract was found to be the most active 
extract increasing 2-[3H]–DOG by 100% in the Chang cell culture and 76.6% in the HepG2 
culture, respectively when compared to metformin and other extracts. Induction of 2-[3H]–
DOG uptkae in IR Chang cells by S. frutescens observed in this present study is consistent with 
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similar findings by Williams et al. (2013) [382]. Similarly, Cordero-Herrera et al. (2014) 
showed that 1 μg/mL of phenolic extracts of Theobroma cacao prevented high-glucose induced 
downregulation on GLUT2 levels and glucose uptake in HepG2 cells [443]. Hence it is possible 
that extracts of S. frutescens act in a similar manner to mediate glucose uptake in these cells. 
Moreover, we have previously shown that hot aqueous S. frutescens can upregulate the 
expression of transporter genes including Vesicle-associated membrane protein 3 (VAMP3), 
N-ethylmaleimide-sensitive factor (NSF), Synaptosomal-associated protein 25 (SNAP25), 
VAMP-associated protein A (VAPA), and Syntaxin binding protein 2 (STXB2) in IR hepatic 
cells [382]. Likewise, I found that the aqueous and organic extracts of S. frutescens were found 
to up-regulate the expression of VAMP3 in IR HepG2 and Chang hepatic cells with varying 
intensity (Figures 3.5a I and bI). The combinatorial effect of insulin and the aqueous extract of 
S. frutescens on VAMP3 expression, partly supports the adjunct use of  S. frutescens by T2DM 
patients.  
In the adipocytes and myocytes, insulin mediated exocytosis of GLUT4 bears a resemblance 
to the regulated exocytosis of synaptic vesicles found in the axon end of motor neurons [444, 
445]. In particular, GLUT4 vesicles contains vesicle-soluble NSF attachment protein receptor 
(v-SNARE) proteins VAMP2 and VAMP3, which physically interact with their target (t)-
SNARE counterparts (syntaxin 4 and SNAP family) in the plasma membrane during GLUT4 
vesicle translocation [446]. Although, GLUT4 is not expressed in the hepatocytes, most of the 
GLUT4 trafficking machinery has been found in the liver [447], making it very likely that S. 
frutescens enables glucose uptake in IR hepatocytes by increasing GLUT2 translocation. 
Furthermore, in their study, Cordero-Herrera and colleagues showed that treatment with 10 μM 
(−)-epicatechin, a natural occuring plant flavonoid [448], also upregulated GLUT2 levels and 
induced glucose uptake in HepG2 cells made IR by exposure to a  high concentration of glucose 
and insulin [443]. Prior studies by  Shaik et al. (2011) and Tobwala et al. (2014) have shown 
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that aqueous and organic extracts of S. frutescens leaf contain substantial levels of flavonoids 
[449, 450]. It is therefore plausible that flavonoids present in the S. frutescens extracts used in 
this study are responsible for the induction of 2-[3H]–DOG uptake in these cells. In addition, 
Tobwala and colleagues reported that the hot aqueous extract contained the highest 
concentration of total flavonoids (28.7 µg/mg) when compared to cold aqueous, acetone, 
acetonitrile, methanol and ethanol extracts respectively [450]. Hence, it is very likely that the 
high concentration of flavonoids present in the hot aqueous extract might be responsible for its 
higher activity, as observed in this study.  
The association between lipids and insulin resistance is widely accepted [451]. A variety of 
abnormalities in lipid metabolism have been described in insulin-resistant state [452]. In the 
liver, IR has been identified as a crucial pathophysiological factor in the accumulation of 
various classes of lipids [453], leading to hepatic steatosis [375], and subsequent development 
of non-alcoholic fatty liver disease (NAFLD) [454, 455]. In this present study, the effect of the 
IR  state, created by exposure to combined insulin and fructose or to the saturated fatty acid 
palmitate, on lipid accumulation in Chang and HepG2 cells was assesed using the Oil-red-O 
assay and the fluorescent Nile Red stain, in the presence or absence of metformin or extracts 
of S. frutescens (Figures 3.3a, b and c). Data obtained indicate that treatment with insulin and 
fructose or palmitate significantly increased lipid accumulation in both Chang and HepG2 liver 
cells (P < 0.001). However, treatment with extracts of S. frutescens or metformin significantly 
reversed the effects of fructose and insulin  or palmitate on lipid accumulation (P < 0.01). These 
in-vitro findings agree with prior observations by Mackenzie et al. (2009, 2012) who showed 
that ingestion of a high fat diet by Wistar rats led to the develoment of the IR state, with 
subsequent free fatty acid (FFA) accumulation. These metabolic changes were prevented and 
completely reversed by S. frutescens[422, 423] 
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Fructose has been shown to enter hepatocytes in an unregulated manner [456, 457] and 
fructolysis lacks the tight metabolic regulation present in glycolysis [375]. In the liver, fructose 
is rapidly phosphorylated by fructokinase to fructose-1-phosphate, a precursor for the 
triacylglycerols (TAG) backbone, which is subsequently converted to glycerol and acetyl-CoA 
for fatty acid synthesis [458]. Hence, excess fructose can lead to increased intra-cellular 
accumulation of TAG [458, 459]. This is corroborated by findings from my thin layer 
chromatography analysis of the classes of lipid components within Chang and HepG2 cells 
treated with a high concentration of fructose and insulin (MIF). I found that exposure to a high 
concentration of fructose and insulin significantly increased the levels of triacylglycerols 
(TAG) (2.25 fold increase), diacylglycerol (DAG) (14.47 fold increase) and monoacylglycerol 
(MAG) (37.81 fold increase) in Chang cells (Figures 3.4a I and II; P < 0.001) and 
diacylglycerol (DAG) (1.74 fold increase) and monoacylglycerol (2.48 fold increase) in HepG2 
cells (Figures 3.4b I and II). In addition, to TAG, DAG and MAG, I observed that MIF also 
increases the levels of other unidentified classes of lipids (e.g. sterols). This suggests that these 
groups of lipids are responsible for the total lipid accumulation observed in MIF treated Chang 
and HepG2 cells, as discussed earlier. This is in agreement with similar in vitro findings by 
Huang et al. (2011), where exposure to a combination of glucose and fructose increased intra-
cellular TAG (palmitate and oleate) in HepG2 cells [460]. Furthermore, I found that the 
increase in intra-cellular accumulation of these classes of lipids was significantly reversed by 
extracts of S. frutescens or metformin (P < 0.05) (Figures 3.4a I, 4b I and 4a II, 4b II). This 
suggests that S. frutescens mediates a reduction in IR-mediated intra-cellular lipid 
accumulation by inhibiting the synthesis of TAG, DAG, and MAG classes of lipids. As 
discussed earlier, we have previously shown that S. frutescens induces the expression of NSF 
and VAPA genes in IR Chang cells [382]. NSF has been shown to be involved in lipid droplet 
formation, movement and fusion; while VAPA has been suggested to regulate lipid metabolism 
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by binding to lipoproteins and targeting them to the endoplasmic reticulum for processing 
[461]. This suggests that the effects of S. frutescens extracts on IR mediated intra-cellular lipid 
(TAG, DAG and MAG) accumulation could be as a result of up-regulation of NSF and VAPA 
gene expression. Furthermore, by inducing Peroxisome proliferator-activated receptor alpha 
(PPARα) expression [382], S. frutescens can induce mitochondrial and peroxisomal fatty acid 
β-oxidation in the hepatic cells [462] to provide energy for the cells and at the same time lower 
intra-cellular fatty acids, subsequently reducing lipid accumulation.  
Taken together, using a novel two hepatic cell line (Chang and HepG2) in-vitro model system, 
I have shown that aqueous and organic extracts of S. frutescens can prevent the development 
of hepatic IR,  a vital step in the development of T2DM [463]. Here I show that aqueous and 
organic extracts of S. frutescens prevented and reversed insulin and fructose (MIF) mediated 
IR metabolic changes: increased accumulation of glucose in the culture medium, reduction in 
glucose uptake and increased intra-cellular accumulation of lipids in Chang and HepG2 liver 
cells. The expression of biological activities by all the extracts used in this study suggests that 
a common active principle might be responsible, though at a different concentration, as all the 
extracts displayed varying levels of activity. In conclusion findings presented herein suggest 
that aside from the frequently investigated aqueous extract, organic extracts of S. frutescens 
can also be explored for the development of a newer and efficacious anti-diabetic principle. A 
schematic diagram showing the proposed role of S. frutescens in IR mediated metabolic 
changes in IR hepatocyte IR hepatocyte is shown in Figure 3.6. 
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Figure 3.6: Schematic diagram showing the role of S. frutescens in reversing IR mediated 
metabolic changes in IR hepatocyte. In the IR hepatocyte, metabolic changes such as increased 
gluconeogenesis, increased lipid accumulation and decreased GLUT2 membrane translocation 
and subsequent decrease in hepatic glucose uptake are a common phenomenon. Exposure of 
this cell to S. frutescens extracts prevents and reverse this IR mediated metabolic changes via 
its positive effect on GLUT2 membrane translocation to increase hepatic glucose uptake and 
its inhibitory (negative) effects on hepatic lipid accumulation and hepatic gluconeogenesis to 
prevent increase in hepatic glucose output. 
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CHAPTER FOUR 
GENERAL DISCUSSION 
4.1 General discussion 
Presently, glycaemic control with the use of oral anti-diabetic agents (OAAs) is the main stay 
of clinical management of T2DM [418]. But due to the lack of efficacy and undesirable side 
effects of current OAAs [419], there is a need for the development of newer more efficacious 
and less toxic drugs. Medicinal plants have long played important roles in the treatment and 
management of varying forms of human disease including T2DM [464]. To date, about 7000 
natural compounds are in use in modern medicine [465, 466]. In contrast to conventional 
pharmaceuticals which are based upon a single synthetic chemical, many herbal mixtures exert 
their biological effects through the additive, or synergistic action of several chemical 
compounds acting at single site or multiple target sites associated with a physiological process 
[439]. Various herbal anti-diabetic remedies are used in traditional medical practices around 
the world. However, only a few of them have been scientifically assessed for their efficacy 
[144]. Hence, in this present study using an in-vitro cell line model system, the anti-diabetic 
properties of different aqueous and organic extracts of S. frutescens was investigated. A single 
source of plant material was used to make all the extracts, to ensure that the starting plant 
content was identical and so control for any differences resulting from growth conditions or 
other variation in the plant material. 
The effectiveness of medicinal plant extracts and their pharmacotherapeutic action is due to 
their complex diversity of chemical compounds [47]. Different plants may possess a wide 
spectrum of effects due to the presence of various groups of chemical compounds and various 
microelements [48]. However, successful extraction of biologically active compounds from 
plant material is largely dependent on the extraction procedure and type of solvent used [467]. 
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Hence, using the conventional hot aqueous solvent extraction method and five other solvent 
methods: cold aqueous, 80% ethanol, 100% ethanol, 80% methanol and 100% methanol, I have 
extracted bioactive phytocompounds from S. frutescens. Of these solvents, the hot aqueous 
extractant was quantitatively the best extractant, extracting 1.99 g of plant material, compared 
to the other solvent methods, and while the 100% ethanol had the lowest mass extracted (0.52 
g). This suggests that the application of heat and water (hot aqueous) could play a vital role in 
extraction of bioactive compounds from S. frutescens and also justifies the traditional use of a 
tea infusion of S. frutescens [261].  
Based on their chemical structure, bioactive phytochemicals can be classified into alkaloids, 
glycosides (saponins, phenols, cyanogenic glycoside and cardiac glycosides), lactones, and 
others (e.g. pigments and ecdysones) [48, 49]. Using colorimetric analysis, the presence of 
flavonoids, flavonol, phenol and tannins were confirmed in aqueous and organic extracts of S. 
frutescens. This agrees with findings by Shaik et al. (2011) and Tobwala et al. (2014) where 
aqueous (hot and cold) and organic (ethanol and methanol) extracts of S. frutescens were found 
to contain phytocompounds including flavonoids, phenol and tannins [449, 450]. Furthermore, 
quantification of these compounds using a spectrophotometric method showed higher 
concentration of flavonols and tannin in the organic extracts. Similarly, higher concentration 
of flavonoids was found in both the aqueous (hot and cold) and 100% methanolic extracts, 
while all the extracts contained approximately equal levels of phenols. This is consistent with 
findings by Tobwala et al. (2014) where hot aqueous, cold aqueous and methanolic extracts of 
S. frutescens contained higher concentrations of flavonoids when  compared to acetone, 
acetonitrile, and ethanolic extracts [450]. Flavonoids and flavonols are polyphenolic 
compounds distributed widely in the plant kingdom [280]. Plant mixtures containing 
flavonoids have been used in folk medicine around the world [281]. Flavonoids display a 
number of biological activities, including anti-allergic, anti-inflammatory, anti-oxidant, anti-
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carcinogenic activity, and modulation of enzymatic activities [282-285]. In humans, phenols 
and phenolic compounds have been explored for their anti-cancer [277], anti-oxidant, anti-
atherosclerotic, anti-bacterial, anti-inflammatory, and anti-viral properties [278, 279]. 
Similarly, tannins have been suggested to be potent anti-cancer agents due to their beneficial 
physiological role as scavengers of reactive oxygen intermediates (ROI) [295]. The presence 
of these compounds in S. frutescens gives credence to the folklore use of herbal mixtures of S. 
frutescens as an anti-inflammatory and anti-cancer agents.  
Several bioactive phytocompounds have been isolated from S. frutescens extracts [35, 206, 
224-226]. Some of these bioactive principle constituents have been linked to the therapeutic 
application of S. frutescens in folklore medicine, however each isolated compound alone does 
not have the full activity of the complete extract. Despite extensive biological and 
pharmacological studies, few analyses exist of the chemical constituents of S. frutescens [273], 
and no Triple TOF LC/MS/MS analysis has been performed. In this study, untargeted Triple 
TOF LC-MS/MS analysis in positive and negative ionic mode, revealed the presence of 
multiple compounds in individual crude and SPE fractions of S. frutescens extracts. 
Comparison of these compounds with online databases of anti-diabetic phytocompounds led to 
the preliminary identification of 10 possible anti-diabetic compounds: α-Pinene, Limonene, 
Sabinene, Carvone, Myricetin, Rutin, Stigmasterol, Emodin, Sarpagine and Hypoglycin B in 
extracts of S. frutesecens. These are all glycosidic compounds: α-Pinene, Limonene, Sabinene 
and Carvone are monoterpenes; Myricetin and Rutin are flavonoids; Stigmasterol is a steroid; 
Emodin is a phenol; Sarpagine is an alkaloid, and Hypoglycin B is an amino acid. The 
identification of these groups of anti-diabetic compounds in part supports the folklore use of S. 
frutescens herbal mixture for the management of T2DM. In addition, many other 
phytocompounds were detected by the Triple TOF LC-MS analysis that has not previously 
been recognised as anti-diabetic compounds and it is possible that these contribute to S. 
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frutescens activity. The identification of these multiple bioactive compounds in a single extract 
does suggest a combinatorial or synergistic interaction to effect a biological function.  
Furthermore, using an in-vitro two hepatic cell line model system, made IR by exposure to high 
concentration of fructose and insulin, the anti-diabetic properties of S. frutescens extracts was 
confirmed. Initial cell viability assays showed that S. frutescens, at the concentration used in 
this present study was not toxic to the cells. Aqueous and organic extracts of S. frutescens were 
found to significantly prevent and reverse IR-mediated metabolic changes in IR Chang and 
HepG2 cells. S. frutescens-mediated prevention and reversal of increased glucose production 
in IR hepatic cells seen herein agrees with prior findings in our laboratory [382]. This suggests 
that S. frutescens mimics insulin activity by inhibiting the activities of gluconeogenic enzymes 
G-6-pase and PEPCK. More so, I showed that extracts of S. frutescens were shown to regulate 
the mRNA expression of MAPK8 and IRS1 in IR hepatic cells. This corroborates prior findings 
in our laboratory that show S. frutescens can mediate the up-regulation of PI3-kinase-Akt, 
MAP-kinase and IRS1 genes [382], to activate their respective signaling pathways and prevent 
hepatic gluconeogenesis in IR hepatic cells. In both the metabolic assay of glucose production 
and the molecular assays of MAPK8 and IRS1 mRNA expression, all extracts acted to prevent 
or reverse the changes caused by IR, but the hot aqueous extract showed the greatest activity. 
This may indicate that S. frutescens acts via the IRS1 intra-cellular signalling pathway to 
regulate cellular responses to metabolic changes, with the compounds in the hot aqueous 
extract providing the best response. In addition, all of the S. frutescens extracts were found to 
prevent and reverse IR-mediated decrease in hepatic glucose uptake. This was also associated 
with up-regulation of VAMP3 expression, a transporter gene required for successful membrane 
translocation of members of the GLUT family. This suggests that the S. frutescens extracts 
investigated in this present study can act via VAMP3-mediatd translocation of GLUT2 to the 
hepatic cell membrane to mediate an increase in hepatic glucose uptake. These findings are in 
 
 
180 
 
accordance with similar in vitro findings by Williams et al. (2013), where S. frutescens was 
shown to increase glucose uptake in IR Chang cell cultures [382].  
Furthermore, S. frutescens was shown to prevent hepatic lipid accumulation, in particular TAG, 
DAG and MAG in IR Chang and HepG2 cells. This corroborates with prior findings by 
Mackenzie et al. (2009, 2012) who showed that IR-mediated free fatty acid (FFA) 
accumulation in Wistar rats fed on a high fat diet was prevented and completely reversed by S. 
frutescens [422, 423]. The hot aqueous extract is the most potent of all the extracts investigated 
in this study, though this was not statistically significant, while all the organic extracts 
displayed similar potency. 
Taken together, the findings presented in this present study support the burgeoning body of in-
vitro literature evidence on the anti-diabetic properties of S. frutescens and its use in folklore 
medicine. Overall, the hot aqueous extract was the optimal anti-diabetic extract. Previous 
studies have also indicated the activity of a hot aqueous extract and generally the organic 
extracts are reported to be less active. This is the first study to directly compare different 
extracts prepared from the same single source of plant material, thus I have shown that the 
combination of phytocompounds within the hot aqueous extract forms the most effective anti-
diabetic concoction.    
 
 
 
 
 
  
 
 
181 
 
CHAPTER FIVE 
CONCLUSION AND FUTURE STUDIES 
5.1 Conclusion 
Taken together, this study showed that extracts of S. frutescens contain potential anti-diabetic 
compounds that can be explored for the production of newer more efficacious and less toxic 
anti-diabetic agents. Ten anti-diabetic principles were identified from the DIACAN and Phyto 
diab care databases following Triple TOF LC-MS analysis, it is likely that some of these 
compounds combine or interact synergistically to confer the medicinal/biological activities. 
Furthermore, between 44 (hot aqueous extract) and 224 (80% ethanol extract) known 
phytocompounds were identified using the Plant Metabolic Network (PMN). Although most 
of these compounds have not previously been identified as anti-diabetic, it is possible that they 
have hitherto unknown activity, or that they synergise with the known anti-diabetic compounds 
identified in an extract to enhance the overall activity of that extract.   
The above biochemical analysis is strengthened by the findings from the in-vitro cell line 
assays in which extracts of S. frutescens were shown to prevent and reverse IR-mediated 
changes in hepatic cells. The hot aqueous extraction method extracted more plant material and 
was subsequently the most active of all the extracts investigated, while all the organic extracts 
displayed similar potency. Therefore the potency of the hot aqueous extract may be a result of 
a higher concentration of a key compound(s), and/or the presence of a specific anti-diabetic 
compound(s), or finally it may be the result of the unique combination of compounds within 
that extract.  
Furthermore, findings from the quantitative real-time RT-PCR showed that S. frutescens can 
act at multiple target sites to regulate the expression of diabetic related genes and to mediate 
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anti-diabetic activities, again indicating the potential action of multiple compounds within the 
extracts. 
This study provides scientific evidence for the folklore use of S. frutescens as an adjunct 
therapy in the management of T2DM. However, more explorative study is needed to determine, 
isolate, purify and characterize the anti-diabetic chemical principles in crude and partially 
purified (SPE) extracts of S. frutescens. More so, since previous work by other research groups 
has shown that none of the purified compounds from S. frutescens tested to date demonstrated 
anti-diabetic effects equal to a complete crude S. frutescens extract. It is possible that 
previously unidentified compounds also confer activity. Therefore the chemical analysis 
presented herein has revealed 10 potential anti-diabetic compounds, which can be tested for 
activity alone and in combination.  
 
5.2 Future studies 
In view of the above, future studies will be to; 
 Confirm the anti-diabetic compounds in the crude and SPE fractions of S. frutescens 
extracts by using specific standards on the TOF LC-MS/MS, since an untargeted 
analysis was done in this present studies.  
 Investigate further the expression of signaling proteins involved in normal and impaired 
insulin signaling to determine how S. frutescens regulates functional protein expression 
using qRT-PCR to quantify mRNA expression of selected genes, flow cytometry to 
quantify the protein products and Western blot analysis to investigate their post-
translational modification and/or activation (eg phosphorylation state). 
 Intracellular localization of proteins regulated by S. frutescens during the IR state, using 
immunocytochemistry and confocal analysis. 
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APPENDIX I 
List of compounds found in untargeted LC-MS/MS analysis of crude and SPE fractions 
of S. frutescens extracts  
Table I:  List of compounds in crude cold aqueous extract of S. frutescens  
Name   Found at 
RT (min) 
(+)-(4R)-limonene   10.63 
(+)-2-carene   10.63 
(+)-3-carene   10.63 
(+)-sesamolinol   15.26 
(+)-ß-pinene   10.63 
(-)-camphene   10.63 
(-)-ß-phellandrene   10.63 
(-)-ß-pinene   10.63 
(22a)-hydroxy-campest-4-en-3-
one 
  15.7 
(E)-2-methylbutanal oxime   10.28 
(E)-ß-ocimene   10.63 
(S)-2,3-epoxysqualene   15.35 
(Z)-2-methylbutanal oxime   10.28 
stigmasterol   4.99 
myricetin   4.99 
(Z)-ß-ocimene   10.63 
1,3,7-trihydroxyxanthone   9.72 
acetylnorajmaline   4.54 
acidomycin   4.54 
amorpha-4,11-diene   5.08 
curcumin diglucoside   15.35 
curcumin monoglucoside   15.35 
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Table II: List of compounds in crude cold aqueous strong anionic extracts of S. frutescens  
Name   Found at RT 
(min) 
(+)-6a-hydroxymaackiain   13.31 
(+)-isopimara-7,15-diene   10.61 
(+)-maackiain   11.67 
(+)-pisatin   11.78 
(+)-sesamin   10.39 
(-)-9ß-pimara-7,15-diene   10.61 
(-)-abietadiene   10.61 
(-)-maackiain   11.67 
(-)-maackiain-3-O-glucoside   9.87 
(-)-sophorol   13.31 
(4a)-methyl-(5a)-ergosta-8,14,24(28)-trien-
3ß-ol 
  15.33 
(E)-2-methylbutanal oxime   9.27 
(E)-2-methylpropanal-oxime   0.29 
(Z)-2-methylbutanal oxime   9.27 
(Z)-2-methylpropanal-oxime   0.29 
1,3,7-trihydroxyxanthone   9.86 
1,4-dihydroxy-2-naphthoyl-CoA   13.35 
1,5,7-trihydroxy-6,8-
dimethoxyanthraquinone 
  13.31 
1,6,7-trihydroxy-2-methylanthraquinone   13.31 
1,6-kestotetraose   13.31 
1,7-dihydroxy-5,6,8-
trimethoxyanthraquinone 
  11.78 
1-dodecanol   3.95 
1D-chiro-inositol   11.78 
2-amino-4,6-dinitrotoluene glucoside   9.44 
2-hydroxyferulate   11.67 
2-methyl-6-farnesyl-1,4-benzoquinol   11.21 
2-methylbutyrate   3.52 
serinol   15.87 
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Table III: List of compounds in crude cold aqueous weak anionic extract of S. frutescens  
Name   Found at 
RT (min) 
(+)-6a-hydroxymaackiain   11.26 
(+)-pisatin   11.78 
(-)-sophorol   11.26 
1,6-kestotetraose   11.26 
1,7-dihydroxy-5,6,8-
trimethoxyanthraquinone 
  11.78 
1D-chiro-inositol   11.78 
2-fluorobenzoate   9.24 
2-isopropyl-3-oxosuccinate   10.49 
2-methyl-6-geranylgeranyl-1,4-
benzoquinol 
  15.77 
2-oxindole-3-acetate   8.49 
3,7-di-methylquercetagetin   9.99 
3-deaza-GMP   15.66 
3-hydroxy-15-dihydrolubimin   13.43 
3-hydroxypropionyl-CoA   10.49 
3-rha-gal-glc soyasapogenol B   15.62 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-
olide 
  9.87 
6,7-dimethyl-8-(1-D-ribityl)lumazine   15.6 
6-hydroxymellein   11.26 
6-hydroxymethyl-dihydropterin   10.49 
7-hydroxy-2-oxindole-3-aceate glucoside   11.26 
conhydrine   9.19 
curcumin diglucoside   15.69 
curcumin monoglucoside   15.69 
cysteamine   6.48 
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Table IV: List of compounds in crude aqueous strong cationic extract of S. frutescens  
Name   Found at 
RT (min) 
(+)-(4R)-limonene   2.36 
(+)-2-carene   2.36 
(+)-3-carene   2.36 
(+)-pisatin   11.78 
(+)-ß-pinene   2.36 
(-)-camphene   2.36 
(-)-maackiain   11.68 
(-)-ß-phellandrene   2.36 
(-)-ß-pinene   2.36 
(22a)-hydroxy-campest-4-en-3-one   15.66 
(E)-ß-ocimene   2.36 
1D-chiro-inositol   11.78 
7-O-ß-D-glucosyl-apigenin   12.71 
curcumin diglucoside   15.78 
curcumin monoglucoside   15.78 
cyanoborohydride   4.17 
epicatechin   5.51 
esculetin   10.29 
estolide   11.77 
levopimaradiene   15.78 
linamarin   10.01 
luteolin 7-O-[ß-D-glucuronosyl-(1,2)-ß-
D-glucuronide]-4'-O-ß-D-glucuronide 
  15.78 
quercetin 3, 7, 4'-trisulphate   10.29 
a-curcumene   2.36 
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Table V: List of compounds in crude cold aqueous weak cationic extract of S. frutescens 
Name   Found at 
RT (min) 
(+)-6a-hydroxymaackiain   13.29 
(+)-maackiain   11.67 
(+)-pisatin   11.78 
(-)-maackiain   11.67 
(-)-sophorol   13.29 
(4-hydroxyphenyl)acetaldehyde   10.41 
(R)-pantolactone   14.12 
(S)-2,3-epoxysqualene   15.67 
1,3,7-trihydroxyxanthone   9.9 
1,5,7-trihydroxy-6,8-
dimethoxyanthraquinone 
  13.29 
1,6,7-trihydroxy-2-
methylanthraquinone 
  13.29 
1,6-kestotetraose   13.29 
1,7-dihydroxy-5,6,8-
trimethoxyanthraquinone 
  11.78 
1-O-methyl-scyllo-inositol   8.91 
1D-chiro-inositol   11.78 
2-butyl-4-hydroxy-5-methyl-3(2H)-
furanone 
  5.59 
1,2-diaminopropionate   10.5 
1,3,7-trihydroxyxanthone   9.86 
1,5,7-trihydroxy-6,8-
dimethoxyanthraquinone 
  13.66 
1,6,7-trihydroxy-2-
methylanthraquinone 
  13.66 
1,6-kestotetraose   13.66 
1,7-dihydroxy-5,6,8-
trimethoxyanthraquinone 
  11.77 
1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate 
  10.23 
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Table VI: List of compounds in crude hot aqueous extract of S. frutescens  
Name   Found at 
RT (min) 
(+)-2-carene   12.69 
(+)-3-carene   12.69 
(+)-ß-pinene   12.69 
(-)-camphene   12.69 
(-)-ß-phellandrene   12.69 
(-)-ß-pinene   12.69 
(E)-ß-ocimene   12.69 
(Z)-ß-ocimene   12.69 
4a-methylfecosterol   3.89 
Acidomycin   4.58 
adenosine 2'-monophosphate   15.64 
aureusidin 6-O-glucoside   12.23 
Bisdemethoxycurcumin   13.29 
D-arabinose 5-phosphate   4.67 
D-myo-inositol (1,2,3,4) tetrakisphosphate   4.67 
Deguelin   11.16 
Dihydrosanguinarine   3.29 
heliocide B3   11.46 
Norfuraneol   15.61 
peonidin-3-(p-coumaroyl)-rutinoside-5-
glucoside 
  5.04 
serinol phosphate   15.61 
Sulfuretin   12.69 
Tetranitromethane   11.46 
a-chaconine   12.69 
a-curcumene   12.69 
a-fenchene   4.67 
a-phellandrene   12.69 
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Table VII: List of compounds in crude hot aqueous strong anionic extract of S. frutescens 
Name   Found at 
RT (min) 
(+)-6a-hydroxymaackiain   13.31 
(+)-maackiain   11.68 
(+)-pisatin   11.79 
(-)-maackiain   11.68 
(-)-sophorol   13.31 
(E)-2-methylpropanal-oxime   1.15 
(S)-2,3-epoxysqualene   15.83 
(Z)-2-methylpropanal-oxime   1.15 
1,3,7-trihydroxyxanthone   9.83 
1,5,7-trihydroxy-6,8-dimethoxyanthraquinone   13.31 
1,6,7-trihydroxy-2-methylanthraquinone   13.31 
1,6-kestotetraose   13.31 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.79 
1-deoxy-D-xylulose 5-phosphate   8.04 
1-phenyl-7-(3,4-dihydroxyphenyl)-hepta-1,3-dien-
5-one 
  8.48 
1D-chiro-inositol   11.79 
2-hydroxyferulate   11.68 
2-mercaptobenzothiazole   6.15 
2-oxo-3-carboxy-4,5-cyclopropylhex-5-enoate   3.42 
24-epi-campesterol   15.83 
246-trinitrobenzene   15.61 
3-hydroxy-15-dihydrolubimin   13.41 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-olide   9.83 
4-methylpentanal   14.91 
5-hydroxyisourate   11.27 
5-methylthiopentyldesulfoglucosinolate   10.46 
5-phosphoribosyl-N-formylglycineamidine   15.61 
6-hydroxymellein   13.31 
7-deoxyloganin   13.41 
7-hydroxy-2-oxindole-3-aceate glucoside   13.31 
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Table VIII: List of compounds in crude hot aqueous weak anionic extract of S. frutescens 
Name   Found at 
RT (min) 
(+)-6a-hydroxymaackiain   10.54 
(+)-maackiain   11.64 
(+)-pisatin   11.76 
(-)-maackiain   11.64 
(-)-sophorol   10.54 
1,3,7-trihydroxyxanthone   9.8 
1,5,7-trihydroxy-6,8-
dimethoxyanthraquinone 
  10.54 
1,6,7-trihydroxy-2-methylanthraquinone   10.54 
1,6-kestotetraose   10.54 
1-phenyl-7-(3,4-dihydroxyphenyl)-hepta-
1,3-dien-5-one 
  8.45 
1D-chiro-inositol   11.76 
2-hydroxyferulate   11.64 
2-mercaptobenzothiazole   6.17 
2-methyl-6-geranylgeranyl-1,4-
benzoquinol 
  15.86 
(+)-6a-hydroxymaackiain   10.54 
3,4,6-trihydroxy-cis-cinnamate   4.19 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-
olide 
  9.88 
6-hydroxyflavone   10.23 
6-hydroxymellein   11.25 
6-O-galloylglucose   10.23 
7-hydroxy-2-oxindole-3-aceate glucoside   11.25 
Acetylnorajmaline   6.12 
Acidomycin   6.12 
Benzoate   15.64 
Cinchonine   8.42 
curcumin diglucoside   15.64 
curcumin monoglucoside   15.64 
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Table IX: List of compounds in crude hot aqueous strong cationic extract of S. frutescens 
Name   Found at 
RT (min) 
(+)-maackiain   11.67 
(+)-pisatin   11.79 
(-)-maackiain   11.67 
(-)-maackiain-3-O-glucoside-6''-malonate   4.24 
1,3,7-trihydroxyxanthone   9.96 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.79 
1-(3-aminopropyl)-4-aminobutanal   3.15 
1D-chiro-inositol   11.79 
2'-hydroxygenistein   8.93 
2-hydroxyferulate   11.67 
2-methyl-6-geranylgeranyl-1,4-benzoquinol   15.92 
246-trinitrobenzene   15.63 
3,4-dihydroxypyridin   10.68 
3-dehydroquinate   11.17 
3-methoxybenzaldehyde   15.61 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-olide   9.96 
4,4'-diisothiocyanostilbene-2,2'-disulfonate   14.92 
5-phosphoribosyl-N-formylglycineamidine   15.63 
Avenacin   8.44 
Berbamunine   4.24 
Butylamine   11.67 
Cyanoborohydride   4.15 
D-arabinose 5-phosphate   3.66 
D-myo-inositol (1,2,3,4) tetrakisphosphate   3.66 
D-myo-inositol (1,2,3,4,6)-pentakisphosphate   3.66 
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Table X: List of compounds in crude hot aqueous weak cationic extract of S. frutescens 
Name   Found 
at RT 
(min) 
(+)-6a-hydroxymaackiain   13.32 
(+)-maackiain   11.67 
(+)-pisatin   11.79 
(-)-maackiain   11.67 
(-)-sophorol   13.32 
(E)-2-methylbutanal oxime   2.44 
(Z)-2-methylbutanal oxime   2.44 
1,3,7-trihydroxyxanthone   9.84 
1,5,7-trihydroxy-6,8-
dimethoxyanthraquinone 
  13.32 
1,7-dihydroxy-5,6,8-
trimethoxyanthraquinone 
  11.79 
1-amino-propan-2-one-3-phosphate   3.83 
10-hydroxygeranial   12.62 
1D-chiro-inositol   11.79 
4-hydroxybutylglucosinolate   8.98 
6-hydroxymellein   13.31 
7-deoxyloganin   13.41 
7-hydroxy-2-oxindole-3-aceate glucoside   13.31 
7-O-acetylsalutaridinol   9.32 
Acetylnorajmaline   5.98 
Acidomycin   5.98 
adenylo-succinate   13.41 
aureusidin 6-O-glucoside   12.23 
D-octopine   6.5 
dephospho-CoA   8.77 
geranylgeranyl-chlorophyll a   4.21 
indole-3-acetate   10.5 
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Table XI: List of compounds in crude 100% methanolic extract of S. frutescens 
Name   found 
at RT 
(min) 
Acetylnorajmaline   4.2 
L-aspartate-semialdehyde   3.6 
Shikonin   14.24 
Shisonin   14.24 
glucono-d-lactone   4.2 
L-histidine   4.2 
D-myo-inositol (1,2,6) trisphosphate   3.95 
Shikimate   12.86 
Acidomycin   4.2 
L-glutamate   4.5 
(Z)-2-methylpropanal-oxime   4.2 
Anol   14.06 
7-methylthioheptylhydroximoyl-
glutathione 
  3.94 
Vanillylamine   14.96 
glyceollidin I   4.22 
Butylamine   14.1 
Serinol   15.72 
D-myo-inositol (1,3,4)-trisphosphate   3.35 
Vitexin   15.66 
Isoalliin   15.52 
9-methylthiononylhydroximoyl-
glutathione 
  15.52 
Strictosidine   15.52 
n-propanol   15.52 
indole-3-acetate   8.47 
L-histidinol-phosphate   4.2 
Linamarin   9.68 
emodin anthrone   4.47 
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Table XII: List of compounds in crude 80% methanolic extract of S. frutescens 
Name   Found at 
RT (min) 
acetylnorajmaline   4.18 
artemisinic aldehyde   3.79 
L-aspartate-semialdehyde   3.63 
shikonin   14.24 
shisonin   14.24 
L-gulose   8.93 
shikimate   12.86 
linamarin   9.69 
L-glutamate   4.48 
vanillylamine   14.85 
dihydrohomopteroate   4.08 
another strange group   15.52 
L-histidinol-phosphate   4.18 
glyceollidin I   4.21 
N-prenylagmatine   10.33 
P(1),P(5)-di(adenosine-5'-
)pentaphosphate 
  10.33 
glyceraldehyde   15.86 
serinol   14.87 
S-8-methylthiooctylhydroximoyl-L-
cysteine 
  13.26 
sn-glycerol-3-phosphate   10.35 
sodium azide   10.35 
(-)-9ß-pimara-7,15-diene   10.35 
heliocide H4   11.03 
echinenone   10.6 
L-tyrosine   10.6 
15-cis-phytoene   11.71 
acidomycin   4.12 
10-hydroxydihydrosanguinarine   14.03 
24-alkyl sterol 2   14.67 
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Table XIII: List of compounds present in crude 100% methanolic strong anionic extract of S. 
frutescens 
Name   Found at 
RT (min) 
(+)-bornane-2,5-dione   9.21 
(+)-maackiain   11.66 
(+)-pisatin   11.78 
(-)-maackiain   11.66 
(-)-medicarpin   12.32 
(E)-2-methylpropanal-oxime   0.54 
(S)-2,3-epoxysqualene   15.64 
(Z)-2-methylpropanal-oxime   0.54 
1,3,7-trihydroxyxanthone   9.8 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.78 
1-O-galloyl-ß-D-glucose   3.91 
10-methyl-5,6,7,8-tetrahydropteroylglutamate   9.21 
1D-chiro-inositol   11.78 
2'-hydroxypseudobaptigenin   12.32 
2-fluorobenzoate   9.17 
2-hydroxyferulate   11.66 
2-oxosuccinamate   4.2 
24-epi-campesterol   15.64 
3-glc-glc-medicagenic acid   15.03 
3-hydroxy-15-dihydrolubimin   13.41 
3-ß-hydroxy-5-a-pregnane-20-one   16.16 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-olide   9.8 
4',2,6,7-tetrahydroxyisoflavone   3.91 
4-methoxy-3-indolylmethylamine   10.66 
4a-methylfecosterol   3.91 
6-methoxy, 4',5,6,7-tetrahydroxyisoflavone   12.61 
7-deoxyloganin   13.42 
8-aminoethyl-2,6-anhydro-3,8-dideoxy-D-
glycero-D-talo-octonate 
  8.96 
9-oxo-nonanoate   14.39 
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Table XIV: List of compounds in crude 100% methanolic weak anionic extract of S. 
frutescens 
Name   Found at 
RT (min) 
(+)-heliannuol K   16.06 
(+)-maackiain   11.67 
(+)-pisatin   11.76 
(-)-heliannuol E   16.06 
(-)-maackiain   11.67 
(-)-maackiain-3-O-glucoside   9.73 
(-)-medicarpin   12.5 
(E)-2-methylpropanal-oxime   4.21 
(R)-amygdalin   4.22 
(S)-2,3-epoxysqualene   15.57 
(Z)-2-methylpropanal-oxime   4.21 
1,3,7-trihydroxyxanthone   9.65 
1,3-diphosphateglycerate   3.73 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.76 
1-O,6-O-digalloyl-ß-D-glucose   8.72 
16a, 17-epoxy gibberellin A4   8.99 
1D-chiro-inositol   11.76 
(+)-(4R)-limonene   3.59 
(+)-2-carene   3.59 
(+)-3-carene   3.59 
(+)-maackiain   14.32 
(+)-pisatin   11.79 
(+)-sesamolinol   15.26 
(+)-ß-pinene   3.59 
(-)-camphene   3.59 
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Table XV: List of compounds in crude 100% methanolic strong cationic extract of S. 
frutescens 
Name   Found at 
RT (min) 
(+)-2-carene   3.67 
(+)-3-carene   3.67 
(+)-isopimara-7,15-diene   10.52 
(+)-maackiain   11.64 
(+)-pisatin   11.74 
(+)-ß-pinene   3.67 
(-)-9ß-pimara-7,15-diene   10.52 
(-)-abietadiene   10.52 
(-)-camphene   3.67 
(-)-maackiain   11.64 
(-)-ß-phellandrene   3.67 
(-)-ß-pinene   3.67 
(4a)-methyl-(5a)-ergosta-8,14,24(28)-trien-3ß-ol   14.58 
(E)-2-methylbutanal oxime   9.39 
(E)-ß-ocimene   3.67 
(Z)-2-methylbutanal oxime   9.39 
(Z)-ß-ocimene   3.67 
1,3,7-trihydroxyxanthone   9.79 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.74 
1D-chiro-inositol   11.74 
2-hydroxyferulate   11.64 
246-trinitrobenzene   15.72 
3-(phosphonoacetylamido)-L-alanine   3.64 
3ß-Hydroxy-9ß-pimara-7,15-diene-19,6ß-olide   9.79 
4,4-dimethyl-14a-formyl-5a-cholesta-8,24-dien-
3ß-ol 
  14.58 
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Table XVI: List of compounds in crude 100% methanolic weak cationic extract of S. 
frutescens 
Name   Found at RT 
(min) 
(+)-6a-hydroxymaackiain   13.31 
(+)-isopimara-7,15-diene   10.47 
(+)-pisatin   11.78 
(-)-9ß-pimara-7,15-diene   10.47 
(-)-abietadiene   10.47 
(-)-sophorol   13.31 
(E)-2-methylbutanal oxime   9.29 
(R)-Prunasin   8.65 
(S)-2,3-epoxysqualene   15.73 
(Z)-2-methylbutanal oxime   9.29 
1,3,7-trihydroxyxanthone   9.68 
1,4-dihydroxy-2-naphthoyl-CoA   13.81 
1,5,7-trihydroxy-6,8-dimethoxyanthraquinone   13.31 
1,6,7-trihydroxy-2-methylanthraquinone   13.31 
(+)-(4R)-limonene   3.64 
(+)-2-carene   3.64 
(+)-3-carene   3.64 
(+)-6a-hydroxymaackiain   13.31 
(+)-isopimara-7,15-diene   10.53 
(+)-maackiain   11.67 
(+)-pisatin   11.76 
(+)-ß-pinene   3.64 
(-)-(1S)-sabinene   3.64 
(-)-9ß-pimara-7,15-diene   10.53 
(-)-abietadiene   10.53 
(-)-camphene   3.64 
(-)-maackiain   11.67 
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Table XVII: List of compounds in crude 100% ethanolic extract of S. frutescens 
Name   Found at 
RT (min) 
24-alkyl sterol 3   15.18 
acetylnorajmaline   6.39 
purine   10.2 
decaprenyl diphosphate   10.2 
dUTP   10.41 
butylamine   14.05 
hesperitin   15.9 
246-trinitrobenzene   14.53 
2-keto-isovalerate   3.83 
coniine   15.04 
L-glyceraldehyde   4.18 
D-erythro-imidazole-glycerol-
phosphate 
  12 
campest-4-en-3ß-ol   10.71 
beta-methylenecyclopropyl pyruvate   9.95 
ß-D-apiofuranosyl-(1->6)-D-glucose   14.21 
precorrin-2   8.61 
3S,3'S-astaxanthin   9.59 
N-methylputrescine   9.57 
shikimate-3-phosphate   11.02 
2,5-diamino-6-(ribosylamino)-4-
(3H)-pyrimidinone 5'-phosphate 
  9.59 
(+)-7-iso-jasmonate   15.92 
punicate   10.2 
gibberellin A4 methyl ester   11.36 
gibberellin A9 methyl ester   11.36 
gibberellin A44 diacid   11.36 
(S)-coclaurine   8.4 
5-pentadecatrienyl resorcinol-3-
methyl ether 
  10.63 
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Table XVIII: List of compounds present in crude 80% ethanolic extract of S. frutescens 
Name   Found at RT 
(min) 
acetylnorajmaline   6.37 
purine   10.21 
decaprenyl diphosphate   10.21 
pelargonidin   4.02 
ribavirin-5'-monophosphate   4 
4-methoxy-3-indolylmethyl 
glucosinolate aglycone 
  3.94 
6-hydroxyprotopine   9.44 
3S,3'S-astaxanthin   9.67 
N,N-dihydroxyvaline   3.81 
24-alkyl sterol 3   14.88 
chelidamate   9.91 
2,5-diamino-6-(ribosylamino)-4-(3H)-
pyrimidinone 5'-phosphate 
  9.66 
246-trinitrobenzene   14.15 
Hesperidin   12.65 
Dethiobiotin   9.76 
magnoflorine   15.86 
phosphoryl-choline   4.26 
Adenosine   11.5 
kaempferol-3-rhamnoside-7-
rhamnoside 
  3.97 
Harmol   3.76 
stemar-13-ene   9.69 
Tris-hydrochloride   9.92 
2,6,7,4'-tetrahydroxyisoflavanone   14.08 
Hesperitin   15.88 
26,27-dehydrozymosterol   9.41 
buthionine sulfoximine   13.98 
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Table XIX: List of compounds in crude 100% ethanolic strong anionic extract of S. 
frutescens 
Name   Found at 
RT (min) 
OPC4-trans-2-enoyl-CoA   11.32 
OPC6-3-hydroxyacyl-CoA   11.32 
OPC4-trans-2-enoyl-CoA   11.32 
acetylnorajmaline   4.18 
2-hydroxyformononetin   12.07 
5a-cholesta-7,24-dien-3ß-ol   12.04 
1,7-dihydroxy-5,6,8-trimethoxyanthraquinone   11.55 
acidomycin   4.2 
(+)-maackiain   11.04 
shikonin   14.17 
shisonin   14.17 
CTAB   9.56 
shikimate-3-phosphate   14.18 
isatin   11.32 
9-methylthiononylhydroximoyl-cysteinylglycine   11.32 
shikimate   14.06 
serinol   14.88 
anol   14.75 
uracil   13.38 
3-cyanopyridine   4.21 
4,4'-diisothiocyanostilbene-2,2'-disulfonate   14.6 
1D-chiro-inositol   13.14 
15-cis-phytoene   11.63 
vanillylamine   14.91 
dihydromyricetin   14.06 
D-sorbitol   14.91 
OPC4-3-ketoacyl-CoA   12.15 
(6aR,11aR)-3,9-dihydroxypterocarpan   11.45 
umbelliferone   11.55 
(-)-curcuhydroquinone   11.46 
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Table XX: List of compounds in crude 100% ethanolic weak anionic extract of S. frutescens 
Name   Found at 
RT (min) 
(+)-maackiain   11.66 
shikonin   14.19 
shisonin   14.19 
campestanol   13.52 
acetylnorajmaline   6.32 
linamarin   10.33 
pyridoxamine   9.16 
6-hydroxymellein   12.51 
E-pyridine-3-aldoxime   10.11 
dTDP-a-L-rhamnose   12.73 
decaprenyl diphosphate   8.62 
purine   8.62 
adenylo-succinate   10.49 
sodium azide   10.29 
(-)-9ß-pimara-7,15-diene   10.29 
sn-glycerol-3-phosphate   10.29 
(4-hydroxyphenyl)acetaldehyde   8.38 
hydroxypyruvate   9.06 
hydroxymethylpyrimidine phosphate   9.06 
OPC6-3-hydroxyacyl-CoA   13.29 
OPC4-trans-2-enoyl-CoA   13.29 
OPC4-trans-2-enoyl-CoA   13.29 
7-O-methylvitexin 2''-O-ß-L-rhamnoside   10.08 
D-myo-inositol (1,2,6) trisphosphate   3.94 
9-methylthiononanaldoxime   10.3 
aminooxyacetate   12.49 
isorhamnetin 3-sulphate   8.41 
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Table XXI: List of compounds in 100% ethanolic strong cationic extract of S. frutescens 
Name   Found at 
RT (min) 
acetylnorajmaline   4.19 
acidomycin   4.24 
kaempferol-3-O-gentiobioside-7-O-
rhamnoside 
  3.96 
glucosyl-(mannosyl)9-(N-
acetylglucosaminyl)2-diphosphodolichol 
  4.08 
2-hydroxyferulate   10.8 
norfuraneol   15.19 
(+)-piperitol   11.55 
(Z)-2-methylpropanal-oxime   4.21 
pelargonidin-3,5-diglucoside-5-O-p-
coumaroylglucoside 
  6.75 
indole-3-acetate   8.73 
P(1),P(5)-di(adenosine-5'-)pentaphosphate   12.98 
N-prenylagmatine   12.98 
3-methoxytyramine   4.22 
columbamine   8.44 
L-histidine   6.32 
L-tyrosine   10.38 
echinenone   10.38 
sn-glycerol-3-phosphate   11.52 
(-)-9ß-pimara-7,15-diene   11.52 
1D-chiro-inositol   9.77 
linamarin   9.49 
10-oxogeranial   15.69 
(+)-pinoresinol   10.59 
D-myo-inositol (1,2,6) trisphosphate   3.95 
leucopelargonidin   15.85 
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Table XXII: List of compounds in 100% ethanolic weak cationic extract of S. frutescens 
Name   Found at 
RT (min) 
conhydrine   9.08 
(-)-maackiain   11.16 
shisonin   14.17 
shikonin   14.17 
norfuraneol   12.55 
linamarin   9.73 
serinol   14.91 
acetylnorajmaline   6.24 
purine   8.64 
decaprenyl diphosphate   8.64 
dTDP-a-L-rhamnose   11.21 
methylsuccinate   15.89 
(+)-pulegone   15.32 
acetylenedicarboxylate   4.19 
7-hydroxy-2-oxindole-3-aceate glucoside   13.1 
aminooxyacetate   12.43 
1D-chiro-inositol   13.14 
5-O-(indol-3-ylacetyl-myo-inositol) D-
galactoside 
  8.28 
levopimaradiene   13.98 
(E)-2-methylbutanal oxime   4.02 
ß-fenchocamphorone   15.55 
heliocide H4   12.36 
2,5-diamino-6-(ribosylamino)-4-(3H)-
pyrimidinone 5'-phosphate 
  11.57 
quinate   12.29 
7-O-ß-D-glucosyl-apigenin   6.73 
uroporphyrin I   11.63 
dalcochinin-8'-O-ß-glucoside   11.52 
abscisic acid glucose ester   16.8 
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APPENDIX II 
 
Names of Phytocompounds with Anti-diabetic properties compiled from online 
Databases DIACAN and Phytoremedial Database for Anti-diabetic. 
 
a-pinene 
allicin 
aminoguanidine 
ampelopsin 
andrographolide 
arbutin 
arecolin 
a-tocopherol 
acetophenone 
achyrofuran 
acylglucosyl Sterols 
ajmalicine 
ajmaline 
alpha-Homonojirimycin 
amarogentin 
amaroswerin 
andrographolide 
apigenin 
arecoline 
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bassic acid 
berberine 
bergenin 
beta Amyrin 
beta-sitosterol 
biguanidine 
bakuchiol 
bellidifolin 
bengalenoside 
berberin 
bergenin 
beta Sitosterol 
beta-Sitosterol 3-D-Glucoside 
beta-Sitosterol-D-Glycoside 
betavulgarosides 2 
breviscapine 
chlorogenic Acid 
corosolic acid 
chrysophanol 
cryptolepine 
crispatine 
curcumin 
caffeic Acid 
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capsaicin 
carvone 
castanospermine 
catechin 
chamaemeloside 
charantin 
christinin-A 
cinchonain Ib 
cinnamaldehyde 
coixan A 
coixan B 
coixan C 
coumarin 
coutareagenin 
cryptolepine 
cycloartanol 
dianex 
dioscoretine 
D-chiro-inositol 
desmanthin-1 
dibenzocyclooctadiene 
dioscoran A 
dioscoran B 
 
 
258 
 
dioscoran C 
dioscoran D 
dioscoran E 
dioscoran F 
D-pinitol (3-O-Methyl-Chiroinositol) 
emodin 
ellagic acid 
eleutheran-A 
eleutheran-B 
eleutheran-C 
eleutheran-D 
eleutheran-F 
eleutheran-G 
emblicanin-A 
emblicanin-B 
enhydrin 
ephedran A 
ephedran B 
ephedran C 
ephedran D 
ephedran E 
epicatechin 
epicatechin-3-O-Gallate 
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epigallocatechin 
epigallocatechin Gallate 
eremanthin 
eugenol 
ferulic acid 
fagomine 
galegine 
gallotannins 
geraniol 
ginkgolides 
glibenclamide 
glycyrrhizic acid 
galactomannan 
galegine 
gallic acid 
gamma-conglutin 
geraniin 
ginsenosides 
girinimbine 
girinimbiol 
glycyrin 
glycyrrhizin 
gossypol 
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guaijaverin 
gymnemic Acid 
harpagoside 
harpagoside-B 
hederagenin 
hydnocarpin 
hydnowightin 
hydroxytyrosol 
hydroxyvernolide 
hypoglycin A 
hypoglycin B 
hypophyllanthin 
isopimpinellin 
isorhamnetin 
indoleacetic Acid 
inositol 
isoorientin 
jatrorrhizine 
jiangtangsu 
kaempferitrin 
kalopanaxsaponin A 
kaempferol 
kaempferol-3-O-Beta-Glucopyranoside 
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kaempferol-3-O-Sophoroside-4'-O-'Beta-Glucoside 
kalopanaxsaponin A 
kaurenoic Acid 
kolaviron 
kotalagenin 16-Acetate 
Kotalanol 
luteolin 
lagerstroemin 
lathyrine 
lectin 
L-Ephedrine 
lepidine 
leucodelphinidin 
leucopelargonidin 
leucopelargonidin-3-O-Alpha-L-Rhamnoside 
leucosceptoside A 
lilium-A-Glucomannan 
lilium-J-Glucomannan 
lilium-S-Glucomannan 
lilium-S-Glucomannan 
limonene 
lithosperman A 
lithosperman B 
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lithosperman C 
lophenol 
luffin-A 
lupanine 
lycoris-R-Glucomannan 
lycoris-S-Glucomannan 
maltodextrin 
masoprocol 
myrcene 
myricetin 
mangiferin 
mangiferin-7-O-Betaglucoside 
masoprocol 
MDG-1 
mearnsitrin 
methylbellidifolin (Swerchirin) 
methylenecyclopropyl Glycine 
methylswertianin 
mimosine 
momordicosides A 
momordicosides B 
momordin-A 
moracin M 
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moracin M-3-O-Beta-D-Glucopyranoside 
moran A 
mucuadinine 
mucunadine 
mucunine 
mulberrofuran U 
mycaminose 
myrciacitrin III 
myrciacitrin IV 
myrciacitrin V 
myrciacitrins I 
myrciacitrins II 
myrciaphenone A 
myrciaphenone B 
myricitrin 
myristicin 
myrtillin 
neohydnocarpin 
neriin 
N-Hydroxyethyl-1-Deoxynojirimycin (Miglitol) 
N-Hydroxyphenyl-1,4-Dideoxy-1,4-Imino-D-Arabinitol 
nigellone 
nuciferine 
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nymphayol 
oleanolic acid 
oleandrin 
oleanoic Acid-28-O-Beta-D-Glucopyranoside 
oleo-Gum-Resin 
Oleuropein 
paeoniflorin 
proanthocyanidins 
paeoniflorin 
palmatine 
pandanus Odorus (Toei-Hom) A 4- Hydroxybenzoic Acid 
paniculatan 
pectin 
pedunculagin 
peptidoglycan MVS-1 
peptidoglycan MVS-IIA 
perlargonidin 3-O-Alpha-L Rhamnoside 
phanoside 
phloridzin 
phyllanthin 
pinitol 
p-Insulin 
proanthocyanidin 
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procyanidin B-2 
punigluconin 
purpureaside C 
quercetin 
quercetin-3-O-Beta-Glucopyranoside 
quercetrin 
quercitrin 
quinoline-2-Methanol 
rutin 
rebaudioside A 
regeol A 
rehmannioside A 
rehmannioside B 
rehmannioside C 
rehmannioside D 
roseoside 
rosmarinic Acid 
sabinene 
salacinol 
sarsasapogenin 
scopoletin 
swerchirin 
saccharan A 
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saccharan B 
saccharan C 
saccharan D 
saccharan E 
saccharan F 
salacinol 
salacinol 
salacinol 
salaquinone A 
salasol A 
salasone A 
salasone B 
salasone C 
salidroside 
S-Allyl Cysteine Sulphoxide (SACS) 
sanguinarine 
sarpagine 
scropolioside-D 
serpentine 
sesquiterpene 
sesquiterpene 
skimmianine 
skimmin 
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S-Methyl Cysteine Sulfoxide (SMCS) 
solasonine 
sonchifolin 
sparteine 
sparteine 
stevioside 
stigmasterol 
sweroside 
swertiamarin 
tecomine 
transß- Ocimene 
tannic Acid 
thymoquinone 
tingenine B 
tingenone 
tormentic Acid 
trans-Dehydrocrotonin 
trichosan A 
trichosan B 
trichosan C 
trichosan D 
trichosan E 
trigonelline 
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triptocalline A 
umbelliferone 
ursolic acid 
uniflorine A 
uniflorine B 
urs-12-En-3beta-Ol-28-Oic Acid 3beta-D-Glucopyranosyl-4'-Octadecanoate 
uvedalin 
vinblastine 
vincamine 
vernodalin 
vernolide 
vernonioside A1-A4 
v-Insulin 
wedelolactone 
yohimbine 
zingiberene 
1,4-Dideoxy-1,4-Imino-D-Ribitol 
18beta-Glycyrrhetinic Acid 
1-Deoxymannojirimycin 
1-Deoxynojirimycin 
2-(2,3,6-Trihydroxy-4-Carboxyphenyl)Ellagic Acid 
2,5-Dideoxy-2,5-Imino-D-Mannitol 
2,5-Dihydroxy-4,3'-Di(Beta-D-Glucopyranosyloxy)-Trans-Stilbene 
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2,5-Dihydroxymethyl-3,4-Dihydroxypyrrolidine 
2,5-Imino-1,2,5-Trideoxy-D-Mannitol 
24-Ethyl-Lophenol 
24-Methylene-Cycloartanol 
24-Methyl-Lophenol 
28Nor-22(R)Witha 2,6,23-Trienolide 
2-Heptyl Acetate 
2-Hydroxy 4-Methoxy Benzoic Acid 
2-Methylbutyl Acetate 
3 ,22 -Dihydroxyolean-12-En-29-Oic Acid 
3-Caffeoylquinic Acid/Chlorogenic Acid 
3-Epifagomine 
4-Hydroxy-Alpha-Tetralone 
4-Hydroxy-Alpha-Tetralone-4-O-Beta-D-[6'-O-(3'4'5'-Trihydroxybenzoyl) 
Glucopyranoside 
4-Hydroxybenzoic Acid 
4-O-Beta-D-Glucopyranosylfagomine 
6-Gingerol 
6-Methyl-4-Chromanone 
6''-O-Acetyl-5-O-Beta-D-Galactopyranosyl-7,3',4'-Trihydroxy-4-Phenylcoumarin 
6''-O-Acetyl-5-O-Beta-D-Galactopyranosyl-7,4'-Dihydroxy-4-Phenylcoumarin 
7-O-Beta-D-Glucopyranosyl Alpha-Homonojirimycin 
8-Debenzoylpaeoniflorin 
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APPENDIX III 
MTT Cell Viability Assay of Chang and HepG2 cells 
(a)
Chang 24Hrs MTT Assay
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. 
(b)
HepG2 24Hrs MTT Assay
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Figure 3.6: Cell viability of (a) Chang cells (b) HepG2 cells as measured by MTT assay, is 
expressed as a % of the control MCDB culture. Chang and HepG2 cells were cultured in 
MCDB-201 medium containing insulin and fructose (MIF) for 24 hrs, with S. frutescens 
extracts or metformin as positive control. The effect of S. frutescens extracts or metformin on 
cell viability in the culture medium is shown. Data are represented as mean ± SEM from 3 
independent experiments of 3 wells per experiment for all analysed conditions. 
